Parkinson's Disease

Complex MONDO:0005180 Pathograph 52 Show in embeddings browser Neurodegenerative Disease Movement Disorder

Parkinson's disease is a progressive neurodegenerative movement disorder caused by the loss of dopaminergic neurons in the substantia nigra pars compacta, producing striatal dopamine deficiency and basal ganglia circuit dysfunction. It manifests as bradykinesia, resting tremor, rigidity, and postural instability, with non-motor features. The pathological hallmark is intraneuronal aggregation of misfolded alpha-synuclein (Lewy bodies), with mitochondrial dysfunction and oxidative stress contributing to neurodegeneration.

Ask OpenScientist

Ask a research question about Parkinson's Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🔗

Mappings

MONDO

MONDO:0008199 late-onset Parkinson disease Not Yet Curated

MONDO:0008199 (late-onset Parkinson disease, OMIM:168600, "PARK"/"LOPD"; onset after ~age 50) is the common sporadic/idiopathic adult-onset form and a child of MONDO:0005180. This entry curates Parkinson disease at the broad MONDO:0005180 level, and its pathophysiology (α-synucleinopathy and dopaminergic neurodegeneration, SNCA/LRRK2/GBA1) substantively covers the late-onset form. Recorded as a narrowMatch so coverage tooling resolves MONDO:0008199 to this entry rather than flagging it as uncurated.

◈

Mechanistic Hypotheses

Canonical α-Synucleinopathy and Dopaminergic Neurodegeneration Model

canonical_synucleinopathy_dopaminergic_neurodegeneration_model CANONICAL

Evidence balance 1 support

Misfolded α-synuclein aggregates into oligomers and Lewy bodies, propagates trans-synaptically in a prion-like manner, and induces progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta. The resulting striatal dopamine deficiency causes the cardinal motor signs (bradykinesia, rigidity, tremor, postural instability), while broader Lewy pathology in autonomic, brainstem, and cortical regions accounts for the non-motor symptoms (REM-sleep behavior disorder, hyposmia, constipation, cognitive impairment). Pathway evidence implicates impaired autophagy/lysosomal clearance (GBA), mitochondrial dysfunction (PINK1/Parkin), and oxidative stress as upstream amplifiers; loss of dopaminergic feedback to the indirect/direct basal ganglia circuits explains the motor circuit signature.

Retained as CANONICAL. The 2026 falcon hypothesis-search report (kb/hypotheses/Parkinsons_Disease/canonical_synucleinopathy_dopaminergic_neurodegeneration_model; openscientist timed out) confirms misfolded α-synuclein aggregation, Lewy-body formation, and progressive substantia-nigra pars-compacta dopaminergic neuron loss as the central mechanism. Three qualifications: (1) the prion-like cell-to-cell propagation model is well-validated in mouse and primate models (intracerebral PFF injection seeds endogenous aggregates and produces motor deficits), but its rate-limiting role in human sporadic PD remains debated; (2) GBA1 heterozygosity, mitochondrial dysfunction (PINK1/Parkin), impaired autophagy/lysosomal clearance, and gut-brain axis (vagal Lewy pathology, microbiome) are increasingly recognized upstream amplifiers — particularly the gut-first Braak hypothesis, supported by hyposmia and REM-sleep behavior disorder preceding motor symptoms by 10-20 years; (3) LRRK2 G2019S and other genetic PD subtypes display Lewy-pathology variability, indicating molecular heterogeneity within the unified clinical syndrome. Anti-α-synuclein immunotherapies (prasinezumab, cinpanemab) have shown target engagement but limited clinical efficacy, suggesting aggregation may be a downstream marker rather than the rate-limiting therapeutic target.

Deep research

Falcon citations 56 citations 2026-05-23T19:21:21.440028

Show evidence (1 reference)

PMID:37048085 SUPPORT Human Clinical

"dopaminergic neuronal loss in substantia nigra pars compacta of the brain and aggregation of intracellular protein α-synuclein are the pathological characterizations"

Canonical mechanism review used as the seed reference for the hypothesis-search deep-research run.

Body-First Enteric α-Synuclein Initiation Model

body_first_enteric_alpha_synuclein_model ALTERNATIVE

Evidence balance 10 support 1 refute

Alpha-synuclein pathology initiates in the enteric nervous system or other peripheral autonomic sites, then propagates through vagal connections to the dorsal motor nucleus and broader brainstem before joining the central alpha-synuclein propagation and dopaminergic-neurodegeneration cascade. This model best explains Parkinson disease presentations with early constipation, REM-sleep behavior disorder, autonomic dysfunction, and early peripheral/cardiac sympathetic denervation.

Evidence is strongest for the gut-to-brain propagation route in animal models where truncal vagotomy or alpha-synuclein deficiency blocks spread. Human clinical and imaging studies support a body-first subtype pattern, but microbiome dysbiosis and enteric seeding remain unresolved as causal triggers versus modifiers or consequences. The 2026 OpenScientist hypothesis-search report (kb/hypotheses/Parkinsons_Disease/body_first_enteric_alpha_synuclein_model) judges this model PARTIALLY SUPPORTED and recommends retaining ALTERNATIVE status: it is one well-supported origin-site pathway (an estimated ~20-30% of PD) within the multi-origin Synuclein Origin and Connectome (SOC) framework, not a universal disease mechanism. Convergent support spans mouse gut-to-brain transmission (vagotomy and α-syn knockout each block spread), human truncal-vagotomy epidemiology (reduced PD risk at long follow-up), gut-microbiota dependence in α-syn-overexpressing mice, and a distinct body-first clinical-imaging signature (more symmetric nigrostriatal degeneration, early cardiac sympathetic denervation). Key qualifications: (1) the upstream trigger for enteric α-syn misfolding is unknown; (2) enteric α-syn immunohistochemistry lacks diagnostic specificity (positive also in controls); (3) LRRK2-associated PD is frequently α-syn seed amplification assay (SAA)-negative, showing α-syn-independent parkinsonian pathways; (4) 6-43% of cases deviate from caudo-rostral Braak staging, iRBD prodrome is heterogeneous, FMT trials are inconsistent, and anti-α-syn immunotherapies have failed in established PD.

Pathograph links

Gut Microbiome Dysbiosis -> Intestinal Inflammation and Barrier Dysfunction INDIRECT UNKNOWN INTERMEDIATES PD-associated dysbiosis may promote a pro-inflammatory intestinal state and barrier dysfunction, but the direction and necessity of this link remain unresolved in humans.

Intestinal Inflammation and Barrier Dysfunction -> Enteric Alpha-Synuclein Seeding INDIRECT UNKNOWN INTERMEDIATES Local gut inflammation and barrier leakiness may increase enteric alpha-synuclein expression or amyloidogenic exposure, providing a permissive setting for enteric alpha-synuclein seeding.

Enteric Alpha-Synuclein Seeding -> Vagal-Brainstem Alpha-Synuclein Propagation DIRECT Enteric alpha-synuclein seeds can propagate first to vagal brainstem nuclei and then to additional brain regions.

Enteric Alpha-Synuclein Seeding -> Constipation UNKNOWN Enteric or autonomic involvement is a plausible contributor to early constipation in body-first PD, but this edge remains clinically inferred.

Vagal-Brainstem Alpha-Synuclein Propagation -> Alpha-Synuclein Aggregation INDIRECT KNOWN INTERMEDIATES Vagal-brainstem propagation links gut-origin pathology to the broader central alpha-synuclein aggregation cascade. Intermediates: dorsal motor nucleus and nucleus tractus solitarius involvement; caudal hindbrain and higher brain region propagation

Vagal-Brainstem Alpha-Synuclein Propagation -> Pontine Tegmental Alpha-Synuclein Pathology DIRECT As vagal-brainstem propagation continues rostrally, the pontine tegmentum - the site of the REM-atonia-generating circuit - is reached ahead of the nigrostriatal and cortical structures that define overt motor and cognitive disease.

Pontine Tegmental Alpha-Synuclein Pathology -> Loss of Descending Drive to Inhibitory Premotor Neurons DIRECT Pathology involving the pontine REM-on glutamatergic population removes the excitatory drive its descending axons carry to medullary and spinal inhibitory premotor neurons.

Loss of Descending Drive to Inhibitory Premotor Neurons -> REM Sleep Muscle Atonia Loss DIRECT Without descending excitation of the inhibitory premotor pool, skeletal motor neurons are not hyperpolarised during REM sleep and muscle tone persists.

Deep research

OpenScientist citations 42 citations 2026-07-06T10:39:19.549709

Show evidence (11 references)

PMID:38519273 SUPPORT Human Clinical

"the initial pathology starts either in the olfactory bulb or amygdala leading to a brain-first subtype, or in the enteric nervous system leading to a body-first subtype."

Recent review-level synthesis of human imaging, clinical, and pathology studies explicitly frames enteric-origin body-first PD as an alternative subtype within the ASOC model.

PMID:31255487 SUPPORT Model Organism

"Truncal vagotomy and α-syn deficiency prevented the gut-to-brain spread of α-synucleinopathy and associated neurodegeneration and behavioral deficits."

Mouse gut-to-brain transmission experiments support the vagus nerve and alpha-synuclein as required components of the body-first propagation route.

PMID:39241780 SUPPORT Model Organism

"Truncal vagotomy and α-Syn deficiency significantly inhibited synucleinopathy or tauopathy spreading."

Gut-inducible mouse models provide independent support that vagotomy and alpha-synuclein deficiency inhibit gut-origin propagation into the brain.

+ 8 more references

Brain-First Central α-Synuclein Initiation Model

brain_first_central_alpha_synuclein_model ALTERNATIVE

Evidence balance 9 support 1 refute

Alpha-synuclein pathology initiates within central nervous system sites such as the olfactory bulb or amygdala and spreads centrifugally to brainstem and peripheral autonomic structures. This model best explains Parkinson disease presentations where central dopaminergic or olfactory involvement precedes prominent autonomic and enteric manifestations.

The model is supported mainly by subtype-level human imaging, clinical, and neuropathological patterns. It competes with, rather than refutes, the body-first model because both origin routes may exist within clinically diagnosed Parkinson disease. The 2026 OpenScientist hypothesis-search report (kb/hypotheses/Parkinsons_Disease/brain_first_central_alpha_synuclein_model) judges this model PARTIALLY SUPPORTED and recommends retaining ALTERNATIVE status. Supporting evidence is convergent at the subtype level: large-scale neuropathological trajectory modelling (81.9% of Lewy-body donors have earliest pathology in the olfactory bulb), multimodal imaging showing asymmetric central dopaminergic loss preceding peripheral autonomic denervation in RBD-negative PD, and primate/mouse olfactory-bulb PFF injection reproducing olfactory-to-limbic-to-brainstem spread. Key qualifications: (1) no prospective longitudinal human study has tracked α-syn pathology from a CNS origin outward; (2) RBD as a body-first proxy is unreliable (PSG-confirmed prevalence 17.8-62.5% by ascertainment); (3) structural MRI is conflicting - a 255-patient PPMI cohort found no gray matter volume asymmetry difference between putative subtypes; (4) dermal SAA cannot differentiate subtypes in established disease and origin-site is not yet integrated into NSD-ISS/SynNeurGe biological staging; (5) α-syn strain differences that might determine origin route remain uncharacterized between subtypes.

Pathograph links

Central Alpha-Synuclein Initiation -> Alpha-Synuclein Aggregation INDIRECT KNOWN INTERMEDIATES Central initiation feeds into the broader alpha-synuclein aggregation and propagation cascade through connected brain networks. Intermediates: central network propagation from olfactory bulb or amygdala

Deep research

OpenScientist citations 36 citations 2026-07-06T06:14:58.676310

Show evidence (10 references)

PMID:38519273 SUPPORT Human Clinical

"the initial pathology starts either in the olfactory bulb or amygdala leading to a brain-first subtype, or in the enteric nervous system leading to a body-first subtype."

The ASOC model explicitly defines an olfactory bulb/amygdala origin as the brain-first subtype that competes with the enteric body-first route.

PMID:38519273 SUPPORT Human Clinical

"These subtypes should be distinguishable early in the disease course on a range of imaging, clinical, and neuropathological markers."

Human subtype distinguishability supports representing brain-first and body-first disease routes as alternative mechanistic hypothesis groups.

PMID:32830221 SUPPORT Human Clinical

"the PDRBD- data were compatible with a brain-first trajectory, characterized by primary loss of putaminal FDOPA uptake followed by a secondary loss of cardiac MIBG signal and 11C-donepezil signal."

Primary multimodal imaging data support a brain-first trajectory in RBD-negative de novo PD, where central dopaminergic dysfunction appears before peripheral autonomic marker loss.

+ 7 more references

Discussions and Knowledge Gaps

Does restoring PGC-1alpha signaling protect nigral dopaminergic neurons in human Parkinson disease, given that rescue is seen in cellular models while sustained supraphysiological expression in the adult rat nigrostriatal system is itself dopaminergic-toxic?

HUMAN MODEL MISMATCH OPEN pd_pgc1a_therapeutic_window

Attached to

pathophysiology#PGC-1alpha Transcriptional Program Repression pathophysiology#Mitochondrial Dysfunction

The direction of the human observation is not in doubt: PGC-1alpha-responsive bioenergetic genes are underexpressed in laser-captured human nigral neurons early in disease, and the repressor PARIS accumulates in human Parkinson disease brain. What does not transfer cleanly from model to patient is the therapeutic inverse. Cellular models show that activating PGC-1alpha blocks alpha-synuclein- and rotenone-induced dopaminergic loss, but AAV-mediated sustained overexpression in the adult rat nigrostriatal system selectively impairs dopaminergic function and, at higher levels, causes overt degeneration - and it does not rescue alpha-synuclein-induced degeneration. PGC-1alpha therefore behaves as a rheostat with an activation-level, cell-type, isoform and disease-stage dependence rather than as a monotonic neuroprotective switch, so a positive result in one model system cannot be read as evidence that pathway activation is protective in patients. Recording this as a HUMAN_MODEL_MISMATCH rather than a plain KNOWLEDGE_GAP is deliberate: the model evidence exists and is abundant on both sides; it is its translational validity, and specifically the existence and width of a therapeutic window, that is unresolved. This gap is shared with other neurodegenerative entries (Huntington disease, Alzheimer disease, amyotrophic lateral sclerosis) in which the same coactivator is implicated.

Proposed experiments

Dose-graded PGC-1alpha activation in nigrostriatal models

dose-response perturbation study

exp_pd_pgc1a_dose_response_nigrostriatal

Titrate PGC-1alpha activity across a graded range - from partial restoration toward physiological levels up to the supraphysiological levels used in the AAV overexpression studies - in human iPSC-derived midbrain dopaminergic neurons and in an in vivo nigrostriatal model, reading out respiratory-chain subunit expression, mitochondrial membrane potential, dopamine content and dopaminergic survival at each level.

Decision criterion

A therapeutic window exists if there is a contiguous range of PGC-1alpha activity in which bioenergetic readouts improve without loss of dopaminergic markers or dopamine content; the rheostat model predicts an inverted-U with toxicity at the high end, whereas a simple neuroprotective model predicts monotonic benefit.

Human target-engagement biomarker for PGC-1alpha modulation

biomarker validation study

exp_pd_pgc1a_target_engagement_biomarker

Establish and validate a measurable readout of PGC-1alpha pathway engagement in living patients - for example a peripheral or CSF transcriptional signature of the PGC-1alpha-responsive gene set benchmarked against the postmortem nigral signature - so that a trial of any PGC-1alpha-directed agent can distinguish target-engagement failure from mechanism failure.

Decision criterion

The biomarker is usable if it shifts dose-dependently with a known PGC-1alpha modulator and correlates with the nigral PGC-1alpha-responsive gene-set deficit; absent such a readout, a negative clinical trial cannot be interpreted as refuting the mechanism.

Raised from dismech issue #6114 ([kgap-scan:scope] PGC-1alpha-mediated neuroprotection), which asked whether the Parkinson, Alzheimer and amyotrophic lateral sclerosis entries should carry a PGC-1alpha node. The Huntington disease entry already curates the mHTT-driven PGC-1alpha repression chain; Alzheimer disease and amyotrophic lateral sclerosis remain uncurated for this mechanism.

Show evidence (3 references)

PMID:22246294 SUPPORT Model Organism

"In the adult rat nigrostriatal system, adeno-associated virus (AAV)-mediated overexpression of PGC-1α induces the selective loss of dopaminergic markers and increases dopamine (DA) catabolism, leading to a reduction in striatal DA content."

The in vivo counterexample to the cellular rescue result: sustained pathway activation is itself dopaminergic-toxic, which is what creates the translational uncertainty.

PMID:22246294 SUPPORT Model Organism

"These results highlight the central role of PGC-1α in the function and survival of dopaminergic neurons and the critical need for maintaining physiological levels of PGC-1α activity."

States the therapeutic-window requirement directly - benefit is conditional on activity level, not on activation per se.

PMID:42430091 SUPPORT Other

"These observations suggest that PGC-1α is not a simple neuroprotective switch, but a flexible regulatory hub whose therapeutic value depends on cell type, isoform profile, disease stage, and activation level."

Cross-disease review framing that generalizes the mismatch beyond Parkinson disease and names the four context variables that determine whether modulation helps.

In body-first Parkinson disease, are gut microbiome dysbiosis and intestinal barrier/inflammatory changes causal triggers for enteric alpha-synuclein seeding, modifiers that amplify an already initiated synucleinopathy, or secondary consequences of autonomic gut dysfunction?

KNOWLEDGE GAP OPEN gap_pd_microbiome_causal_direction_body_first

Attached to

pathophysiology#Gut Microbiome Dysbiosis pathophysiology#Intestinal Inflammation and Barrier Dysfunction pathophysiology#Enteric Alpha-Synuclein Seeding pathophysiology#Vagal-Brainstem Alpha-Synuclein Propagation

Cross-sectional human studies support PD-associated dysbiosis and elevated intestinal inflammatory/permeability markers, while animal studies support gut-to-brain alpha-synuclein propagation through the vagus nerve. The unresolved step is temporal and causal: whether dysbiosis or barrier dysfunction initiates enteric alpha-synuclein misfolding in humans, merely accelerates propagation, or appears after autonomic denervation has already altered gut physiology.

Proposed experiments

Prodromal microbiome-barrier alpha-synuclein longitudinal cohort

longitudinal prodromal multi-omics cohort study

exp_pd_prodromal_microbiome_barrier_alpha_syn_longitudinal_cohort

Follow iRBD-, constipation-, and hyposmia-enriched prodromal cohorts with serial stool metagenomics, SCFA/metabolite profiling, fecal and serum calprotectin/zonulin, autonomic imaging, and standardized enteric alpha-synuclein biopsy assays before motor conversion.

Readouts

Microbiome dysbiosis trajectory

pathophysiology#Gut Microbiome Dysbiosis

Determine whether reproducible microbiome shifts precede, track with, or follow enteric alpha-synuclein and autonomic biomarker changes.

shotgun metagenomic sequencing fecal metabolomics

Direction: POSITIVE

Intestinal inflammation and barrier trajectory

pathophysiology#Intestinal Inflammation and Barrier Dysfunction

Measure whether inflammatory and permeability markers rise before enteric alpha-synuclein detection and clinical conversion.

calprotectin assay zonulin assay

Direction: POSITIVE

Enteric alpha-synuclein seeding

pathophysiology#Enteric Alpha-Synuclein Seeding

Track phosphorylated or aggregated alpha-synuclein in standardized enteric biopsies as a candidate initiating event.

immunohistochemistry alpha-synuclein seed amplification assay

Direction: POSITIVE

Decision criterion

Microbiome and barrier changes would support a trigger model only if they reproducibly precede enteric alpha-synuclein positivity and autonomic denervation in converters; changes that follow autonomic dysfunction would support a consequence or modifier model.

Would support

pathophysiology#Gut Microbiome Dysbiosis pathophysiology#Intestinal Inflammation and Barrier Dysfunction pathophysiology#Enteric Alpha-Synuclein Seeding

Show evidence (4 references)

PMID:34220443 SUPPORT Human Clinical

"A causal relationship has not been established, but gut dysbiosis is prevalent in PD and may lead to intestinal inflammation and barrier dysfunction."

The human marker study states the core causal-direction uncertainty motivating this knowledge gap.

PMID:36332796 SUPPORT Other

"However, it remains unclear how these mechanisms relate to sporadic PD, a more common form of PD."

Review-level synthesis highlights uncertainty about how gut-related mechanisms map onto sporadic PD pathogenesis.

PMID:41826284 SUPPORT Human Clinical

"Microbiome profiling revealed greater similarity to donor composition and a marked reduction in Escherichia-Shigella, correlating with decreased colonic α-synuclein aggregation"

The strongest interventional human evidence bearing on this gap: in a 72-patient phase 2 trial of repeated donor fecal transplantation the induced microbiome shift correlated with reduced colonic alpha-synuclein aggregation. A correlation between two changes measured after treatment does not order dysbiosis before enteric alpha-synuclein misfolding, which is the question this gap asks.

+ 1 more reference

Which Parkinson disease risk and causal variants produce convergent dopaminergic-neuron mechanisms in a controlled human genetic background, and which phenotypes are variant-specific, modifier-dependent, or culture artifacts?

KNOWLEDGE GAP OPEN gap_pd_variant_specific_isogenic_hpsc_mechanisms

Attached to

pathophysiology#Dopaminergic Neuron Loss pathophysiology#Alpha-Synuclein Aggregation pathophysiology#Mitochondrial Dysfunction pathophysiology#Autophagy-Lysosome Pathway Dysfunction

Patient-derived iPSC comparisons are powerful but confounded by background genetic variation. Large WGS-QC'd isogenic hPSC panels, differentiated into midbrain dopaminergic neurons and phenotyped with imaging and sequencing, can separate variant-specific causal mechanisms from shared downstream neurodegenerative states.

Proposed experiments

Automated isogenic hPSC Parkinson variant panel

high-throughput isogenic stem-cell perturbation experiment

exp_pd_automated_isogenic_hpsc_variant_panel

Generate or extend a WGS-QC'd isogenic hPSC panel carrying high-risk or causal Parkinson disease alleles, differentiate lines into midbrain dopaminergic neurons, and benchmark variant-specific effects on alpha-synuclein handling, mitochondrial state, lysosomal function, and dopaminergic-neuron survival.

Model systems

Genome-edited hPSC-derived midbrain dopaminergic neuron panel

Isogenic human pluripotent stem cell collection carrying Parkinson disease variants, differentiated into disease-relevant dopaminergic neurons for mechanism-resolved phenotyping.

IPSC DERIVED MODEL PMID:38405931 link

human NCBITaxon:9606

midbrain dopaminergic neuron CL:0000700

Designed to be compatible with automated hPSC genome-engineering and clonal QC workflows such as ATTIS-style high-throughput line generation.

Perturbations

Parkinson disease variant editing

pathophysiology#Dopaminergic Neuron Loss

Introduce or compare causal and high-risk Parkinson alleles in a shared genetic background.

SNCA hgnc:11138 LRRK2 hgnc:18618 GBA1 hgnc:4177 PINK1 hgnc:14581 PRKN hgnc:8607

Prime-editing generation or correction

gene#LRRK2

Use prime editing or correction to create reciprocal disease and rescue alleles where feasible.

LRRK2 hgnc:18618

Readouts

Alpha-synuclein aggregation burden

pathophysiology#Alpha-Synuclein Aggregation

High-content imaging and biochemical readouts of alpha-synuclein accumulation in differentiated dopaminergic neurons.

high-content imaging immunocytochemistry

Direction: POSITIVE

Mitochondrial dysfunction

pathophysiology#Mitochondrial Dysfunction

Mitochondrial respiration, membrane-potential, and stress-state measurements across edited variants and corrected controls.

mitochondrial organization GO:0007005

mitochondrial respiration assay

Direction: NEGATIVE

Autophagy-lysosome pathway dysfunction

pathophysiology#Autophagy-Lysosome Pathway Dysfunction

Lysosomal function, autophagic flux, and transcriptomic readouts stratified by causal allele and rescue status.

autophagy GO:0006914

lysosomal function assay single-cell transcriptomic profiling

Direction: NEGATIVE

Dopaminergic neuron survival and identity

pathophysiology#Dopaminergic Neuron Loss

Cell survival, dopaminergic identity, and dopamine biosynthesis readouts after differentiation.

dopamine biosynthetic process GO:0042416

high-content imaging targeted transcriptomic profiling

Direction: NEGATIVE

Controls

Isogenic unedited parental hPSC line

Same genetic background without Parkinson-associated edits.

Corrected rescue alleles

Reciprocal correction of disease alleles where editing design allows.

Decision criterion

A mechanism is prioritized when multiple independently edited clones for the same variant show a reproducible phenotype that is attenuated by isogenic correction and maps to a declared pathophysiology node.

Would support

pathophysiology#Alpha-Synuclein Aggregation pathophysiology#Mitochondrial Dysfunction pathophysiology#Autophagy-Lysosome Pathway Dysfunction pathophysiology#Dopaminergic Neuron Loss

Would refute

pathophysiology#Alpha-Synuclein Aggregation pathophysiology#Mitochondrial Dysfunction pathophysiology#Autophagy-Lysosome Pathway Dysfunction

Show evidence (3 references)

PMID:38405931 SUPPORT In Vitro

"we generated a collection of 65 human stem cell lines genetically engineered to harbor high risk or causal variants in genes associated with PD"

Demonstrates the feasibility of a large isogenic hPSC Parkinson variant collection for mechanism-resolved experiments.

PMID:38405931 SUPPORT In Vitro

"rigorous quality controls, including whole-genome sequencing of each line."

Supports WGS-QC as a design requirement for the proposed panel.

+ 1 more reference

Show evidence (1 reference)

PMID:38405931 SUPPORT In Vitro

"Our iSCORE-PD collection represents an easily accessible and valuable platform to study PD, which can be used by investigators to understand the molecular pathophysiology of PD in a human cellular setting."

Establishes the existence of a human isogenic hPSC resource for studying Parkinson molecular pathophysiology, while the specific knowledge gap remains the standardized phenotype-to-mechanism adjudication.

Weight loss is a long-observed non-motor symptom of Parkinson disease, yet its mechanisms remain incompletely understood. Which of the proposed pathways — metabolic dysregulation, neuroendocrine disruption, gastrointestinal dysfunction, cognitive decline, and pharmacologic effects — are primary drivers versus secondary consequences, and how do they interact across the disease course?

KNOWLEDGE GAP OPEN gap_pd_weight_loss_multifactorial_mechanisms

Attached to

pathophysiology#Dopaminergic Neuron Loss pathophysiology#Intestinal Inflammation and Barrier Dysfunction pathophysiology#Basal Ganglia Circuit Dysfunction

Weight loss exerts substantial morbidity and mortality in PD, yet limited mechanistic understanding constrains treatment options. The Gabriel et al. (2026) review identifies six interacting pathways: (1) metabolic dysregulation (altered energy expenditure or intake), (2) neuroendocrine disruption (leptin/ghrelin/GLP-1 signaling), (3) gastrointestinal dysfunction (dysmotility, malabsorption, barrier dysfunction), (4) cognitive decline (reduced appetite awareness), (5) dopaminergic-medication effects (appetite suppression), and (6) brain stimulation paradoxes (DBS-induced weight changes). The relative contribution and temporal ordering of these mechanisms remain unknown. Resolving cross-mechanism interactions would enable targeted metabolic interventions in PD.

Proposed experiments

Longitudinal weight loss phenotype stratification with multi-mechanism readouts

longitudinal multi-omics observational cohort study

exp_pd_weight_loss_longitudinal_mechanisms

Follow a large PD cohort with serial body composition (DXA, bioimpedance), resting metabolic rate, circulating metabolic hormones (leptin, adiponectin, GLP-1, ghrelin), dopamine-agonist doses and appetite-affecting medications, cognitive testing, gastrointestinal symptom questionnaires, and GI transit imaging. Stratify the cohort into weight-loss phenotypes (progressive vs. stable) and identify mechanistic signatures.

Readouts

Metabolic rate and body composition trajectories

pathophysiology#Dopaminergic Neuron Loss

Measure resting metabolic rate, energy expenditure, and changes in lean vs. fat mass to distinguish metabolic dysregulation from reduced intake.

indirect calorimetry dual-energy X-ray absorptiometry

Direction: NEGATIVE

Circulating neuroendocrine hormone patterns

pathophysiology#Dopaminergic Neuron Loss

Quantify leptin, ghrelin, adiponectin, GLP-1, and other appetite-regulating hormones to identify dysregulation of satiety/hunger signaling.

serum hormone quantification

Direction: NEGATIVE

Gastrointestinal function and symptoms

pathophysiology#Intestinal Inflammation and Barrier Dysfunction

Assess gastric emptying (breath test), small-bowel transit, colonic function, permeability markers (zonulin, calprotectin), and GI symptom severity to establish causal vs. consequential GI involvement.

gastric-emptying scintigraphy fecal calprotectin assay

Direction: NEGATIVE

Cognitive decline severity

pathophysiology#Basal Ganglia Circuit Dysfunction

Administer validated cognitive batteries (MoCA, MMSE) and assess appetite awareness to test the cognitive-suppression hypothesis.

cognitive assessment battery

Direction: NEGATIVE

Decision criterion

Mechanistic dominance is supported by: (1) trajectories preceding or independent of weight loss (dysmetabolism, hormone changes, GI dysfunction); (2) stratification of the cohort into mechanistically distinct weight-loss phenotypes; (3) reproducible associations between mechanism-specific markers and subsequent weight-loss progression in converters.

Would support

pathophysiology#Dopaminergic Neuron Loss pathophysiology#Intestinal Inflammation and Barrier Dysfunction pathophysiology#Basal Ganglia Circuit Dysfunction

Show evidence (2 references)

PMID:41781031 SUPPORT Other

"weight loss has long been observed in PD and other neurodegenerative disorders, yet the mechanisms remain incompletely understood. This limited mechanistic insight has left few treatment options for weight loss in PD."

The Gabriel et al. review establishes weight loss as a significant yet mechanistically unexplained PD symptom, directly motivating this knowledge gap.

PMID:41781031 SUPPORT Other

"Emerging research highlights the role of metabolic regulation, neuroendocrine signaling, pharmacologic treatment, cognitive decline, gastrointestinal dysfunction, and brain stimulation in shaping weight trajectories in PD."

This enumerates the six candidate mechanisms for weight loss in PD, supporting the multi-pathway framing of the gap.

Can brain-first versus body-first origin site be operationalized as a measurable layer of the biological staging frameworks for Parkinson disease, and does origin-site stratification carry mechanistic or prognostic information that the existing anchors and data-driven subtypes do not already capture?

KNOWLEDGE GAP OPEN gap_pd_origin_site_operationalization

Attached to

mechanistic_hypotheses#body_first_enteric_alpha_synuclein_model mechanistic_hypotheses#brain_first_central_alpha_synuclein_model

Both origin-site hypotheses in this entry are curated as ALTERNATIVE, and both are assigned in practice from proxies - premotor REM-sleep behavior disorder, autonomic markers, imaging asymmetry - rather than from an observed first site of alpha-synuclein pathology. Two current biological definitions of the disease, the neuronal alpha-synuclein disease integrated staging system and SynNeurGe, are built on alpha-synuclein seeding, neurodegeneration, genetics, and functional impairment; neither carries an origin-site axis. That is an implementation gap rather than evidence against either model, and it should not be read as a scientific qualification of the mechanism. But it leaves the practical question unanswered: no consensus operational definition of origin site exists, so origin-site subtype membership is not portable between cohorts, and there is no agreed way to record it alongside a biological stage. The prognostic side of the question is not favorable either - a 10-year PPMI comparison found that data-driven subtypes separate rapid progressors more efficiently than the pathological brain-first/body-first labels do. That comparison measures prognostic enrichment, not anatomical origin, so it does not test either mechanism; it does mean the case for adding an origin-site layer has to rest on mechanistic rather than prognostic grounds.

Recorded from the 2026 OpenScientist hypothesis-search reports for both origin-site models, which independently raise the missing origin-site layer as a curation-level knowledge gap. The two staging-framework citations and the progression-milestone comparison ground claims that the mechanistic_hypotheses notes previously asserted without references. An earlier preprint of the milestone comparison (PMID:40678221) reported lower milestone proportions (50%, 43%, 42%) than the final publication cited here; cite the published version.

Show evidence (3 references)

PMID:38267190 SUPPORT Other

"Our biological definition establishes a staging system, the neuronal α-synuclein disease integrated staging system (NSD-ISS), rooted in the biological anchors (S and D) and the degree of functional impairment caused by clinical signs or symptoms."

Names the anchors of the NSD-ISS - alpha-synuclein seeding, dopaminergic dysfunction, and functional impairment - none of which encodes where pathology began, which is the gap this discussion records.

PMID:39973492 SUPPORT Other

"However, SynNeurGe provides a broader, more flexible framework that integrates α-synuclein pathology (S), neurodegeneration (N), and genetics (G), linked to clinical features (C)."

The competing biological classification is organized on the same kind of axes, so the absence of an origin-site layer is common to both frameworks rather than particular to one.

PMID:42286020 SUPPORT Human Clinical

"Data-driven subtypes exhibited the highest progression rates, with DM patients attaining 63.0% of milestones, surpassing PIGD (55.6%) and body-first (54.0%) subtypes."

Quantifies the prognostic half of the gap in the PPMI cohort: the body-first label is outperformed by a data-driven subtype for identifying rapid progressors. This bears on the utility of origin-site stratification for trial design, not on whether central or peripheral initiation occurs.

⚙

Pathophysiology

Dopaminergic Neuron Loss

Progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta is the core neuropathological lesion of Parkinson's disease. Motor signs emerge once an estimated 60-80% of these neurons are lost and the resulting loss of nigrostriatal dopamine input can no longer be compensated.

Dopaminergic Neuron CL:0000700

Dopamine Biosynthesis GO:0042416

substantia nigra UBERON:0002038

Downstream

Striatal Dopamine Deficiency Degeneration of substantia nigra pars compacta neurons removes the nigrostriatal projection, depleting dopamine in the striatum.

Show evidence (1 reference)

PMID:37048085 SUPPORT

"Tremor, shaking, movement problems, and difficulty with balance and coordination are among the hallmarks, and dopaminergic neuronal loss in substantia nigra pars compacta of the brain and aggregation of intracellular protein α-synuclein are the pathological characterizations."

This review confirms that dopaminergic neuronal loss in the substantia nigra pars compacta is a pathological hallmark of Parkinson's disease, supporting the core mechanism of dopaminergic neuron degeneration.

Striatal Dopamine Deficiency

Degeneration of nigrostriatal dopaminergic terminals depletes dopamine in the striatum, the principal input nucleus of the basal ganglia. Reduced striatal dopamine withdraws normal modulation of medium spiny projection neurons and is the proximate biochemical deficit linking nigral neuron loss to the motor features of Parkinson's disease.

Striatal medium spiny neuron CL:1001474

Dopaminergic synaptic transmission GO:0001963 ↓ DECREASED Dopamine Secretion GO:0014046 ↓ DECREASED

striatum UBERON:0002435

Computational models

Whole Dopaminergic Neuron SBML Model KINETIC Models dopamine synthesis, storage, release, reuptake, and degradation in dopaminergic-neuron physiology.

PD Map Cohort-Specific Probabilistic Boolean Models BOOLEAN NETWORK CaSQ, pyMaBoSS, CellDesigner Dopamine transcription pathways are among the enriched PD map diagrams converted to Boolean models and show distinct behaviour across subtypes.

Downstream

Basal Ganglia Circuit Dysfunction Loss of striatal dopamine unbalances the direct and indirect basal ganglia pathways.

Show evidence (1 reference)

PMID:28332488 SUPPORT

"Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease."

This review identifies striatal dopamine deficiency as a defining neuropathological hallmark of Parkinson's disease.

Basal Ganglia Circuit Dysfunction

Striatal dopamine loss shifts the basal ganglia-thalamocortical motor circuit toward excessive inhibitory output: the indirect pathway becomes hyperactive and the direct pathway hypoactive, increasing inhibitory drive from the globus pallidus pars interna onto the motor thalamus and cortex. This aberrant circuit activity, rather than neuron loss alone, generates the cardinal motor signs of Parkinson's disease.

Striatal medium spiny neuron CL:1001474 GABAergic neuron CL:0000617

GABAergic synaptic transmission GO:0051932 ↕ DYSREGULATED

basal ganglia UBERON:0002420

Computational models

Basal Ganglia Spiking Neural Network PHYSIOLOGICAL Models dopamine-modulated basal ganglia circuit dynamics, beta-band oscillations, and DBS effects.

Downstream

Resting Tremor

Bradykinesia

Rigidity

Postural Instability

Show evidence (2 references)

PMID:18781672 SUPPORT

"The parkinsonian state is characterized by disruption of the internal balance of the BG leading to hyperactivity in the two main entry points of the network (striatum and STN) and excessive inhibitory output from the GPi."

This review characterizes the parkinsonian basal ganglia by disrupted internal balance and excessive inhibitory GPi output, supporting basal ganglia circuit dysfunction as a distinct mechanism node.

PMID:30897356 SUPPORT

"We will then describe the basal ganglia-thalamocortical circuit, the major locus of PD-related circuit dysfunction, and some of the models that have influenced its study."

This review identifies the basal ganglia-thalamocortical circuit as the major locus of PD-related circuit dysfunction.

Alpha-Synuclein Aggregation

Misfolded alpha-synuclein protein accumulates to form Lewy bodies and Lewy neurites. These aggregates spread through the nervous system in a prion-like manner, contributing to neurodegeneration.

inclusion body assembly GO:0070841

Computational models

Alpha-Synuclein Aggregation BST Model KINETIC Models alpha-synuclein aggregation kinetics and degradation-pathway effects in dopaminergic neurons.

Alpha-Synuclein Prion-like Spreading Model AGENT BASED Models connectome-based propagation of misfolded alpha-synuclein pathology.

Downstream

Dopaminergic Neuron Loss

Neuroinflammation

Show evidence (3 references)

PMID:38245249 SUPPORT

"Parkinson's disease is a progressive neurodegenerative condition associated with the deposition of aggregated α-synuclein."

This authoritative Lancet review establishes that aggregated α-synuclein deposition is a defining feature of Parkinson's disease pathogenesis.

PMID:38245249 SUPPORT

"Biochemical studies, investigation of transplanted neurons in patients with Parkinson's disease, and cell and animal model studies suggest that abnormal aggregation of α-synuclein and spreading of pathology between the gut, brainstem, and higher brain regions probably underlie the development..."

This provides direct evidence for the prion-like spreading mechanism of α-synuclein pathology across neural networks, supporting the mechanism of trans-neuronal propagation.

PMID:36598534 SUPPORT

"Parkinson's disease (PD) is the second most common neurodegenerative disease, and is characterized by accumulation of α-synuclein (α-syn)."

Confirms that α-synuclein accumulation is a key pathological characterization of PD, reinforcing the central role of protein aggregation in disease pathology.

Mitochondrial Dysfunction

Impaired mitochondrial function, particularly complex I deficiency, leads to oxidative stress and neuronal death. Multiple PD genes (PINK1, Parkin, DJ-1) regulate mitochondrial quality control.

mitochondrion organization GO:0007005

Computational models

Whole Dopaminergic Neuron SBML Model KINETIC Models mitochondrial metabolism alongside dopamine handling in dopaminergic neurons.

Downstream

Dopaminergic Neuron Loss

Show evidence (4 references)

PMID:38245249 SUPPORT

"At a cellular level, abnormal mitochondrial, lysosomal, and endosomal function can be identified in both monogenic and sporadic Parkinson's disease, suggesting multiple potential treatment approaches."

This establishes that mitochondrial dysfunction is a common cellular feature across both genetic and sporadic forms of PD, supporting its central role in disease pathogenesis.

PMID:25611507 SUPPORT

"Biochemical and genetic studies reveal that the products of two genes that are mutated in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together in the same pathway to govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved in..."

This directly supports the role of PINK1 and Parkin genes in mitochondrial quality control and confirms that mitochondrial damage is involved in PD pathogenesis.

PMID:27911343 SUPPORT

"For the past 30 years, mitochondrial dysfunction has been hypothesized to play a central role in the pathobiology of this devastating neurodegenerative disease. The identifications of mutations in genes encoding PINK1 (PTEN-induced kinase 1) and Parkin (E3 ubiquitin ligase) in familial PD and..."

This review confirms the long-standing central role of mitochondrial dysfunction in PD and validates the connection between PINK1/Parkin mutations and mitochondrial quality control defects.

+ 1 more reference

PGC-1alpha Transcriptional Program Repression

Reduced activity of the PPARGC1A-encoded transcriptional coactivator PGC-1alpha downregulates the nuclear-encoded bioenergetic program it drives - mitochondrial biogenesis, respiratory-chain subunit expression, and antioxidant defenses - in nigral dopaminergic neurons. Two routes converge on this node. In the parkin-dependent route, loss of parkin E3 ligase function allows its substrate PARIS (ZNF746) to accumulate and transcriptionally repress the PPARGC1A promoter. In sporadic disease, PGC-1alpha-responsive bioenergetic gene sets are already underexpressed in laser-captured human nigral dopaminergic neurons at subclinical stages, placing this lesion early in the cascade rather than as a terminal consequence of neuron loss. The therapeutic corollary is not symmetric: restoring PGC-1alpha rescues dopaminergic neurons in cellular models, but sustained supraphysiological expression is itself toxic to the nigrostriatal system (see the HUMAN_MODEL_MISMATCH discussion pd_pgc1a_therapeutic_window).

nigral dopaminergic neuron CL:0000700

mitochondrial biogenesis program GO:0007005 ↓ DECREASED

transcription coactivator activity GO:0003713 ↓ DECREASED

Downstream

Mitochondrial Dysfunction Loss of PGC-1alpha coactivation lowers expression of nuclear-encoded respiratory-chain subunits, producing the electron-transport deficit already curated on the Mitochondrial Dysfunction node.

Oxidative Stress PGC-1alpha coordinates the antioxidant arm of the mitochondrial stress response, so its repression lowers reactive-oxygen-species buffering capacity in nigral neurons.

Show evidence (3 references)

PMID:21376232 SUPPORT Human Clinical

"PARIS is a KRAB and zinc finger protein that accumulates in models of parkin inactivation and in human PD brain."

Establishes that the repressor upstream of PGC-1alpha accumulates in human Parkinson disease brain, not only in experimental models.

PMID:21376232 SUPPORT Model Organism

"Conditional knockout of parkin in adult animals leads to progressive loss of dopamine (DA) neurons in a PARIS-dependent manner."

Genetic epistasis in adult conditional parkin knockout mice shows the dopaminergic loss is routed through PARIS, the PPARGC1A repressor.

PMID:20926834 SUPPORT Human Clinical

"Genes controlling cellular bioenergetics that are expressed in response to peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) are underexpressed in Parkinson's disease patients."

Direct human transcriptomic evidence that the PGC-1alpha-responsive program is underexpressed in Parkinson disease, which is the claim this node asserts.

MAPK Dysregulation

Dysregulation of mitogen-activated protein kinase (MAPK) signaling, particularly through overactivation of the JNK and p38 cascades, accelerates neurodegeneration and promotes alpha-synuclein accumulation and microglial activation. While basal MAPK activity is essential for neuroprotection and neuronal growth, pathological MAPK overactivation inhibits neuroprotective PI3K/AKT and PP2A pathways and activates detrimental GSK-3β and PTEN signaling, driving dopaminergic neurotoxicity.

Dopaminergic Neuron CL:0000700 Microglia CL:0000129

MAPK cascade GO:0000165 ↑ INCREASED JNK cascade GO:0007254 ↑ INCREASED p38MAPK cascade GO:0038066 ↑ INCREASED

Downstream

Alpha-Synuclein Aggregation MAPK dysregulation promotes alpha-synuclein accumulation.

Neuroinflammation MAPK overactivation drives microglial activation and pro-inflammatory cytokine release.

Dopaminergic Neuron Loss MAPK-driven oxidative stress, impaired neuroprotection, and neuroinflammation converge to promote dopaminergic neurotoxicity.

Show evidence (2 references)

PMID:42320726 SUPPORT Other

"While basal MAPK activity is essential for neuroprotection and neuronal growth, its overactivation, specifically via the JNK and p38 cascades, accelerates neurodegeneration."

This review establishes MAPK/JNK/p38 overactivation as a central driver of PD neurodegeneration, providing strong evidence for MAPK dysregulation as a distinct pathophysiological node.

PMID:42320726 SUPPORT Other

"highlights critical crosstalk between MAPK and other vital pathways, including the inhibition of the neuroprotective PI3K/AKT and PP2A pathways and the detrimental activation of GSK-3β and PTEN signaling."

This describes the broader signaling context of MAPK dysregulation, including inhibition of neuroprotective and activation of pro-degenerative pathways.

Neuroinflammation

Sustained glial activation in the PD brain, driven principally by microglia, with pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6), M1-like phenotype polarization, and complement cascade activation. Reactive astrocytes feed this state through their own release of inflammatory mediators; that arm is modeled separately as Reactive Astrogliosis.

Microglia CL:0000129 Astrocyte CL:0000127

TNF-alpha production GO:0032640 ↑ INCREASED IL-1beta production GO:0032611 ↑ INCREASED IL-6 production GO:0032635 ↑ INCREASED

Downstream

Dopaminergic Neuron Loss

Complement C3-C3aR Activation in Depression Microglial neuroinflammation drives complement cascade activation (C3-C3aR axis) as part of the broader innate immune response, with convergent upregulation of complement and coagulation pathways in depression associated with PD. This complement-mediated branch contributes to depression-like behavior via microglial synaptic pruning, distinct from dopaminergic motor pathology.

Show evidence (3 references)

PMID:38245249 SUPPORT

"Recent work has also highlighted maladaptive immune and inflammatory responses, possibly triggered in the gut, that accelerate the pathogenesis of Parkinson's disease."

This establishes that maladaptive immune and inflammatory responses play an active role in accelerating PD pathogenesis, supporting the neuroinflammation mechanism.

PMID:37048085 SUPPORT

"Neuroinflammation has emerged as an involving mechanism at the initiation and development of PD. It is a complex network of interactions comprising immune and non-immune cells in addition to mediators of the immune response. Microglia, the resident macrophages in the CNS, take on the leading..."

This directly supports the role of microglia-mediated neuroinflammation in PD initiation and progression, confirming the importance of microglial activation in disease pathology.

PMID:36598534 SUPPORT

"Neuroinflammation driven by microglia is an important pathological manifestation of PD. α-Syn is a crucial marker of PD, and its accumulation leads to microglia M1-like phenotype polarization, activation of NLRP3 inflammasomes, and impaired autophagy and phagocytosis in microglia."

This links α-synuclein accumulation to microglial activation and pro-inflammatory M1 phenotype polarization, supporting the mechanism by which neuroinflammation contributes to neurodegeneration in PD.

Reactive Astrogliosis

Conversion of astrocytes from a homeostatic, broadly neuroprotective state — neurotrophic factor secretion, blood-brain barrier regulation, and water-electrolyte and glutamate homeostasis — to a reactive state that releases inflammatory mediators, fails to clear synaptic glutamate, and triggers oxidative stress. Studies indicate that mutations in PD-associated genes may induce functional alterations in astrocytes; the cited review names no individual genes, so no per-gene claim is made here. Whether astrocytes protect or accelerate dopaminergic degeneration is regulated by bidirectional astrocyte-neuron and astrocyte-glia crosstalk.

Astrocyte CL:0000127

Astrocyte activation GO:0048143 ↑ INCREASED Astrocytic clearance of synaptic glutamate GO:0098712 ↓ DECREASED

Downstream

Dopaminergic Neuron Loss

Neuroinflammation Reactive astrocytes release inflammatory mediators, adding an astrocytic arm to the glial inflammatory state that microglia principally drive.

Oxidative Stress

Blood-Brain Barrier Dysfunction Astrocytes are one of the cell types regulating the blood-brain barrier, so loss of that homeostatic function on reactive conversion is a route into barrier breakdown. The cited review establishes the astrocytic BBB-regulatory role but does not itself report barrier breakdown caused by reactive astrocytes, so this edge is left uncited rather than over-claimed.

Show evidence (2 references)

PMID:42599550 SUPPORT Other

"Recent studies indicate that mutations in PD-associated genes may induce functional alterations in astrocytes."

Supports a genetic contribution to astrocyte dysfunction in PD, hedged as "may induce functional alterations" and naming no individual gene.

PMID:42599550 SUPPORT Other

"Furthermore, bidirectional regulatory interactions exist between astrocytes and both dopaminergic neurons and other glial cells in PD."

Identifies bidirectional astrocyte-neuron and astrocyte-glia crosstalk as the regulator of which arm predominates.

Complement C3-C3aR Activation in Depression

Elevated complement cascade activation, particularly the C3-C3aR signaling axis, drives microglial synaptic engulfment and loss. In depression associated with Parkinson disease, hippocampal complement components (C1Q, C3, C3aR) and downstream signaling (p-STAT3, p-P65) are upregulated, promoting microglial phagocytosis of synapses and contributing to depressive symptoms. This represents a distinct complement-mediated pathogenic pathway in depression, separable from canonical dopaminergic motor circuit involvement.

Microglia CL:0000129

complement activation GO:0006956 ↑ INCREASED synapse pruning GO:0098883 ↑ INCREASED

hippocampal formation UBERON:0002421

Downstream

Depression Complement C3-C3aR-mediated microglial synaptic engulfment leads to hippocampal synaptic loss and dysfunction, manifesting as depression and mood disturbance in Parkinson disease.

Show evidence (3 references)

PMID:42263400 SUPPORT Model Organism

"In MPTP-treated male and female mice, hippocampal complement components (C1Q, C3, C3aR) and downstream signalling (p-STAT3, p-P65) were elevated, accompanied by microglial synapse phagocytosis and depressive-like behaviours."

MPTP mouse model demonstrates upregulation of complement cascade components in hippocampus alongside microglial synaptic phagocytosis and depression-like behaviors, establishing the complement pathway as a mechanism driving depression in PD.

PMID:42263400 SUPPORT Human Clinical

"DPD exhibits distinct sex-specific immune signatures, with convergent complement pathway activation driving microglial synaptic pruning and depressive symptoms."

Human plasma proteomic analysis from PPMI cohort reveals that depression in PD exhibits sex-specific complement pathway dysregulation, establishing complement activation as a mechanism contributing to depressive symptoms.

PMID:42263400 SUPPORT Model Organism

"The antidepressant effect of BoNT/A is mediated through inhibition of the C3-C3aR signalling axis."

Mouse model studies demonstrate that complement pathway inhibition (via BoNT/A blocking C3-C3aR signaling) alleviates depressive-like symptoms and reduces microglial synaptic engulfment, providing mechanistic validation of C3-C3aR as a therapeutic target in depression.

Autophagy-Lysosome Pathway Dysfunction

Impairment of the autophagy-lysosome pathway disrupts clearance of misfolded proteins including alpha-synuclein. Multiple PD genes (GBA, LRRK2, VPS35, ATP13A2) regulate lysosomal function, and their mutations impair protein degradation capacity leading to toxic protein accumulation.

Dopaminergic Neuron CL:0000700

Autophagy GO:0006914 Chaperone-mediated Autophagy GO:0061684

Computational models

PD Map Cohort-Specific Probabilistic Boolean Models BOOLEAN NETWORK CaSQ, pyMaBoSS, CellDesigner PRKN mitophagy is one of the enriched PD map pathways converted into a cohort-parameterised Boolean model, and autophagy/mitophagy activity is one of the axes on which the subtypes separate.

Downstream

Alpha-Synuclein Aggregation

Dopaminergic Neuron Loss

Show evidence (1 reference)

PMID:31761667 SUPPORT

"In recent years, multiple lines of evidence from human genetic and molecular studies have highlighted the importance of the autophagy lysosomal pathway (ALP) in Parkinson's disease (PD). Genes such as GBA and LRRK2, which harbor some of the most common mutations associated with PD, have..."

This review establishes the genetic basis for autophagy-lysosome dysfunction in PD, identifying key genes and their mechanistic roles.

LRRK2 GTPase Domain Dysregulation

Leucine-rich repeat kinase 2 (LRRK2) mutations disrupt the conformational dynamics of its ROC (Ras of complex proteins) G-domain, impairing GTPase activity and nucleotide (GTP/GDP) cycling. The arginine residue at position 1398 acts as a critical GTP-γ-phosphate sensor that regulates the ROC domain's active-to-inactive state transition. Pathogenic ROC/GTPase-domain mutations (e.g., R1441C/G/H) impair GTP hydrolysis, stabilize the constitutively active GTP-bound state, and enhance Rab29-dependent recruitment of LRRK2 to the trans-Golgi network. This dysregulation impairs vesicular trafficking, autophagosome-lysosome fusion, and clearance of alpha-synuclein aggregates, promoting neurodegeneration. Protective variants (e.g., R1398H) stabilize the GDP-bound inactive state and reduce disease risk, suggesting that GTPase domain normalization rather than kinase inhibition may be a disease-modifying therapeutic strategy.

Dopaminergic neuron CL:0000700 Neuron CL:0000540

LRRK2 hgnc:18618

Autophagy GO:0006914 ↓ DECREASED Intracellular protein localization GO:0008104 ↕ DYSREGULATED Vesicle-mediated transport GO:0016192 ↓ DECREASED

Downstream

Autophagy-Lysosome Pathway Dysfunction Dysregulated LRRK2 GTPase activity impairs Rab29-dependent autophagosome-lysosome fusion and alpha-synuclein clearance.

Dopaminergic Neuron Loss Impaired protein clearance and autophagy promote accumulation of toxic protein aggregates and neuronal death.

Show evidence (3 references)

PPR:PPR1263597 Preprint · not peer-reviewed SUPPORT In Vitro

"A naturally occurring protective variant, R1398H, provides an alternative route for understanding how reduced disease risk may be achieved by tuning the regulatory GTPase domain rather than the kinase domain itself."

Preprint demonstrates that GTPase domain tuning via protective R1398H variant may be a disease-modifying strategy, supporting the model that ROC domain conformational control is critical for LRRK2-related PD.

PPR:PPR1263597 Preprint · not peer-reviewed SUPPORT In Vitro

"Purified ROC carrying R1398H is folded but resolves as a stable homodimer corresponding to the GDP-bound off state previously defined for wild-type ROC."

Biochemical analysis demonstrates that the protective R1398H variant stabilizes the inactive GDP-bound state, providing structural evidence for GTPase domain regulation as a disease-modifying mechanism.

PPR:PPR1263597 Preprint · not peer-reviewed SUPPORT In Vitro

"R1398H reduces GTP hydrolysis, selectively weakens GTP-state stabilization while preserving GDP binding, and decreases Rab29-dependent trans-Golgi recruitment of full-length LRRK2."

The protective variant reduces aberrant trans-Golgi recruitment, supporting the model that GTPase domain normalization may prevent pathological LRRK2 localization and consequent autophagy impairment.

Gut Microbiome Dysbiosis

Parkinson disease cohorts show reproducible but modest gut microbiome shifts, including depletion of short-chain-fatty-acid-producing taxa and enrichment of genera linked to mucin or inflammatory biology. In the body-first model, dysbiosis is modeled as a plausible upstream trigger or modifier of intestinal inflammation and barrier dysfunction, not as an established direct cause of alpha-synuclein initiation.

Body-First Enteric α-Synuclein Initiation Model

Enteroendocrine Cell CL:0000164

intestine UBERON:0000160

Downstream

Intestinal Inflammation and Barrier Dysfunction PD-associated dysbiosis may promote a pro-inflammatory intestinal state and barrier dysfunction, but the direction and necessity of this link remain unresolved in humans.

Show evidence (2 references)

PMID:33692356 SUPPORT Human Clinical

"We found significant alterations in the PD-associated microbiome, which are robust to study-specific technical heterogeneities, although differences in microbiome structure between PD and controls are small."

Meta-analysis across ten 16S datasets supports a reproducible PD-associated gut microbiome signature, while noting small effect sizes.

PMID:36332796 SUPPORT Other

"Alterations in the gut microbiome and associated metabolites may contribute to pathogenesis in PD."

Review-level evidence supports gut microbiome changes as plausible contributors to PD pathogenesis, but not as proven initiators.

Intestinal Inflammation and Barrier Dysfunction

Sporadic Parkinson disease is associated with elevated intestinal inflammatory and permeability markers. These changes may create a local milieu that increases alpha-synuclein expression or exposes enteric neurons to amyloidogenic microbial or dietary compounds, but whether they initiate body-first PD or arise secondary to gut autonomic dysfunction remains open.

Body-First Enteric α-Synuclein Initiation Model

Inflammatory Response GO:0006954

Downstream

Enteric Alpha-Synuclein Seeding Local gut inflammation and barrier leakiness may increase enteric alpha-synuclein expression or amyloidogenic exposure, providing a permissive setting for enteric alpha-synuclein seeding.

Show evidence (2 references)

PMID:34220443 SUPPORT Human Clinical

"Calprotectin and zonulin are markers of intestinal inflammation and barrier permeability, respectively."

Establishes the measured marker interpretation for this intestinal inflammation and barrier dysfunction node.

PMID:34220443 SUPPORT Human Clinical

"Mean calprotectin was higher in PD, both in serum (14.26 mcg/ml ± 4.50 vs. 5.94 mcg/ml ± 3.80, p = 0.0125) and stool (164.54 mcg/g ± 54.19 vs. 56.19 mcg/g ± 35.88, p = 0.0048)."

Case-control data support elevated intestinal inflammatory markers in PD.

Enteric Alpha-Synuclein Seeding

In the body-first model, misfolded alpha-synuclein appears first in enteric or peripheral autonomic neural tissue and serves as the initiating seed for subsequent gut-to-brain spread. Direct causal support comes primarily from animal models that seed pathologic alpha-synuclein in the gastrointestinal wall.

Body-First Enteric α-Synuclein Initiation Model

Enteric Neuron CL:0007011

inclusion body assembly GO:0070841

enteric nervous system UBERON:0002005

Downstream

Vagal-Brainstem Alpha-Synuclein Propagation Enteric alpha-synuclein seeds can propagate first to vagal brainstem nuclei and then to additional brain regions.

Constipation Enteric or autonomic involvement is a plausible contributor to early constipation in body-first PD, but this edge remains clinically inferred.

Show evidence (2 references)

PMID:31255487 SUPPORT Model Organism

"fibrils were injected into the duodenal and pyloric muscularis layer"

The gut-to-brain transmission model experimentally seeds pathologic alpha-synuclein in the gastrointestinal wall.

PMID:34220443 SUPPORT Human Clinical

"The coexistence of an amyloidogenic gut microbiota with intestinal inflammation (leading to local overexpression of alpha-synuclein) and altered intestinal barrier permeability (exposing alpha-synuclein to the amyloidogenic xenobiotics) may play a key role in triggering the initial..."

Human review/discussion within the marker study supports enteric alpha-synuclein seeding as a plausible but not proven event in some sporadic PD cases.

Vagal-Brainstem Alpha-Synuclein Propagation

Pathologic alpha-synuclein seeded in the gastrointestinal wall can propagate through vagal connections to the dorsal motor nucleus, nucleus tractus solitarius, caudal hindbrain, and ultimately midbrain and forebrain regions. Vagotomy experiments provide the strongest causal evidence for this body-first conduit.

Body-First Enteric α-Synuclein Initiation Model

vagus nerve UBERON:0001759 midbrain UBERON:0001891

Downstream

Alpha-Synuclein Aggregation Vagal-brainstem propagation links gut-origin pathology to the broader central alpha-synuclein aggregation cascade.

Pontine Tegmental Alpha-Synuclein Pathology As vagal-brainstem propagation continues rostrally, the pontine tegmentum - the site of the REM-atonia-generating circuit - is reached ahead of the nigrostriatal and cortical structures that define overt motor and cognitive disease.

Show evidence (2 references)

PMID:31255487 SUPPORT Model Organism

"Analysis of human pathology led Braak to postulate that α-synuclein (α-syn) pathology could spread from the gut to brain via the vagus nerve."

Establishes the gut-to-brain vagal propagation hypothesis tested by the mouse transmission model.

PMID:39241780 SUPPORT Model Organism

"α-Syn and Tau co-pathology can propagate from the gut to the brain, triggering behavioral disorders."

Supports gut-to-brain propagation in a gut-inducible transgenic mouse system.

Pontine Tegmental Alpha-Synuclein Pathology

Braak staging places pontine tegmental involvement ahead of substantia nigra pathology in the same caudo-rostral progression that vagal-brainstem propagation follows. The pontine tegmentum houses the glutamatergic REM-on circuit whose descending limb generates REM sleep muscle atonia. In Parkinson disease the lesion at this site is degenerative rather than structural, narcoleptic, or drug-induced, and it arrives at a topographic stage that precedes the nigrostriatal degeneration defining overt motor disease.

Body-First Enteric α-Synuclein Initiation Model

glutamatergic REM-on neuron of the sublaterodorsal nucleus CL:0000540 ↓ DECREASED

inclusion body assembly GO:0070841

sublaterodorsal nucleus UBERON:8440035 pons UBERON:0000988 brainstem UBERON:0002298

Downstream

Loss of Descending Drive to Inhibitory Premotor Neurons Pathology involving the pontine REM-on glutamatergic population removes the excitatory drive its descending axons carry to medullary and spinal inhibitory premotor neurons.

Show evidence (3 references)

PMID:20187227 SUPPORT Human Clinical

"The proportion of cases that fit the PD staging scheme was 67% for incidental LBs; 86% for PSP with LBs; 86% for pure LBD; and 84% for LBD with AD"

Dickson's own autopsy series, rather than its statement of what Braak proposed: the caudo-rostral ordering that places pontine tegmental involvement before substantia nigra pathology holds in 84-86% of Lewy body disease cases. This is what licenses placing this node upstream of the nigrostriatal nodes in the pathograph.

PMID:17412731 SUPPORT Other

"The hypothesized pathophysiology of RBD is presented in relation to the Braak staging system for Parkinson's disease, in which the topography and temporal sequence of synuclein pathology in the brain could explain the evolution of parkinsonism and/or dementia well after the onset of RBD."

Ties the Braak sequence specifically to RBD pathophysiology rather than to brainstem involvement in general, which is the step that licenses placing this node upstream of the atonia nodes and that the staging paper alone does not make. Graded OTHER rather than HUMAN_CLINICAL because the quoted sentence states a hypothesis this Brain review advances, not a patient observation it reports - matching the grade `rem_sleep_atonia_control_failure.yaml` gives the comparable "is proposed as" sentence from the same paper.

PMID:39577924 SUPPORT Human Clinical

"In all participants, α-synuclein was found in the structures that regulate REM sleep atonia (eg, subcoeruleus nucleus, gigantocellular reticular nucleus, laterodorsal tegmentum, and amygdala)"

Places the pathology in the atonia-generating nuclei themselves, not merely somewhere in the pontine tegmentum. The pontine tegmentum is a large region and Braak stage 2 is classically locus coeruleus and caudal raphe, so without this the lesion claim would rest on the region-level ordering alone. Note the inferential step: this cohort is isolated RBD rather than diagnosed Parkinson disease, so it evidences the lesion topography rather than its presence in established PD.

Loss of Descending Drive to Inhibitory Premotor Neurons

REM atonia is actively imposed rather than passively permitted: the glutamatergic REM-on population excites glycinergic and GABAergic premotor neurons in the ventromedial medulla and spinal cord, which hyperpolarise skeletal motor neurons. Losing the descending drive therefore releases motor neurons from an inhibition that should be present. This descending pathway is separate from the ascending pathway that generates the EEG features of REM sleep, so it can be lost while REM sleep itself proceeds normally - which is what polysomnography shows in Parkinson disease.

Body-First Enteric α-Synuclein Initiation Model

glutamatergic synaptic transmission GO:0035249 ↓ DECREASED inhibitory regulation of skeletal motor neuron output GO:0006937 ↓ DECREASED

brainstem UBERON:0002298

Downstream

REM Sleep Muscle Atonia Loss Without descending excitation of the inhibitory premotor pool, skeletal motor neurons are not hyperpolarised during REM sleep and muscle tone persists.

Show evidence (2 references)

PMID:17884926 SUPPORT Model Organism

"In the REM-on area are two populations of glutamatergic neurons, the first of which projects to the basal forebrain and regulates EEG components of REM sleep and the second of which projects to the ventromedial medulla and spinal cord and regulates atonia during REM sleep."

The two-population anatomy this node depends on: a descending atonia limb separable from the ascending EEG limb.

PMID:17884926 SUPPORT Model Organism

"Our findings demonstrating independent pathways mediating atonia and the EEG components of REM provide a basis for their occasional dissociation in pathological states, e.g. REM sleep behaviour disorder."

States the dissociation explicitly and names RBD as its pathological instance, which is what permits atonia to fail here while REM sleep itself is preserved.

REM Sleep Muscle Atonia Loss

Excess tonic or phasic electromyographic activity during scored REM sleep, the measurable abnormality that underlies dream enactment in Parkinson disease. Polysomnography confirms REM sleep without atonia in the majority of PD patients studied - more often than the clinical behavioural history alone identifies - so the electrophysiological finding runs ahead of, and is more sensitive than, a clinical diagnosis of REM sleep behavior disorder.

REM sleep GO:0042747 ⚠ ABNORMAL skeletal muscle contraction during REM sleep GO:0003009 ↑ INCREASED

Downstream

REM Sleep Behavior Disorder Where atonia loss is accompanied by dream-enactment behaviour rather than remaining electrophysiologically silent, the released motor programmes generated during dreaming are enacted, producing the clinical phenotype.

Show evidence (2 references)

PMID:12196654 SUPPORT Human Clinical

"Nineteen (58%) of 33 patients with PD but only 1 of 16 control subjects had REM sleep without atonia."

Direct polysomnographic quantification of REM sleep without atonia in a PD cohort versus controls - the measurement this node's conformance claim requires.

PMID:12196654 SUPPORT Human Clinical

"One third of patients with PD met the diagnostic criteria of RBD based on PSG recordings."

Shows the polysomnographic finding is more prevalent than, and only partly overlaps with, a clinical RBD diagnosis - consistent with the module's requirement that the electrophysiological finding, not the behavioural history, is what satisfies conformance at this node.

Central Alpha-Synuclein Initiation

In the brain-first model, the initial alpha-synuclein pathology begins in central sites such as the olfactory bulb or amygdala, then spreads through connected brain regions and later to peripheral autonomic structures. This node captures the competing central-origin route without asserting that it applies to all Parkinson disease.

Brain-First Central α-Synuclein Initiation Model

Dopaminergic Neuron CL:0000700

inclusion body assembly GO:0070841

olfactory bulb UBERON:0002264 amygdala UBERON:0001876

Downstream

Alpha-Synuclein Aggregation Central initiation feeds into the broader alpha-synuclein aggregation and propagation cascade through connected brain networks.

Show evidence (6 references)

PMID:38519273 SUPPORT Human Clinical

"Molecular imaging studies were generally in agreement with the model, whereas structural imaging studies, such as MRI volumetry, showed conflicting findings."

Review-level synthesis supports the brain-first/body-first model while noting that not all imaging modalities agree.

PMID:32830221 SUPPORT Human Clinical

"the PDRBD- data were compatible with a brain-first trajectory, characterized by primary loss of putaminal FDOPA uptake followed by a secondary loss of cardiac MIBG signal and 11C-donepezil signal."

Primary PET, MIBG, MRI, and gut-transit imaging evidence supports the central-first route by identifying a de novo PD subgroup with primary putaminal dopaminergic dysfunction followed by peripheral autonomic loss.

PMID:40209563 SUPPORT Human Clinical

"The degeneration of amygdala is distinctively pronounced in "brain-first" Parkinson's disease, supporting differential disease progression patterns between subtypes."

Diffusion microstructure MRI gives the amygdala half of this node a human in vivo correlate: amygdala free interstitial fluid is higher in the brain-first group, matching the amygdala as a candidate central initiation site.

+ 3 more references

Oxidative Stress

Excessive reactive oxygen species from dopamine metabolism and mitochondrial dysfunction causes lipid peroxidation, protein carbonylation, and DNA damage. Dopamine auto-oxidation generates toxic quinones that preferentially damage substantia nigra neurons.

Dopaminergic Neuron CL:0000700

Response to Oxidative Stress GO:0006979 ROS Metabolic Process GO:0072593

Downstream

Mitochondrial Dysfunction

Dopaminergic Neuron Loss

Alpha-Synuclein Aggregation

Show evidence (1 reference)

PMID:37303175 SUPPORT

"Reactive oxygen species (ROS)-induced oxidative stress triggers the vicious cycle leading to the degeneration of dopaminergic neurons in the nigra pars compacta."

This review directly describes the mechanism by which oxidative stress drives dopaminergic neurodegeneration.

Calcium Dysregulation

Substantia nigra dopaminergic neurons rely on L-type calcium channels (CaV1.3) for autonomous pacemaking, making them uniquely vulnerable to calcium-mediated toxicity. Disrupted calcium homeostasis in mitochondria, ER, and lysosomes contributes to oxidative stress and cell death.

Dopaminergic Neuron CL:0000700

Calcium Ion Homeostasis GO:0055074 Calcium Ion Transport GO:0070588

Downstream

Mitochondrial Dysfunction

Oxidative Stress

Dopaminergic Neuron Loss

Show evidence (1 reference)

PMID:35339179 SUPPORT

"The dysregulation of VGCC activity has been reported in both Parkinson's disease (PD) and Huntington's (HD)."

This review establishes the fundamental role of calcium channel dysregulation in PD pathogenesis.

Endoplasmic Reticulum Stress

Accumulation of misfolded proteins in the ER activates the unfolded protein response (UPR). Chronic ER stress overwhelms protective mechanisms, triggering apoptotic pathways. Alpha-synuclein aggregates and GBA mutations directly impair ER function.

Dopaminergic Neuron CL:0000700

ER Stress Response GO:0034976 Unfolded Protein Response GO:0030968

Downstream

Autophagy-Lysosome Pathway Dysfunction

Dopaminergic Neuron Loss

Show evidence (1 reference)

PMID:38026955 SUPPORT

"Accumulating evidence shows that endoplasmic reticulum (ER) stress occurring in the SNpc DA neurons is an early event in the development of PD."

This review establishes ER stress as an early and central event in PD pathogenesis.

Synaptic Dysfunction

Impaired synaptic vesicle recycling, particularly defects in clathrin-mediated endocytosis, represents an early feature of PD. Multiple PD genes (DNAJC6, SYNJ1, LRRK2) regulate synaptic vesicle trafficking, and their dysfunction leads to synaptic failure before overt neurodegeneration.

Dopaminergic Neuron CL:0000700

Synaptic Vesicle Cycle GO:0099504 Synaptic Vesicle Endocytosis GO:0048488

Downstream

Dopaminergic Neuron Loss

Alpha-Synuclein Aggregation

Show evidence (1 reference)

PMID:38595283 SUPPORT

"Notably, several of these genes are linked to the synaptic vesicle recycling process, particularly the clathrin-mediated endocytosis pathway. This suggests that impaired synaptic vesicle recycling might represent an early feature of Parkinson's disease"

Establishes synaptic vesicle endocytosis dysfunction as an early feature of PD.

Iron Accumulation and Ferroptosis

Abnormal iron deposition in the substantia nigra promotes ferroptosis, an iron-dependent form of cell death characterized by lipid peroxidation. Iron catalyzes Fenton reactions generating hydroxyl radicals, and dysregulated iron metabolism contributes to oxidative damage.

Dopaminergic Neuron CL:0000700

Iron Ion Homeostasis GO:0006879 Ferroptosis GO:0097707

Downstream

Oxidative Stress

Dopaminergic Neuron Loss

Show evidence (1 reference)

PMID:39218077 SUPPORT

"Parkinson's disease (PD) is a prevalent and advancing age-related neurodegenerative disorder, distinguished by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Iron regional deposit in SNpc is a significant pathological characteristic of PD."

This review establishes iron accumulation as a significant pathological characteristic and mechanistic driver of PD.

Blood-Brain Barrier Dysfunction

Altered tight junction proteins, transporter dysfunction, and alpha-synuclein accumulation compromise BBB integrity. BBB breakdown allows infiltration of peripheral immune cells and blood-borne molecules, amplifying neuroinflammation.

Brain Endothelial Cell CL:2000044 Pericyte CL:0000669 Astrocyte CL:0000127

BBB Maintenance GO:0035633 Vascular Permeability GO:0043114

Downstream

Neuroinflammation

Dopaminergic Neuron Loss

Show evidence (2 references)

PMID:39075566 SUPPORT

"There is increasing evidence for blood-brain barrier (BBB) alterations in Parkinson's disease (PD), the second most common neurodegenerative disorder with rapidly rising prevalence."

This comprehensive 2024 review establishes BBB dysfunction as an emerging mechanism in PD pathogenesis.

PMID:42599550 SUPPORT Other

"As the most abundant glial cells in the central nervous system (CNS), astrocytes may exert neuroprotective effects through mechanisms including secretion of neurotrophic factors, regulation of the blood-brain barrier (BBB), and maintenance of water-electrolyte balance."

Supports the astrocyte among the cell types regulating the barrier, which is why this node carries astrocyte as a cell type.

Metabolic Dysfunction and Weight Loss

Parkinson disease is associated with progressive weight loss and metabolic dysregulation through multiple interacting mechanisms. Reduced metabolic rate, dysregulated appetite-regulating hormones (leptin, ghrelin, GLP-1), gastrointestinal dysfunction, cognitive decline affecting appetite awareness, dopaminergic-medication effects, and dopamine-dependent regulation of feeding behavior all contribute to systemic metabolic failure and weight loss. Weight loss occurs in a substantial fraction of PD patients and exerts significant morbidity and mortality, yet mechanistic understanding remains incomplete.

Metabolic process GO:0008152

Downstream

Weight Loss Metabolic dysregulation, reduced energy expenditure, neuroendocrine hormone imbalances, and gastrointestinal dysfunction converge to cause progressive weight loss and nutritional decline in PD.

Show evidence (1 reference)

PMID:41781031 SUPPORT Other

This 2026 review establishes weight loss as a significant, mechanistically complex, and undertreated symptom of Parkinson disease, establishing the rationale for a dedicated metabolic dysfunction mechanism node.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Digestive 1

Constipation FREQUENT HP:0002019

Common non-motor symptom

Show evidence (1 reference)

PMID:7845407 SUPPORT

"We investigated the role of anorectal manometry in evaluating constipation and anorectal function in 15 patients with Parkinson's disease (PD) and compared results with those of 9 patients with idiopathic constipation (IC) and 8 control (C) subjects."

This study directly evaluates constipation in PD patients, supporting constipation as a common non-motor symptom.

Head and Neck 1

Hyposmia FREQUENT HP:0004409

Often precedes motor symptoms by years

Show evidence (1 reference)

PMID:24136244 SUPPORT

"Hyposmia, identified as reduced sensitivity to odor, is a common non-motor symptom of Parkinson's disease (PD) that antedates the typical motor symptoms by several years. It occurs in ∼90% of early-stage cases of PD."

This establishes hyposmia as a highly prevalent prodromal symptom that precedes motor symptoms, supporting its importance as an early marker of PD.

Musculoskeletal 1

Rigidity VERY_FREQUENT HP:0002063

Cogwheel or lead-pipe rigidity

Show evidence (1 reference)

PMID:17955331 SUPPORT

"Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."

This confirms rigidity as a cardinal sign of parkinsonism relevant to PD.

Nervous System 8

Resting Tremor VERY_FREQUENT HP:0002322

Classic "pill-rolling" tremor at rest

Show evidence (1 reference)

PMID:17955331 SUPPORT

"Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."

This identifies resting tremor as a cardinal sign used to detect parkinsonism, supporting it as a core PD phenotype.

Bradykinesia VERY_FREQUENT HP:0002067

Slowness of movement, required for diagnosis

Show evidence (1 reference)

PMID:17955331 SUPPORT

"Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."

This lists bradykinesia among the cardinal signs of parkinsonism, supporting its central role in PD.

Postural Instability FREQUENT HP:0002172

Develops in later disease stages

Show evidence (1 reference)

PMID:17955331 SUPPORT

"Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."

This supports postural instability as a cardinal parkinsonian sign captured in PD assessments.

Depression FREQUENT HP:0000716

Show evidence (2 references)

PMID:41301797 SUPPORT

"Depressive symptoms were similar across groups, but in prodromal PD, higher GDS scores were associated with worse UPDRS III scores (p = 0.02), as well as higher freezing and fall scores."

This indicates depressive symptoms are present and clinically relevant in PD, supporting depression as a non-motor phenotype.

PMID:42646502 SUPPORT REVIEW SYNTHESIS Human Clinical

"PD patients reported more depression, especially with sleep problems, which also worsened anxiety. Factors like age, motor symptoms, and sleep disturbances relate to depression, while sleep issues are linked to anxiety."

Records the reported association between sleep disturbance and depression in PD. The quoted sentence is about sleep disturbance in general rather than REM sleep behavior disorder specifically, so it belongs on this phenotype; it makes no claim about cognition and recommends no therapy.

REM Sleep Behavior Disorder HP:5200291

Prodromal non-motor feature that often precedes motor onset by years and correlates with greater motor severity. Results from dysfunction of brainstem motor inhibition circuits during REM sleep.

Show evidence (3 references)

PMID:41301797 SUPPORT Human Clinical

"Constipation and REM sleep behavioral disorder were independent correlates of worse motor severity in prodromal and established PD"

This PPMI-cohort study establishes REM sleep behavior disorder as a non-motor feature of both prodromal and established Parkinson disease that independently correlates with greater motor severity.

PMID:42646502 SUPPORT REVIEW SYNTHESIS Human Clinical

"It results from dysfunction of the subcoeruleus and magnocellularis nuclei in the brainstem"

Names the brainstem lesion behind RBD. These nuclei are glutamatergic and glycinergic respectively, not dopaminergic, which is the clinical point of RBD in PD: it reflects non-dopaminergic brainstem degeneration that precedes nigral loss, and so appears in the prodromal phase.

PMID:42646502 SUPPORT REVIEW SYNTHESIS Human Clinical

"Dopamine influences motor and non-motor functions, including cognition, mood, sleep, sensory processes, and autonomic systems"

Records that sleep is among the non-motor functions dopamine influences. Kept deliberately narrow: the sentence states dopamine's range of influence, and does not assert depletion, a mechanism independent of motor circuits, or any claim specific to RBD.

Cognitive Impairment FREQUENT HP:0100543

Course: PROGRESSIVE

Spans mild cognitive impairment (typically executive and visuospatial deficits) through to Parkinson disease dementia; the risk of dementia rises with disease duration.

Show evidence (2 references)

PMID:34210995 SUPPORT Human Clinical

"In addition to the defining motor symptoms of PD, multiple non-motor symptoms occur; among them, cognitive impairment is common and can potentially occur at any disease stage."

This Nature Reviews Disease Primers review establishes cognitive impairment as a common non-motor feature of PD that can occur at any disease stage.

PMID:34210995 SUPPORT Human Clinical

"executive and visuospatial impairments are typical and can be accompanied by memory impairment, increasing the risk for early progression to dementia"

Describes the mild-cognitive-impairment-to-dementia progression that underpins the progressive clinical course of cognitive impairment in PD.

Dystonia HP:0001332

Involuntary sustained or intermittent muscle contractions causing abnormal postures. When present in PD, dystonia is predominantly focal, most commonly affecting the lower limbs, followed by cervical involvement, and is associated with advanced Hoehn and Yahr stage (≥3), younger age at PD onset, and shorter disease duration. A population prevalence of dystonia in PD is not established by the cited case-control study, so no frequency band is asserted.

Show evidence (4 references)

PMID:42430982 SUPPORT Human Clinical

"Focal dystonia was the predominant phenotype (75.0%), most commonly involving lower limbs, followed by cervical dystonia."

This clinical study characterizes the somatotopic distribution of dystonia in PD, showing that focal dystonia is the predominant form and lower-limb involvement is most common.

PMID:42430982 SUPPORT Human Clinical

"Data on 246 PD patients (164 with and 82 without dystonia) were analyzed."

Describes the case-control study composition (164 PD patients with dystonia versus 82 without, drawn from the same source population). The 164:82 split is the study's case:control sampling ratio, not a population prevalence, and does not by itself quantify how frequently dystonia occurs in PD.

PMID:42430982 SUPPORT Human Clinical

"advanced H&Y stage ≥3 (OR, 3.61; P = 0.002) was directly associated with it."

Establishes association between dystonia and advanced Hoehn and Yahr stage, supporting dystonia as a clinical marker of disease progression.

+ 1 more reference

Impulse Control Behaviors OCCASIONAL Impulsivity HP:0100710

Reward-seeking impulse control behaviors (gambling, hypersexuality, compulsive shopping, binge eating) represent a major behavioral comorbidity in PD, particularly in patients receiving dopamine agonist therapy. These behaviors arise from dopaminergic sensitization of reward-processing circuits and are distinct from classic obsessive-compulsive compulsions. Bound to HP:0100710 Impulsivity, which is the closest available HP term; preferred_term carries the more specific clinical concept. What HP lacks is a term for the dopaminergic-therapy-related ICB syndrome as such - one that distinguishes it from trait impulsivity and from HP:0000722 Compulsive behaviors - not a term for impulsivity. The frequency band is OCCASIONAL (5-29%): the meta-analytic point estimate is 19% (95% CI 15-24%) and the DOMINION cross-sectional estimate is 13.6%, so both the pooled estimate and its confidence interval sit inside that band.

Show evidence (4 references)

PMID:20457959 SUPPORT Human Clinical

"An ICD was identified in 13.6% of patients (gambling in 5.0%, compulsive sexual behavior in 3.5%, compulsive buying in 5.7%, and binge-eating disorder in 4.3%), and 3.9% had 2 or more ICDs."

Peer-reviewed point-prevalence estimate from 3090 patients at 46 movement disorder centres, with the four constituent behaviors counted separately. Corroborates the preprint meta-analysis and independently places the frequency in the OCCASIONAL band.

PPR:PPR1298507 Preprint · not peer-reviewed SUPPORT Human Clinical

"A random-effects meta-analysis of 27 studies (n = 17,906) found a mean event rate for at least one ICB in PD of 0.19 [95% CI = 0.15, 0.24]"

Pooled event rate across 27 studies, giving the 19% (95% CI 15-24%) estimate behind the OCCASIONAL band. A non-peer-reviewed preprint, cited alongside the peer-reviewed DOMINION prevalence above rather than as sole support.

PMID:20457959 SUPPORT Human Clinical

"Impulse control disorders were more common in patients treated with a dopamine agonist than in patients not taking a dopamine agonist (17.1% vs 6.9%; odds ratio [OR], 2.72; 95% confidence interval [CI], 2.08-3.54; P < .001)."

Quantifies dopamine agonist exposure as a risk factor for this phenotype, which is the peer-reviewed counterpart of the preprint's qualitative statement below.

+ 1 more reference

Growth 1

Weight Loss HP:0001824

Course: PROGRESSIVE

Progressive unintentional weight loss is a well-recognized non-motor feature of Parkinson disease, arising from multiple interacting mechanisms (metabolic dysregulation, neuroendocrine/appetite-hormone disruption, gastrointestinal dysfunction, cognitive decline, and medication effects). It carries substantial morbidity and mortality.

Show evidence (1 reference)

PMID:41781031 SUPPORT Other

Establishes weight loss as a long-recognized non-motor symptom of Parkinson disease with substantial clinical impact.

🧬

Genetic Associations

SNCA (Causative)

Gene: SNCA hgnc:11138 relationship_type: CAUSATIVE

Show evidence (2 references)

PMID:9197268 SUPPORT

"A mutation was identified in the alpha-synuclein gene, which codes for a presynaptic protein thought to be involved in neuronal plasticity, in the Italian kindred and in three unrelated families of Greek origin with autosomal dominant inheritance for the PD phenotype."

This landmark 1997 Science paper identified the first SNCA mutations in familial PD with autosomal dominant inheritance, establishing SNCA as a causative gene for Parkinson's disease.

CGGV:assertion_d21593ae-ed10-4442-8167-24f96f917302-2022-05-03T134931.425Z SUPPORT Other

ClinGen classifies the SNCA-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.

LRRK2 (Risk Factor)

Gene: LRRK2 hgnc:18618 relationship_type: CAUSATIVE

Show evidence (3 references)

PMID:19945904 SUPPORT

"The LRRK2 G2019S mutation is the most frequent known cause of familial and sporadic Parkinson's disease."

This systematic review establishes that LRRK2 G2019S is the most common genetic cause of both familial and sporadic PD, supporting its role as the major genetic risk factor.

CGGV:assertion_2728e13a-b95a-4c55-8cba-082260094ecd-2021-05-03T160000.000Z SUPPORT Other

ClinGen classifies the LRRK2-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.

PMID:38750146 SUPPORT Model Organism

"Chronic intestinal damage in genetically predisposed male mice promotes α-synuclein aggregation in the substantia nigra, loss of dopaminergic neurons and motor impairment."

Offers a candidate explanation for the incomplete, age-dependent penetrance recorded in the notes above: in human LRRK2 G2019S transgenic mice a prodromal gut-inflammatory insult is what converts the genotype into nigral alpha-synuclein aggregation, dopaminergic loss, and motor impairment, and the effect is restricted to males. Whether the same gene-environment interaction modifies penetrance in human carriers is untested.

PINK1 (Causative)

Gene: PINK1 hgnc:14581 relationship_type: CAUSATIVE

Show evidence (2 references)

PMID:25611507 SUPPORT

This identifies PINK1 mutations in autosomal recessive parkinsonism, supporting its causative role in PD.

CGGV:assertion_1999e6c4-eb15-438a-a4ea-98989112dcbb-2023-01-18T190000.000Z SUPPORT Other

ClinGen classifies the PINK1-Parkinson disease gene-disease relationship as definitive with autosomal recessive inheritance.

GBA1 (Risk Factor)

Gene: GBA1 hgnc:4177 relationship_type: RISK_FACTOR

Show evidence (2 references)

PMID:30097731 SUPPORT

"DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation at GBA and SNCA."

This identifies GBA as a genetic risk locus shared with PD, supporting its role as a PD risk factor.

CGGV:assertion_9201c03f-10de-447c-9b84-194f14b549b6-2022-05-03T134810.206Z SUPPORT Other

ClinGen classifies the GBA1-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.

PARK7 (Causative)

Gene: PARK7 hgnc:16369 relationship_type: CAUSATIVE

Show evidence (1 reference)

CGGV:assertion_d79439d2-844b-4ba6-aceb-e6b179eaaa01-2022-06-27T160000.000Z SUPPORT Other

ClinGen classifies the PARK7-Parkinson disease gene-disease relationship as definitive with autosomal recessive inheritance.

PRKN (Causative)

Gene: PRKN hgnc:8607 relationship_type: CAUSATIVE

Show evidence (2 references)

PMID:25611507 SUPPORT

This establishes Parkin (PRKN, formerly PARK2) as a gene mutated in autosomal recessive parkinsonism, supporting its causative role.

CGGV:assertion_6b39c4a0-f6bd-4afc-b2a7-f234eab5a667-2023-01-18T190000.000Z SUPPORT Other

ClinGen classifies the PRKN-Parkinson disease gene-disease relationship as definitive with autosomal recessive inheritance.

VPS35 (Causative)

Gene: VPS35 hgnc:13487 relationship_type: CAUSATIVE

Show evidence (1 reference)

CGGV:assertion_b0e546d6-8a44-4e9d-83aa-f781ec4ec166-2021-11-03T134517.796Z SUPPORT Other

ClinGen classifies the VPS35-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.

💊

Medical Actions

Levodopa/Carbidopa

Action: Pharmacotherapy NCIT:C15986

Agent: levodopa CHEBI:15765 carbidopa CHEBI:3395

Gold standard treatment, replaces dopamine precursor.

Mechanism Target:

RESTORES Striatal Dopamine Deficiency — Levodopa supplies dopamine precursor to partially restore dopaminergic signaling in dopamine-depleted striatal circuits.

Show evidence (1 reference)

PMID:27577098 SUPPORT

"The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."

This review identifies L-Dopa as a core pharmacotherapy for PD motor symptoms.

Dopamine Agonists

Action: Pharmacotherapy NCIT:C15986

Directly stimulate dopamine receptors. Carries a class-level risk of impulse control behaviors: dopamine agonist exposure raises the odds of an ICD roughly 2- to 3.5-fold, and the association holds across pramipexole and ropinirole rather than being specific to one agent. See the Impulse Control Behaviors phenotype.

Mechanism Target:

BYPASSES Striatal Dopamine Deficiency — Dopamine agonists bypass reduced endogenous dopamine by directly stimulating dopamine receptors in downstream circuits.

Show evidence (2 references)

PMID:27577098 SUPPORT

This review identifies dopamine agonists as part of standard pharmacotherapy for PD.

PMID:20457959 SUPPORT Human Clinical

"Dopamine agonist treatment in PD is associated with 2- to 3.5-fold increased odds of having an ICD. This association represents a drug class relationship across ICDs."

Establishes the impulse-control adverse effect as a property of the dopamine agonist drug class rather than of an individual agent, which is why it is recorded on this treatment entry and not only on the phenotype.

Impulse Control Behavior Management

Action: Therapeutic Procedure NCIT:C49236

Management of dopaminergic-therapy-related impulse control behaviors. The first-line step in practice is reduction or withdrawal of the dopamine agonist; the interventions studied beyond that are cognitive behavioural therapy, levodopa infusion, atomoxetine, naltrexone, valproic acid, and deep brain stimulation. The evidence base is small and preliminary - a narrative synthesis of 10 studies totalling 283 patients - so this is recorded as a treatable target rather than as established therapy.

Mechanism Target:

INHIBITS Impulse Control Behaviors — These interventions are studied as ways to reduce impulse control behaviors themselves, which is what connects this phenotype to the treatment graph.

Show evidence (1 reference)

PPR:PPR1298507 Preprint · not peer-reviewed SUPPORT Human Clinical

"A narrative synthesis of 10 studies (n = 283) found preliminary evidence for the effectiveness of cognitive behavioural therapy, levodopa infusion, atomoxetine, naltrexone, valproic acid, and deep brain stimulation in supporting ICB reduction."

The source for the intervention list and for the strength of the claim - preliminary evidence from a narrative synthesis, not pooled effect estimates.

MAO-B Inhibitors

Action: Pharmacotherapy NCIT:C15986

Prevent dopamine breakdown (selegiline, rasagiline).

Mechanism Target:

MODULATES Striatal Dopamine Deficiency — MAO-B inhibitors prolong dopamine signaling by reducing dopamine breakdown.

Show evidence (1 reference)

PMID:27577098 SUPPORT

This review lists MAO-B inhibitors among standard PD pharmacotherapies.

COMT Inhibitors

Action: Pharmacotherapy NCIT:C15986

Extend levodopa duration (entacapone).

Mechanism Target:

MODULATES Striatal Dopamine Deficiency — COMT inhibitors extend levodopa-derived dopaminergic signaling and indirectly modulate striatal dopamine deficiency.

Show evidence (1 reference)

PMID:27577098 SUPPORT

This review lists COMT inhibitors among standard PD pharmacotherapies.

Deep Brain Stimulation

Action: deep brain stimulation Ontology label: Deep Brain Stimulation NCIT:C21024

Surgical therapy for advanced motor fluctuations.

Mechanism Target:

MODULATES Basal Ganglia Circuit Dysfunction — DBS modulates abnormal basal ganglia motor circuit activity rather than acting upstream on dopaminergic neuron loss.

Show evidence (1 reference)

PMID:27577098 SUPPORT

This review identifies deep brain stimulation as a standard symptomatic therapy for PD.

Physical Therapy

Action: Physical Therapy NCIT:C15302

Platform: Behavioral / lifestyle

Maintains mobility and reduces fall risk. Exercise programs including PWR!Moves, Rock Steady Boxing, Dance for Parkinson's, yoga, and tai chi are evidence-based approaches that specifically reduce rigidity, improve postural stability, and enhance motor fluidity through rebalancing of basal ganglia circuits.

Mechanism Target:

MODULATES Basal Ganglia Circuit Dysfunction — Structured exercise is reported to shift the excitatory/inhibitory balance within the basal ganglia rather than route around it. Cueing and compensation strategies, which do work around the circuit, are delivered alongside it; MODULATES records the claim this entry actually cites evidence for.

Show evidence (1 reference)

PMID:42646502 SUPPORT REVIEW SYNTHESIS Other

"Exercise helps reestablish the balance between excitatory and inhibitory signals in the basal ganglia, decreasing excitotoxicity and enhancing movement"

Link-level evidence for the mechanism of action asserted by this edge. Graded OTHER with quote_role REVIEW_SYNTHESIS: the sentence is the review's synthesis of its references [305-308] under the heading "Modulation of glutamate and motor circuits", not a result this publication reports.

Show evidence (4 references)

PMID:27577098 SUPPORT

This review lists physiotherapy as part of symptomatic treatment for PD.

PMID:42646502 SUPPORT Human Clinical

"Stretching and range-of-motion exercises (e.g., PWR!Moves), strengthening exercises (e.g., Rock Steady Boxing), dancing (e.g., Dance for Parkinson's Disease), and yoga and tai chi help reduce stiffness"

Comprehensive review identifies multiple evidence-based exercise modalities that effectively reduce rigidity and motor stiffness in PD.

PMID:42646502 SUPPORT Human Clinical

"Tai Chi was found to be effective, alongside resistance and stretching, for improving motor symptoms, physical abilities, and quality of life in early to mid-stage PD"

Tai Chi demonstrates measurable benefit for multiple motor domains including endurance, control, and postural stability in PD.

+ 1 more reference

Botulinum Neurotoxin A (BoNT/A) for Depression

Action: botulinum toxin type A therapy Ontology label: Botulinum Toxin Therapy NCIT:C157775

Botulinum toxin type A alleviates depression in Parkinson's disease by inhibiting the complement C3-C3aR signaling axis and reducing microglial synaptic phagocytosis. This represents a novel complement-targeted approach to managing depression as a non-motor symptom in PD, distinct from BoNT/A's canonical motor symptom applications.

Mechanism Target:

INHIBITS Complement C3-C3aR Activation in Depression — BoNT/A suppresses complement C3-C3aR signaling through modulation of microglial phagocytosis-related functions, reducing microglial activation and synaptic phagocytosis, thereby alleviating depression-like symptoms in PD models.

Show evidence (1 reference)

PMID:42263400 SUPPORT Model Organism

"BoNT/A treatment alleviated depressive-like behaviours and reduced microglial synaptic engulfment in an MPTP model; these therapeutic effects were abolished in C3-/- and C3aR-/- mice."

Mouse PD model demonstrates that BoNT/A alleviates depression-like behavior through inhibition of the C3-C3aR complement axis, preventing microglial synaptic engulfment and protecting against synapse loss in the hippocampus.

🌍

Environmental Factors

Pesticide Exposure

Rotenone and paraquat linked to increased risk

Show evidence (1 reference)

PMID:15177059 SUPPORT

"there is general agreement that smoking and exposure to pesticides affect the probability of developing PD."

This review supports pesticide exposure as an environmental factor influencing PD risk.

Mechanism Target:

TRIGGERS Mitochondrial Dysfunction — Rotenone is a complex I inhibitor, and complex I deficiency is what this node is built around, so in the animal model the exposure acts on the node with nothing in between. The directness is taken from that model and not from the human data, which is worth stating rather than leaving to inference: the human evidence here reaches only the association between pesticide exposure and developing the disease, and both items are graded partial for that reason. The same rat study also reproduced alpha-synuclein-containing nigral inclusions, which would support an edge into the aggregation node, but that arm is not drawn because rodent inclusion pathology would then be its only support.

Show evidence (2 references)

PMID:11100151 SUPPORT Model Organism

"We report that chronic, systemic inhibition of complex I by the lipophilic pesticide, rotenone, causes highly selective nigrostriatal dopaminergic degeneration that is associated behaviorally with hypokinesia and rigidity"

Names the pesticide, the complex I inhibition this node holds, and the nigrostriatal degeneration downstream of it. Rat work, so it carries the mechanism without establishing it in human disease.

PMID:15177059 SUPPORT Other

"there is general agreement that smoking and exposure to pesticides affect the probability of developing PD."

Review reporting general agreement that pesticide exposure affects the probability of developing the disease. It establishes the exposure at the level of the disease and says nothing about mitochondria.

Rural Living

Associated with pesticide/herbicide exposure

Show evidence (1 reference)

PMID:15177059 SUPPORT

"While clear links to rural living, dietary factors, exposure to metals, head injury, and exposure to infectious diseases during childhood have not been established, there is general agreement that smoking and exposure to pesticides affect the probability of developing PD."

This review notes that clear links to rural living are not established, indicating mixed evidence for this risk factor.

Head Trauma

Possible risk factor

Show evidence (1 reference)

PMID:36781627 SUPPORT

"The risk ratio of TBI among PD and controls by a combination of 15 studies using a random-effect model was 1.48 (95% CI 1.22-1.74)."

This meta-analysis supports head trauma (TBI) as a risk factor for developing PD.

Mechanism Target:

PREDISPOSES Dopaminergic Neuron Loss — Traumatic brain injury raises later risk of the disease by about half again. Pointed at the core neuropathological lesion rather than at a mechanism node because no cited sentence follows the injury to any particular step: neuroinflammation is the usual proposal and this entry holds a node for it, but nothing here measures that route, so the intermediates stay unknown.

Show evidence (1 reference)

PMID:36781627 SUPPORT Human Clinical

"The risk ratio of TBI among PD and controls by a combination of 15 studies using a random-effect model was 1.48 (95% CI 1.22-1.74)."

Meta-analysis of 15 studies giving a risk ratio of 1.48 for traumatic brain injury. It quantifies the exposure-disease association and not the neuronal loss this link targets.

🪜

Stages

Stage 1: Unilateral Disease

Symptoms are present on one side of the body only. Mild unilateral involvement with minimal or no functional impairment. Patients may exhibit resting tremor, rigidity, or bradykinesia on one limb or side. Daily activities are not significantly affected.

Original Hoehn and Yahr staging scale from 1967 (PMID:6067254). A modified scale with 0.5 increments (Stages 1.5, 2.5) has been widely adopted but lacks formal clinimetric validation.

Show evidence (2 references)

PMID:27918765 SUPPORT

"the Hoehn and Yahr scale, with the lowest grade indicating unilateral involvement with minimal or no functional impairment"

This describes Stage 1 (the lowest grade) as unilateral involvement with minimal or no functional impairment.

PMID:34461264 SUPPORT Model Organism

"Clinical findings indicate that LID typically only occurs following the progression of PD motor symptoms from the unilateral (Hoehn and Yahr (HY) Stage I) to the bilateral stage (HY Stage II)."

This identifies Stage I as the unilateral phase of PD motor symptoms.

Stage 2: Bilateral Disease Without Balance Impairment

Symptoms are present on both sides of the body or at the midline. Bilateral involvement without impairment of balance. Patients show bilateral tremor, rigidity, and bradykinesia but maintain normal postural reflexes and physical independence.

Show evidence (2 references)

PMID:34461264 SUPPORT Model Organism

"Clinical findings indicate that LID typically only occurs following the progression of PD motor symptoms from the unilateral (Hoehn and Yahr (HY) Stage I) to the bilateral stage (HY Stage II)."

This identifies Stage II as the bilateral stage of PD motor symptom progression.

PMID:15372591 SUPPORT

"the scale fulfills at least some criteria for reliability and validity, especially for the midranges of the scale (Stages 2-4)."

The MDS Task Force report validates the reliability of midrange stages (2-4) of the Hoehn and Yahr scale.

Stage 3: Bilateral Disease With Postural Instability

Mild to moderate bilateral disease with early postural instability. The first sign of impaired righting reflexes appears. Patients remain physically independent in daily activities but have clinically evident balance impairment.

Show evidence (2 references)

PMID:20181069 SUPPORT

"The modified Hoehn and Yahr scale was 3: mild to moderate bilateral disease; some postural instability; physically independent."

This directly defines Stage 3 as mild to moderate bilateral disease with some postural instability while remaining physically independent.

PMID:15372591 SUPPORT

"Because the HY scale is weighted heavily toward postural instability as the primary index of disease severity, it does not capture completely impairments or disability from other motor features of PD and gives no information on nonmotor problems."

This highlights that the Hoehn and Yahr scale weights postural instability as a primary severity index, providing context for why balance impairment becomes central at Stage 3.

Stage 4: Severe Disability, Still Ambulatory

Fully developed, severely disabling disease. Patients remain ambulatory but have marked loss of independence in daily activities. More than half require assistance with most activities of daily living, despite retained ability to complete walk-based assessments.

Show evidence (2 references)

PMID:34125001 SUPPORT

"Her disease severity was classified as Hoehn and Yahr stage 4. The unified Parkinson's disease rating scale (UPDRS) part 3, 10-m walk test (10MWT), timed up-and-go test (TUG), Berg balance scale (BBS), and 30-s chair stand test (30-s CST) were used for assessment before and after intervention."

This stage 4 case report shows that advanced patients can remain ambulatory enough to perform walk-based assessments despite severe motor impairment.

PMID:40162911 SUPPORT

"In the H-Y Stage 4 group, more than half of the patients required assistance with most ADLs, except feeding and bowel control."

This directly supports substantial dependence in daily activities as a defining functional feature of Stage 4 disease.

Stage 5: Wheelchair-Bound or Bedridden

Patient is confined to wheelchair or bedridden unless aided. Complete dependence on caregivers for all activities. Represents the most severe stage of motor disability in Parkinson's disease.

Show evidence (1 reference)

PMID:27918765 SUPPORT

"the highest grade defining patients with complete confinement to wheelchair or bed."

This directly defines Stage 5 (the highest grade) as complete confinement to wheelchair or bed.

📊

Prevalence

Population aged 65 years and older (worldwide)

Point Prevalence 2500.0 per 100,000 (2000.0–3000.0) >1 in 1,000

Parkinson disease affects 2-3% of the population aged 65 years and older, making it the second-most common neurodegenerative disorder. Prevalence rises steeply with age.

Show evidence (1 reference)

PMID:28332488 SUPPORT Human Clinical

"Parkinson disease is the second-most common neurodegenerative disorder that affects 2-3% of the population ≥65 years of age."

This Nature Reviews Disease Primers review states that PD affects 2-3% of people aged 65 and older, supporting the point-prevalence estimate.

📊

Related Datasets

Large-scale metagenomics of Parkinson's disease gut microbiome bioproject:PRJNA834801

Shotgun metagenomics from the NeuroGenetics Research Consortium (NGRC) with over 30% of species, genes and pathways showing altered abundances in PD. Identified polymicrobial clusters and competitive relationships.

human gut metagenome WGS

fecal sample OBI:0002503

Conditions: Parkinson's disease healthy controls

PMID:36357667

Nature Communications 2022 - largest PD metagenomics to date

Show evidence (1 reference)

PMID:37449597 SUPPORT

"This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."

This supports the relevance of gut microbiome datasets to PD mechanisms.

Multi-omics analysis of PD gut microbiome gene expression bioproject:PRJNA782492

Integrated metagenomics and metatranscriptomics analyzing microbiome gene co-expression networks in Parkinson's disease. Observed significant depletion of hub genes in PD patients.

human gut metagenome WGS

fecal sample OBI:0002503

Conditions: Parkinson's disease healthy controls

npj Biofilms and Microbiomes 2025 - multi-omics approach

Show evidence (1 reference)

PMID:37449597 SUPPORT

"This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."

This supports the relevance of gut microbiome datasets to PD mechanisms.

Longitudinal gut microbiome in Parkinson's disease bioproject:PRJNA808166

Longitudinal study investigating gut microbiome changes in PD patients and impact of device-assisted therapies. Tracks microbiome alterations with disease progression.

human gut metagenome

fecal sample OBI:0002503

Conditions: Parkinson's disease baseline Parkinson's disease follow-up

Frontiers Aging Neuroscience 2022 - longitudinal design

Show evidence (1 reference)

PMID:37449597 SUPPORT

"This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."

This supports the relevance of gut microbiome datasets to PD mechanisms.

PD gut microbiome meta-analysis cohort bioproject:PRJNA530401

Metagenomic sequencing data from PD patients and controls contributing to cross-cohort meta-analyses. Identified alterations linked to intestinal inflammation including reduced butyrate producers.

human gut metagenome WGS

fecal sample OBI:0002503

Conditions: Parkinson's disease healthy controls

npj Parkinson's Disease 2021 - meta-analysis contributing cohort

Show evidence (1 reference)

PMID:37449597 SUPPORT

"This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."

This supports the relevance of gut microbiome datasets to PD mechanisms.

Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease metabolights:MTBLS2266

LC-MS sebum metabolomics in Parkinson's disease, including drug-naive and medicated cohorts, compared with well-matched controls to identify lipid pathway alterations.

human METABOLOMICS n=274

Conditions: Parkinson's disease drug-naive Parkinson's disease medicated Parkinson's disease healthy controls

Findings

Sebum metabolomics in PD shows alterations in lipid metabolism pathways, including the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis.

Show evidence (1 reference)

metabolights:MTBLS2266 SUPPORT

"Pathway enrichment analysis shows alterations in lipid metabolism related to the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis."

The dataset description reports lipid pathway alterations detected in sebum metabolomics for PD.

LC-MS profiling of 274 participants detected metabolites predictive of PD phenotype.

Show evidence (1 reference)

metabolights:MTBLS2266 SUPPORT

"We used liquid chromatography-mass spectrometry (LC-MS) to analyse 274 samples from participants (80 drug naïve PD, 138 medicated PD and 56 well matched control subjects) and detected metabolites that could predict PD phenotype."

The dataset description specifies LC-MS profiling and the PD/control cohort sizes.

PMID:33707447

Metabolomics profiling of sebum as a non-invasive biofluid for PD.

Show evidence (1 reference)

metabolights:MTBLS2266 SUPPORT

"Here, we use a metabolomics profiling approach to identify changes to lipids in PD observed in sebum, a non-invasively available biofluid."

Establishes that the dataset focuses on PD sebum metabolomics.

Metabolomic Changes in Idiopathic and GBA1 Parkinson’s Disease metabolights:MTBLS10743

Mass spectrometry metabolomics comparing idiopathic Parkinson's disease and GBA1-associated Parkinson's disease cohorts with controls.

human METABOLOMICS

Conditions: idiopathic Parkinson's disease GBA1-associated Parkinson's disease healthy controls

Findings

Metabolomic signatures differ between GBA1-PD and idiopathic PD in sebum and serum with good specificity and sensitivity.

Show evidence (1 reference)

metabolights:MTBLS10743 SUPPORT

"Differences in metabolomic signatures were seen between ... GBA1-PD and iPD in sebum and serum with good specificity and sensitivity."

The dataset description reports discriminative metabolomic signatures between GBA1-PD and idiopathic PD.

Serum pathways implicated include sphingolipid metabolism, amino sugar metabolism and amino acid pathways, while sebum features are hypothesised to be lipid degradation products.

Show evidence (1 reference)

metabolights:MTBLS10743 SUPPORT

"Significant pathways in serum included sphingolipid metabolism, amino sugar metabolism and amino acid pathways, whereas significant features between groups in sebum are hypothesised to be lipid degradation products."

The dataset description lists pathway-level differences in serum and hypothesized lipid degradation products in sebum.

Preprint dataset describing metabolic changes in idiopathic vs GBA1 PD.

Show evidence (1 reference)

metabolights:MTBLS10743 SUPPORT

"Here, we use mass spectrometry based metabolomics to analyse serum and sebum samples from 50 genotyped participants and find differences in lipid and sugar regulation, oxidative stress and the production of amino acids and neurotransmitters which distinguish ... GBA1-PD from iPD."

Establishes the dataset's serum and sebum metabolomics design distinguishing GBA1-PD from idiopathic PD.

A multi-region single nucleus transcriptomic atlas of Parkinson's disease cellxgene:d5d0df8f-4eee-49d8-a221-a288f50a1590

Single-nucleus RNA-seq atlas of Parkinson's disease spanning multiple brain regions, providing cell-type-resolved transcriptomic profiles of dopaminergic neurons and glial populations in PD and healthy controls.

human SINGLE CELL RNA SEQ

brain tissue UBERON:0000955

Conditions: Parkinson's disease healthy controls

PMID:39317733

CZI CELLxGENE collection. DOI 10.1038/s41597-024-04117-y. Multi-region snRNA-seq atlas enabling virtual cell model training on PD-relevant cell states.

🧮

Computational Models

Alpha-Synuclein Aggregation BST Model KINETIC

Biochemical Systems Theory (BST) model of alpha-synuclein aggregation kinetics in dopaminergic neurons. Integrates dopamine metabolism, ubiquitin-proteasome system, and lysosomal degradation pathways. Simulates effects of oxidative stress and proteasome inhibition on synuclein accumulation.

Repository ↗ PMID:19136028

Pathograph links

Alpha-Synuclein Aggregation Models alpha-synuclein aggregation kinetics and degradation-pathway effects in dopaminergic neurons.

First comprehensive kinetic model of PD-related protein aggregation

Whole Dopaminergic Neuron SBML Model SBML KINETIC

Large-scale Systems Biology Markup Language (SBML) model of dopaminergic neuron containing 139 reactions and 111 metabolites. Captures dopamine synthesis, vesicular storage, release, reuptake, and degradation alongside mitochondrial function and oxidative stress.

Repository ↗ PMID:24196439

Pathograph links

Striatal Dopamine Deficiency Models dopamine synthesis, storage, release, reuptake, and degradation in dopaminergic-neuron physiology.

Mitochondrial Dysfunction Models mitochondrial metabolism alongside dopamine handling in dopaminergic neurons.

Enables simulation of drug effects on dopaminergic neurotransmission

Basal Ganglia Spiking Neural Network PHYSIOLOGICAL

Computational model of the basal ganglia circuit capturing dopamine-modulated dynamics between striatum, globus pallidus, subthalamic nucleus, and substantia nigra. Simulates pathological beta-band oscillations and motor dysfunction in PD.

PMID:29666208

Pathograph links

Basal Ganglia Circuit Dysfunction Models dopamine-modulated basal ganglia circuit dynamics, beta-band oscillations, and DBS effects.

Models circuit-level effects of dopamine depletion and DBS therapy

Alpha-Synuclein Prion-like Spreading Model AGENT_BASED

Network diffusion model simulating prion-like propagation of misfolded alpha-synuclein through brain connectome. Uses graph-theoretical approach to predict spatial patterns of neurodegeneration from initial seeding sites.

Pathograph links

Alpha-Synuclein Aggregation Models connectome-based propagation of misfolded alpha-synuclein pathology.

Predicts Braak staging patterns from connectivity-based spreading

PD Map Cohort-Specific Probabilistic Boolean Models SBML-qual CaSQ, pyMaBoSS, CellDesigner BOOLEAN_NETWORK

Probabilistic Boolean Networks (PBNs) built from the Parkinson's disease map, the largest curated repository of PD pathway diagrams. Pathways enriched in the Parkinson's Progression Markers Initiative (PPMI) cohort were exported from the PD map in CellDesigner SBML format, translated to SBML-qual with CaSQ, and parameterised against cohort miRNA and transcriptomic data so that each model represents a specific PD subgroup (prodromal, SWEDD, parkinsonism). Simulating the resulting models with pyMaBoSS reveals subtype-specific differences in dopamine transcription, PI3K/AKT signalling, FOXO3 activity, mTOR-MAPK signalling and PRKN mitophagy. The probabilistic parameterisation, rather than plain Boolean logic, is what lets cohort-level data enter the model.

Repository ↗ PMID:39429779

Pathograph links

Autophagy-Lysosome Pathway Dysfunction recapitulates fidelity: moderate PRKN mitophagy is one of the enriched PD map pathways converted into a cohort-parameterised Boolean model, and autophagy/mitophagy activity is one of the axes on which the subtypes separate.

Limitations: The model is parameterised from cohort-level miRNA and transcriptomic data rather than from direct measurement of autophagic flux, so it represents transcriptional regulation of the pathway rather than the degradative process itself.

Readouts

PRKN-mitophagy model activity across PD subgroups

Direction: ALTERED

Interpretation: Mitophagy and autophagy activities differ between the SWEDD, prodromal and parkinsonism subgroups rather than moving in one direction across all of PD.

Show evidence (1 reference)

PMID:39429779 SUPPORT Computational

"differences in autophagy and mitophagy activities were observed, suggesting unique disease mechanisms within each PD subtype"

Reports the subtype-dependent autophagy/mitophagy readout this link records.

Show evidence (1 reference)

PMID:39429779 SUPPORT Computational

"The enriched pathways included dopamine transcription pathways, PI3k/AKT signaling, FOXO3 activity, mTOR-MAPK signaling, and PRKN mitophagy"

Names PRKN mitophagy among the pathways modelled, linking this model to the autophagy-lysosome node.

Striatal Dopamine Deficiency partially recapitulates fidelity: low Dopamine transcription pathways are among the enriched PD map diagrams converted to Boolean models and show distinct behaviour across subtypes.

Limitations: The model represents transcriptional regulation of dopamine synthesis in a cohort-parameterised signalling network; it does not represent striatal dopamine concentration, nigrostriatal terminal loss, or the presynaptic deficit that defines this node clinically.

Show evidence (1 reference)

PMID:39429779 SUPPORT INDIRECT Computational

"These models revealed distinct behaviors in key molecular pathways across PD subtypes, including dopamine transcription, PI3K/AKT signaling, FOXO3 activity, mTOR-MAPK signaling, and PRKN mitophagy"

Supports a transcription-level dopamine claim. Indirect: the quote asserts subtype-specific behaviour of dopamine-transcription pathways, and striatal dopamine deficiency follows only by an inference step across transcription, synthesis and terminal survival -- which is also why fidelity here is LOW.

Findings

Cohort-level and real-world patient data were integrated into the logical models to represent subtype-specific pathway deregulation.

Show evidence (1 reference)

PMID:39429779 SUPPORT Computational

"By integrating cohort-level and real-world patient data, we modeled PD's subtype-specific pathway deregulations, providing a refined representation of its molecular landscape"

States the data-integration step that makes these models cohort-specific.

Curated as part of the Boolean/logical modelling track; see docs/superpowers/plans/2026-08-28-boolean-modeling-and-pathographs.md. Literature-referenced, not runnable in-repo: dismech-perturb has no SBML-qual execution path yet. Note this is a *probabilistic* Boolean network — cohort data enter as node transition probabilities, so it is not a plain deterministic Boolean model.

Show evidence (2 references)

PMID:39429779 SUPPORT Computational

"we employed systems medicine approaches using the PD map, a detailed repository of PD-related interactions and applied Probabilistic Boolean Networks (PBNs) to capture the stochastic nature of molecular dynamics"

Establishes the PD map as the knowledge source and PBNs as the modelling formalism for this entry.

PMID:39429779 SUPPORT Computational

"The pathways identified via the enrichment analysis were exported from the PD map in CellDesigner SBML format and translated into SBML-qual files by the CaSQ tool"

Documents the CaSQ map-to-model translation and the SBML-qual format recorded in model_format.

{ }

Source YAML

click to show

name: Parkinson's Disease
creation_date: '2025-12-18T17:01:35Z'
description: >-
  Parkinson's disease is a progressive neurodegenerative movement disorder caused
  by the loss of dopaminergic neurons in the substantia nigra pars compacta,
  producing striatal dopamine deficiency and basal ganglia circuit dysfunction.
  It manifests as bradykinesia, resting tremor, rigidity, and postural instability,
  with non-motor features. The pathological hallmark is intraneuronal aggregation
  of misfolded alpha-synuclein (Lewy bodies), with mitochondrial dysfunction and
  oxidative stress contributing to neurodegeneration.
category: Complex
parents:
- Neurodegenerative Disease
- Movement Disorder
disease_term:
  preferred_term: Parkinson disease
  term:
    id: MONDO:0005180
    label: Parkinson disease
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0008199
      label: late-onset Parkinson disease
    mapping_predicate: skos:narrowMatch
    mapping_source: manual curation
    mapping_justification: >
      MONDO:0008199 (late-onset Parkinson disease, OMIM:168600, "PARK"/"LOPD";
      onset after ~age 50) is the common sporadic/idiopathic adult-onset form and
      a child of MONDO:0005180. This entry curates Parkinson disease at the broad
      MONDO:0005180 level, and its pathophysiology (α-synucleinopathy and
      dopaminergic neurodegeneration, SNCA/LRRK2/GBA1) substantively covers the
      late-onset form. Recorded as a narrowMatch so coverage tooling resolves
      MONDO:0008199 to this entry rather than flagging it as uncurated.
gene_sets:
- gene_set: MYGENESET:KEGG_PARKINSONS_DISEASE
  relationship: CANONICAL_PATHWAY
  note: >-
    KEGG Parkinson disease pathway.
- gene_set: MYGENESET:WP_PARKINSONS_DISEASE_PATHWAY
  relationship: CANONICAL_PATHWAY
  note: >-
    WikiPathways Parkinson disease pathway.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_synucleinopathy_dopaminergic_neurodegeneration_model
  hypothesis_label: Canonical α-Synucleinopathy and Dopaminergic Neurodegeneration Model
  status: CANONICAL
  description: >-
    Misfolded α-synuclein aggregates into oligomers and Lewy bodies, propagates trans-synaptically in a prion-like manner, and induces progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta. The resulting striatal dopamine deficiency causes the cardinal motor signs (bradykinesia, rigidity, tremor, postural instability), while broader Lewy pathology in autonomic, brainstem, and cortical regions accounts for the non-motor symptoms (REM-sleep behavior disorder, hyposmia, constipation, cognitive impairment). Pathway evidence implicates impaired autophagy/lysosomal clearance (GBA), mitochondrial dysfunction (PINK1/Parkin), and oxidative stress as upstream amplifiers; loss of dopaminergic feedback to the indirect/direct basal ganglia circuits explains the motor circuit signature.
  notes: >-
    Retained as CANONICAL. The 2026 falcon
    hypothesis-search report
    (kb/hypotheses/Parkinsons_Disease/canonical_synucleinopathy_dopaminergic_neurodegeneration_model;
    openscientist timed out) confirms misfolded α-synuclein
    aggregation, Lewy-body formation, and progressive substantia-nigra
    pars-compacta dopaminergic neuron loss as the central
    mechanism. Three qualifications: (1) the prion-like cell-to-cell
    propagation model is well-validated in mouse and primate
    models (intracerebral PFF injection seeds endogenous
    aggregates and produces motor deficits), but its rate-limiting
    role in human sporadic PD remains debated; (2) GBA1
    heterozygosity, mitochondrial dysfunction (PINK1/Parkin),
    impaired autophagy/lysosomal clearance, and gut-brain axis
    (vagal Lewy pathology, microbiome) are increasingly
    recognized upstream amplifiers — particularly the gut-first
    Braak hypothesis, supported by hyposmia and REM-sleep
    behavior disorder preceding motor symptoms by 10-20 years;
    (3) LRRK2 G2019S and other genetic PD subtypes display Lewy-pathology
    variability, indicating molecular heterogeneity
    within the unified clinical syndrome. Anti-α-synuclein
    immunotherapies (prasinezumab, cinpanemab) have shown
    target engagement but limited clinical efficacy, suggesting
    aggregation may be a downstream marker rather than the
    rate-limiting therapeutic target.
  evidence:
  - reference: PMID:37048085
    reference_title: "Microglia Mediated Neuroinflammation in Parkinson's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "dopaminergic neuronal loss in substantia nigra pars compacta of the brain and aggregation of intracellular protein α-synuclein are the pathological characterizations"
    explanation: >
      Canonical mechanism review used as the seed reference for the
      hypothesis-search deep-research run.
- hypothesis_group_id: body_first_enteric_alpha_synuclein_model
  hypothesis_label: Body-First Enteric α-Synuclein Initiation Model
  status: ALTERNATIVE
  description: >-
    Alpha-synuclein pathology initiates in the enteric nervous system or other
    peripheral autonomic sites, then propagates through vagal connections to
    the dorsal motor nucleus and broader brainstem before joining the central
    alpha-synuclein propagation and dopaminergic-neurodegeneration cascade.
    This model best explains Parkinson disease presentations with early
    constipation, REM-sleep behavior disorder, autonomic dysfunction, and
    early peripheral/cardiac sympathetic denervation.
  notes: >-
    Evidence is strongest for the gut-to-brain propagation route in animal
    models where truncal vagotomy or alpha-synuclein deficiency blocks spread.
    Human clinical and imaging studies support a body-first subtype pattern,
    but microbiome dysbiosis and enteric seeding remain unresolved as causal
    triggers versus modifiers or consequences.

    The 2026 OpenScientist hypothesis-search report
    (kb/hypotheses/Parkinsons_Disease/body_first_enteric_alpha_synuclein_model)
    judges this model PARTIALLY SUPPORTED and recommends retaining ALTERNATIVE
    status: it is one well-supported origin-site pathway (an estimated ~20-30%
    of PD) within the multi-origin Synuclein Origin and Connectome (SOC)
    framework, not a universal disease mechanism. Convergent support spans
    mouse gut-to-brain transmission (vagotomy and α-syn knockout each block
    spread), human truncal-vagotomy epidemiology (reduced PD risk at long
    follow-up), gut-microbiota dependence in α-syn-overexpressing mice, and a
    distinct body-first clinical-imaging signature (more symmetric nigrostriatal
    degeneration, early cardiac sympathetic denervation). Key qualifications:
    (1) the upstream trigger for enteric α-syn misfolding is unknown; (2)
    enteric α-syn immunohistochemistry lacks diagnostic specificity (positive
    also in controls); (3) LRRK2-associated PD is frequently α-syn seed
    amplification assay (SAA)-negative, showing α-syn-independent parkinsonian
    pathways; (4) 6-43% of cases deviate from caudo-rostral Braak staging, iRBD
    prodrome is heterogeneous, FMT trials are inconsistent, and anti-α-syn
    immunotherapies have failed in established PD.
  evidence:
  - reference: PMID:38519273
    reference_title: "Brain-first vs. body-first Parkinson's disease: An update on recent evidence."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the initial pathology starts either in the olfactory bulb or amygdala leading to a brain-first subtype, or in the enteric nervous system leading to a body-first subtype."
    explanation: >-
      Recent review-level synthesis of human imaging, clinical, and pathology
      studies explicitly frames enteric-origin body-first PD as an alternative
      subtype within the ASOC model.
  - reference: PMID:31255487
    reference_title: "Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Truncal vagotomy and α-syn deficiency prevented the gut-to-brain spread of α-synucleinopathy and associated neurodegeneration and behavioral deficits."
    explanation: >-
      Mouse gut-to-brain transmission experiments support the vagus nerve and
      alpha-synuclein as required components of the body-first propagation
      route.
  - reference: PMID:39241780
    reference_title: "Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson's and Alzheimer's disease co-pathology and behavior impairments."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Truncal vagotomy and α-Syn deficiency significantly inhibited synucleinopathy or tauopathy spreading."
    explanation: >-
      Gut-inducible mouse models provide independent support that vagotomy and
      alpha-synuclein deficiency inhibit gut-origin propagation into the brain.
  - reference: PMID:26031848
    reference_title: "Vagotomy and subsequent risk of Parkinson's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Full truncal vagotomy is associated with a decreased risk for subsequent PD, suggesting that the vagal nerve may be critically involved in the pathogenesis of PD."
    explanation: >-
      Danish register-based cohort provides human epidemiological support that
      complete disruption of vagal afferents from the gut reduces later PD
      risk, consistent with a vagal gut-to-brain propagation route.
  - reference: PMID:28446653
    reference_title: "Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Overall, vagotomy was not associated with PD risk (HR 0.96, 95% CI 0.78-1.17)."
    explanation: >-
      Qualifies the vagotomy epidemiology above. In the larger Swedish register
      cohort (9,430 vagotomized patients) vagotomy as a whole showed no
      association with later Parkinson disease; the protective signal is
      confined to the truncal subgroup at long latency, so the vagotomy
      literature is weaker corroboration of a vagal gut-to-brain route than the
      subgroup hazard ratios alone imply.
  - reference: PMID:28446653
    reference_title: "Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Taken together, these data provide preliminary and indirect support for the Braak and prion-like hypotheses for PD prodromal development."
    explanation: >-
      The same authors grade their own truncal-vagotomy result as preliminary
      and indirect with respect to the gut-to-brain propagation hypothesis,
      which is the level of support the body-first model can currently claim
      from human surgical epidemiology.
  - reference: PMID:41105632
    reference_title: "Distinct cutaneous α-synuclein signatures in body-first and brain-first Parkinson's disease subtypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Body-first PD patients displayed a distal-to-proximal α-syn gradient (DL, 86.1% versus C7. 55.7%), contrasting with the proximal-dominant pattern in brain-first PD patients (DL, 40.5% versus C7, 50.8%)."
    explanation: >-
      Skin-biopsy pathology in 205 patients shows the distal-predominant
      cutaneous alpha-synuclein gradient predicted by a peripheral,
      autonomically distributed origin, contrasting with the proximal-dominant
      pattern of the brain-first group.
  - reference: PMID:41105632
    reference_title: "Distinct cutaneous α-synuclein signatures in body-first and brain-first Parkinson's disease subtypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subtype classification was based on the presence of REM sleep behaviour disorder preceding motor symptoms."
    explanation: >-
      Records the circularity limit on that result: subtype membership was
      assigned from the REM-sleep-behavior-disorder proxy rather than from an
      observed origin site, so the cutaneous gradient is a correlated feature of
      the proxy-defined groups, not a direct measurement of where pathology
      began.
  - reference: PMID:27912057
    reference_title: "Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "gut microbiota are required for motor deficits, microglia activation, and αSyn pathology. Antibiotic treatment ameliorates, while microbial re-colonization promotes, pathophysiology in adult animals, suggesting that postnatal signaling between the gut and the brain modulates disease."
    explanation: >-
      In α-synuclein-overexpressing mice the gut microbiota are causally
      required for α-syn pathology and motor deficits, supporting a gut-origin
      contribution to the body-first cascade.
  - reference: PMID:34334424
    reference_title: "Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson's Disease Subtypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nigrostriatal degeneration was significantly more symmetric in patients with RBD versus patients without RBD or with unknown RBD status in both FDOPA (p = 0.001) and DaT SPECT (p = 0.001) datasets."
    explanation: >-
      Body-first (RBD+) PD shows the more symmetric nigrostriatal degeneration
      predicted by symmetric bilateral vagal propagation, differentiating it
      from brain-first PD on molecular imaging.
  - reference: PMID:27044604
    reference_title: "Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Positive alpha-synuclein staining was observed by all 5 judges in most of the slides from control cases, regardless of the staining methods that were used."
    explanation: >-
      Qualifies the model: enteric α-synuclein immunohistochemistry stains
      control gut biopsies too, so it lacks the specificity needed to establish
      enteric α-syn as a disease-defining body-first biomarker.
- hypothesis_group_id: brain_first_central_alpha_synuclein_model
  hypothesis_label: Brain-First Central α-Synuclein Initiation Model
  status: ALTERNATIVE
  description: >-
    Alpha-synuclein pathology initiates within central nervous system sites
    such as the olfactory bulb or amygdala and spreads centrifugally to
    brainstem and peripheral autonomic structures. This model best explains
    Parkinson disease presentations where central dopaminergic or olfactory
    involvement precedes prominent autonomic and enteric manifestations.
  notes: >-
    The model is supported mainly by subtype-level human imaging, clinical,
    and neuropathological patterns. It competes with, rather than refutes, the
    body-first model because both origin routes may exist within clinically
    diagnosed Parkinson disease.

    The 2026 OpenScientist hypothesis-search report
    (kb/hypotheses/Parkinsons_Disease/brain_first_central_alpha_synuclein_model)
    judges this model PARTIALLY SUPPORTED and recommends retaining ALTERNATIVE
    status. Supporting evidence is convergent at the subtype level: large-scale
    neuropathological trajectory modelling (81.9% of Lewy-body donors have
    earliest pathology in the olfactory bulb), multimodal imaging showing
    asymmetric central dopaminergic loss preceding peripheral autonomic
    denervation in RBD-negative PD, and primate/mouse olfactory-bulb PFF
    injection reproducing olfactory-to-limbic-to-brainstem spread. Key
    qualifications: (1) no prospective longitudinal human study has tracked
    α-syn pathology from a CNS origin outward; (2) RBD as a body-first proxy is
    unreliable (PSG-confirmed prevalence 17.8-62.5% by ascertainment); (3)
    structural MRI is conflicting - a 255-patient PPMI cohort found no gray
    matter volume asymmetry difference between putative subtypes; (4) dermal SAA
    cannot differentiate subtypes in established disease and origin-site is not
    yet integrated into NSD-ISS/SynNeurGe biological staging; (5) α-syn strain
    differences that might determine origin route remain uncharacterized between
    subtypes.
  evidence:
  - reference: PMID:38519273
    reference_title: "Brain-first vs. body-first Parkinson's disease: An update on recent evidence."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the initial pathology starts either in the olfactory bulb or amygdala leading to a brain-first subtype, or in the enteric nervous system leading to a body-first subtype."
    explanation: >-
      The ASOC model explicitly defines an olfactory bulb/amygdala origin as
      the brain-first subtype that competes with the enteric body-first route.
  - reference: PMID:38519273
    reference_title: "Brain-first vs. body-first Parkinson's disease: An update on recent evidence."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These subtypes should be distinguishable early in the disease course on a range of imaging, clinical, and neuropathological markers."
    explanation: >-
      Human subtype distinguishability supports representing brain-first and
      body-first disease routes as alternative mechanistic hypothesis groups.
  - reference: PMID:32830221
    reference_title: "Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the PDRBD- data were compatible with a brain-first trajectory, characterized by primary loss of putaminal FDOPA uptake followed by a secondary loss of cardiac MIBG signal and 11C-donepezil signal."
    explanation: >-
      Primary multimodal imaging data support a brain-first trajectory in
      RBD-negative de novo PD, where central dopaminergic dysfunction appears
      before peripheral autonomic marker loss.
  - reference: PMID:38879548
    reference_title: "Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most donors (81.9%) show earliest pathology in the olfactory bulb, followed by accumulation in either limbic (60.8%) or brainstem (21.1%) regions."
    explanation: >-
      Data-driven neuropathological trajectory modelling of 814 brain donors
      shows olfactory-bulb-initiated (brain-first) pathology is the predominant
      spread pattern, the strongest large-scale support for a central origin.
  - reference: PMID:35989519
    reference_title: "Lewy Body Disease Primate Model with α-Synuclein Propagation from the Olfactory Bulb."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Severe α-Syn pathology was observed within the olfactory pathway and limbic system, while mild α-Syn pathology was seen in a wide range of brain regions, including the substantia nigra pars compacta, locus coeruleus, and even dorsal motor nucleus of the vagus nerve."
    explanation: >-
      Marmoset olfactory-bulb PFF injection reproduces the predicted centrifugal
      olfactory-to-limbic-to-brainstem propagation reaching the substantia nigra,
      demonstrating anatomical plausibility of a central origin.
  - reference: PMID:35943058
    reference_title: "Gray Matter Volume Loss in Proposed Brain-First and Body-First Parkinson's Disease Subtypes."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "the degree of putaminal DaT asymmetry was not associated with reduced GMV or higher GMV asymmetry. Furthermore, RBD-negative and RBD-positive patients did not demonstrate a significant difference in GMV or GMV asymmetry."
    explanation: >-
      A 255-patient PPMI structural MRI study found no gray-matter-volume
      asymmetry difference between putative brain-first and body-first PD,
      failing to support a core structural prediction of the model.
  - reference: PMID:41105632
    reference_title: "Distinct cutaneous α-synuclein signatures in body-first and brain-first Parkinson's disease subtypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Body-first PD patients displayed a distal-to-proximal α-syn gradient (DL, 86.1% versus C7. 55.7%), contrasting with the proximal-dominant pattern in brain-first PD patients (DL, 40.5% versus C7, 50.8%)."
    explanation: >-
      Skin-biopsy pathology gives the brain-first group a proximal-dominant
      cutaneous alpha-synuclein pattern with lower overall peripheral burden,
      the peripheral distribution a centrally initiated, centrifugally
      spreading process would predict.
  - reference: PMID:41714532
    reference_title: "Stage-specific interactions among PLM, RBD, and OSAHS in parkinson's disease and MSA."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MSA exhibited more severe disturbances than PD: RBD prevalence 47.1% vs 17.8%"
    explanation: >-
      Polysomnography in 264 Parkinson disease patients puts REM-sleep behavior
      disorder prevalence at 17.8%, the low end of the range that makes an
      RBD-only proxy an unstable basis for assigning brain-first versus
      body-first membership.
  - reference: PMID:29084403
    reference_title: "High Frequency of Sleep Disorders in Parkinson's Disease and Its Relationship with Quality of Life."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We observed sleep disorders in 96.5% of the participants, with REM-sleep behavior disorder found in 62.5%, obstructive sleep apnea in 62.5%, insomnia in 55.7%, and restless legs syndrome in 28.4%."
    explanation: >-
      Video-polysomnography in a separate Parkinson disease outpatient cohort
      puts REM-sleep behavior disorder prevalence at 62.5%. Read against the
      17.8% figure above, the roughly threefold spread in ascertained RBD
      prevalence is what limits an RBD-only origin-site proxy; the two cohorts
      differ in population and objectives, so the contrast bounds the proxy's
      stability rather than isolating a single ascertainment method.
  - reference: PMID:31797870
    reference_title: "Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "there was a greater structural heterogeneity among α-synuclein fibrils from the PD brain compared to those from the MSA brain, possibly reflecting on the greater variability of disease phenotypes evident in PD."
    explanation: >-
      Fibrils amplified from PD brain show conformational strain heterogeneity;
      whether strain differences determine brain-first versus body-first origin
      remains uncharacterized, qualifying the mechanistic basis of the model.
pathophysiology:
- name: Dopaminergic Neuron Loss
  conforms_to: "parkinsonism_dopaminergic_degeneration#Nigrostriatal Dopaminergic Neurodegeneration"
  description: >
    Progressive degeneration of dopaminergic neurons in the substantia nigra
    pars compacta is the core neuropathological lesion of Parkinson's disease.
    Motor signs emerge once an estimated 60-80% of these neurons are lost and
    the resulting loss of nigrostriatal dopamine input can no longer be
    compensated.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  locations:
  - preferred_term: substantia nigra
    term:
      id: UBERON:0002038
      label: substantia nigra
  biological_processes:
  - preferred_term: Dopamine Biosynthesis
    term:
      id: GO:0042416
      label: dopamine biosynthetic process
  downstream:
  - target: Striatal Dopamine Deficiency
    causal_link_type: DIRECT
    description: >
      Degeneration of substantia nigra pars compacta neurons removes the
      nigrostriatal projection, depleting dopamine in the striatum.
    evidence:
    - reference: PMID:28332488
      reference_title: "Parkinson disease."
      supports: SUPPORT
      snippet: "Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease."
      explanation: >
        This Nature Reviews Disease Primers review states that substantia nigra
        neuronal loss causes striatal dopamine deficiency, supporting this
        causal edge.
  evidence:
  - reference: PMID:37048085
    reference_title: "Microglia Mediated Neuroinflammation in Parkinson's Disease."
    supports: SUPPORT
    snippet: "Tremor, shaking, movement problems, and difficulty with balance and coordination are among the hallmarks, and dopaminergic neuronal loss in substantia nigra pars compacta of the brain and aggregation of intracellular protein α-synuclein are the pathological characterizations."
    explanation: This review confirms that dopaminergic neuronal loss in the substantia nigra pars compacta is a pathological hallmark of Parkinson's disease, supporting the core mechanism of dopaminergic neuron degeneration.
- name: Striatal Dopamine Deficiency
  biological_scale: TISSUE
  conforms_to: "parkinsonism_dopaminergic_degeneration#Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction"
  description: >
    Degeneration of nigrostriatal dopaminergic terminals depletes dopamine in
    the striatum, the principal input nucleus of the basal ganglia. Reduced
    striatal dopamine withdraws normal modulation of medium spiny projection
    neurons and is the proximate biochemical deficit linking nigral neuron
    loss to the motor features of Parkinson's disease.
  cell_types:
  - preferred_term: Striatal medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: Dopaminergic synaptic transmission
    term:
      id: GO:0001963
      label: synaptic transmission, dopaminergic
    modifier: DECREASED
  - preferred_term: Dopamine Secretion
    term:
      id: GO:0014046
      label: dopamine secretion
    modifier: DECREASED
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  downstream:
  - target: Basal Ganglia Circuit Dysfunction
    causal_link_type: DIRECT
    description: >
      Loss of striatal dopamine unbalances the direct and indirect basal
      ganglia pathways.
    evidence:
    - reference: PMID:18781672
      reference_title: "Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease."
      supports: SUPPORT
      snippet: "Dopaminergic depletion in Parkinson's disease disrupts the corticostriatal balance leading to increased activity the indirect circuit and reduced activity in the direct circuit."
      explanation: >
        This review states that dopaminergic depletion disrupts the
        corticostriatal balance, raising indirect-pathway and lowering
        direct-pathway activity, supporting striatal dopamine deficiency as the
        cause of basal ganglia circuit dysfunction.
  evidence:
  - reference: PMID:28332488
    reference_title: "Parkinson disease."
    supports: SUPPORT
    snippet: "Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease."
    explanation: >
      This review identifies striatal dopamine deficiency as a defining
      neuropathological hallmark of Parkinson's disease.
- name: Basal Ganglia Circuit Dysfunction
  description: >
    Striatal dopamine loss shifts the basal ganglia-thalamocortical motor
    circuit toward excessive inhibitory output: the indirect pathway becomes
    hyperactive and the direct pathway hypoactive, increasing inhibitory drive
    from the globus pallidus pars interna onto the motor thalamus and cortex.
    This aberrant circuit activity, rather than neuron loss alone, generates
    the cardinal motor signs of Parkinson's disease.
  cell_types:
  - preferred_term: Striatal medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: GABAergic synaptic transmission
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
    modifier: DYSREGULATED
  locations:
  - preferred_term: basal ganglia
    term:
      id: UBERON:0002420
      label: basal ganglion
  downstream:
  - target: Resting Tremor
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:17955331
      reference_title: "The Rotterdam Study: objectives and design update."
      supports: SUPPORT
      snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
      explanation: >
        This identifies resting tremor as a cardinal parkinsonian sign; its
        precise circuit origin within basal ganglia dysfunction remains
        debated, so the edge directness is left UNKNOWN.
  - target: Bradykinesia
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17955331
      reference_title: "The Rotterdam Study: objectives and design update."
      supports: SUPPORT
      snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
      explanation: This establishes bradykinesia as a cardinal parkinsonian sign downstream of basal ganglia circuit dysfunction.
    - reference: PMID:19127584
      reference_title: "The basal ganglia in Parkinson's disease: current concepts and unexplained observations."
      supports: SUPPORT
      snippet: "In the parkinsonian state, dopamine depletion shifts the BG toward inhibiting cortically generated movements by increasing the gain in the globus pallidus pars externa-subthalamic nucleus-globus pallidus pars interna network and reducing activity in \"direct\" cortico-putaminal-globus pallidus pars interna projections."
      explanation: >
        This review describes how parkinsonian basal ganglia circuit
        dysfunction inhibits cortically generated movements, supporting
        bradykinesia as a direct downstream consequence.
  - target: Rigidity
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17955331
      reference_title: "The Rotterdam Study: objectives and design update."
      supports: SUPPORT
      snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
      explanation: This identifies rigidity as a cardinal parkinsonian sign downstream of basal ganglia circuit dysfunction.
    - reference: PMID:19127584
      reference_title: "The basal ganglia in Parkinson's disease: current concepts and unexplained observations."
      supports: SUPPORT
      snippet: "In the parkinsonian state, dopamine depletion shifts the BG toward inhibiting cortically generated movements by increasing the gain in the globus pallidus pars externa-subthalamic nucleus-globus pallidus pars interna network and reducing activity in \"direct\" cortico-putaminal-globus pallidus pars interna projections."
      explanation: >
        This review describes dopamine-depletion-driven basal ganglia output
        changes that inhibit cortically generated movements, supporting a
        mechanistic basal ganglia circuit contribution to parkinsonian motor
        signs including rigidity.
  - target: Postural Instability
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:17955331
      reference_title: "The Rotterdam Study: objectives and design update."
      supports: SUPPORT
      snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
      explanation: >
        This supports impaired postural reflexes as a cardinal parkinsonian
        sign; postural instability has a recognized non-dopaminergic
        component, so the edge directness is left UNKNOWN.
  evidence:
  - reference: PMID:18781672
    reference_title: "Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease."
    supports: SUPPORT
    snippet: "The parkinsonian state is characterized by disruption of the internal balance of the BG leading to hyperactivity in the two main entry points of the network (striatum and STN) and excessive inhibitory output from the GPi."
    explanation: >
      This review characterizes the parkinsonian basal ganglia by disrupted
      internal balance and excessive inhibitory GPi output, supporting basal
      ganglia circuit dysfunction as a distinct mechanism node.
  - reference: PMID:30897356
    reference_title: "Circuit Mechanisms of Parkinson's Disease."
    supports: SUPPORT
    snippet: "We will then describe the basal ganglia-thalamocortical circuit, the major locus of PD-related circuit dysfunction, and some of the models that have influenced its study."
    explanation: >
      This review identifies the basal ganglia-thalamocortical circuit as the
      major locus of PD-related circuit dysfunction.
- name: Alpha-Synuclein Aggregation
  conforms_to: "parkinsonism_dopaminergic_degeneration#Alpha-Synuclein Aggregation and Lewy Pathology"
  description: >
    Misfolded alpha-synuclein protein accumulates to form Lewy bodies and
    Lewy neurites. These aggregates spread through the nervous system in a
    prion-like manner, contributing to neurodegeneration.
  biological_processes:
  - preferred_term: inclusion body assembly
    term:
      id: GO:0070841
      label: inclusion body assembly
  downstream:
  - target: Dopaminergic Neuron Loss
    evidence:
    - reference: PMID:38245249
      reference_title: "The pathogenesis of Parkinson's disease."
      supports: SUPPORT
      snippet: "Biochemical studies, investigation of transplanted neurons in patients with Parkinson's disease, and cell and animal model studies suggest that abnormal aggregation of α-synuclein and spreading of pathology between the gut, brainstem, and higher brain regions probably underlie the development and progression of Parkinson's disease."
      explanation: This indicates that α-synuclein aggregation drives disease development and progression, supporting downstream dopaminergic neuron loss.
  - target: Neuroinflammation
    evidence:
    - reference: PMID:36598534
      reference_title: "Role of α-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson's disease."
      supports: SUPPORT
      snippet: "α-Syn is a crucial marker of PD, and its accumulation leads to microglia M1-like phenotype polarization, activation of NLRP3 inflammasomes, and impaired autophagy and phagocytosis in microglia."
      explanation: This links α-synuclein accumulation to microglial activation, supporting neuroinflammation as a downstream effect.
  evidence:
  - reference: PMID:38245249
    reference_title: "The pathogenesis of Parkinson's disease."
    supports: SUPPORT
    snippet: "Parkinson's disease is a progressive neurodegenerative condition associated with the deposition of aggregated α-synuclein."
    explanation: This authoritative Lancet review establishes that aggregated α-synuclein deposition is a defining feature of Parkinson's disease pathogenesis.
  - reference: PMID:38245249
    reference_title: "The pathogenesis of Parkinson's disease."
    supports: SUPPORT
    snippet: "Biochemical studies, investigation of transplanted neurons in patients with Parkinson's disease, and cell and animal model studies suggest that abnormal aggregation of α-synuclein and spreading of pathology between the gut, brainstem, and higher brain regions probably underlie the development and progression of Parkinson's disease."
    explanation: This provides direct evidence for the prion-like spreading mechanism of α-synuclein pathology across neural networks, supporting the mechanism of trans-neuronal propagation.
  - reference: PMID:36598534
    reference_title: "Role of α-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson's disease."
    supports: SUPPORT
    snippet: "Parkinson's disease (PD) is the second most common neurodegenerative disease, and is characterized by accumulation of α-synuclein (α-syn)."
    explanation: Confirms that α-synuclein accumulation is a key pathological characterization of PD, reinforcing the central role of protein aggregation in disease pathology.
- name: Mitochondrial Dysfunction
  conforms_to: "parkinsonism_dopaminergic_degeneration#Mitochondrial Complex I Inhibition and Oxidative Stress"
  description: >
    Impaired mitochondrial function, particularly complex I deficiency,
    leads to oxidative stress and neuronal death. Multiple PD genes
    (PINK1, Parkin, DJ-1) regulate mitochondrial quality control.
  biological_processes:
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
  downstream:
  - target: Dopaminergic Neuron Loss
    evidence:
    - reference: PMID:27911343
      reference_title: "PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson's Disease Pathobiology?"
      supports: SUPPORT
      snippet: "For the past 30 years, mitochondrial dysfunction has been hypothesized to play a central role in the pathobiology of this devastating neurodegenerative disease."
      explanation: This supports mitochondrial dysfunction as a central driver of neurodegeneration in PD, consistent with dopaminergic neuron loss.
  evidence:
  - reference: PMID:38245249
    reference_title: "The pathogenesis of Parkinson's disease."
    supports: SUPPORT
    snippet: "At a cellular level, abnormal mitochondrial, lysosomal, and endosomal function can be identified in both monogenic and sporadic Parkinson's disease, suggesting multiple potential treatment approaches."
    explanation: This establishes that mitochondrial dysfunction is a common cellular feature across both genetic and sporadic forms of PD, supporting its central role in disease pathogenesis.
  - reference: PMID:25611507
    reference_title: "The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease."
    supports: SUPPORT
    snippet: "Biochemical and genetic studies reveal that the products of two genes that are mutated in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together in the same pathway to govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved in Parkinson's disease."
    explanation: This directly supports the role of PINK1 and Parkin genes in mitochondrial quality control and confirms that mitochondrial damage is involved in PD pathogenesis.
  - reference: PMID:27911343
    reference_title: "PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson's Disease Pathobiology?"
    supports: SUPPORT
    snippet: "For the past 30 years, mitochondrial dysfunction has been hypothesized to play a central role in the pathobiology of this devastating neurodegenerative disease. The identifications of mutations in genes encoding PINK1 (PTEN-induced kinase 1) and Parkin (E3 ubiquitin ligase) in familial PD and their functional association with mitochondrial quality control provided further support to this hypothesis."
    explanation: This review confirms the long-standing central role of mitochondrial dysfunction in PD and validates the connection between PINK1/Parkin mutations and mitochondrial quality control defects.
  - reference: PMID:2154550
    reference_title: "Mitochondrial complex I deficiency in Parkinson's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These results indicated a specific defect of Complex I activity in the substantia nigra of patients with Parkinson's disease."
    explanation: Direct human postmortem evidence of substantia nigra complex I deficiency in Parkinson's disease, anchoring the node's human relevance beyond the rotenone animal model.
- name: PGC-1alpha Transcriptional Program Repression
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: >
    Reduced activity of the PPARGC1A-encoded transcriptional coactivator
    PGC-1alpha downregulates the nuclear-encoded bioenergetic program it
    drives - mitochondrial biogenesis, respiratory-chain subunit expression,
    and antioxidant defenses - in nigral dopaminergic neurons. Two routes
    converge on this node. In the parkin-dependent route, loss of parkin E3
    ligase function allows its substrate PARIS (ZNF746) to accumulate and
    transcriptionally repress the PPARGC1A promoter. In sporadic disease,
    PGC-1alpha-responsive bioenergetic gene sets are already underexpressed
    in laser-captured human nigral dopaminergic neurons at subclinical
    stages, placing this lesion early in the cascade rather than as a
    terminal consequence of neuron loss. The therapeutic corollary is not
    symmetric: restoring PGC-1alpha rescues dopaminergic neurons in cellular
    models, but sustained supraphysiological expression is itself toxic to
    the nigrostriatal system (see the HUMAN_MODEL_MISMATCH discussion
    pd_pgc1a_therapeutic_window).
  molecular_functions:
  - preferred_term: transcription coactivator activity
    term:
      id: GO:0003713
      label: transcription coactivator activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: mitochondrial biogenesis program
    term:
      id: GO:0007005
      label: mitochondrion organization
    modifier: DECREASED
  cell_types:
  - preferred_term: nigral dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  downstream:
  - target: Mitochondrial Dysfunction
    causal_link_type: DIRECT
    description: >
      Loss of PGC-1alpha coactivation lowers expression of nuclear-encoded
      respiratory-chain subunits, producing the electron-transport deficit
      already curated on the Mitochondrial Dysfunction node.
    evidence:
    - reference: PMID:20926834
      reference_title: "PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These gene sets pinpoint defects in mitochondrial electron transport, glucose utilization, and glucose sensing and reveal that they occur early in disease pathogenesis."
      explanation: >
        A meta-analysis of 185 laser-captured human dopaminergic neuron and
        substantia nigra transcriptomes places the PGC-1alpha-responsive
        bioenergetic deficit upstream of, and early relative to, overt
        mitochondrial failure.
    - reference: PMID:20926834
      reference_title: "PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Activation of PGC-1α results in increased expression of nuclear-encoded subunits of the mitochondrial respiratory chain and blocks the dopaminergic neuron loss induced by mutant α-synuclein or the pesticide rotenone in cellular disease models."
      explanation: >
        Rescue in the opposite direction - restoring PGC-1alpha raises
        respiratory-chain subunit expression and prevents dopaminergic loss
        in cellular models - supports the direction of this causal edge.
  - target: Oxidative Stress
    causal_link_type: DIRECT
    description: >
      PGC-1alpha coordinates the antioxidant arm of the mitochondrial stress
      response, so its repression lowers reactive-oxygen-species buffering
      capacity in nigral neurons.
    evidence:
    - reference: PMID:42430091
      reference_title: "The Role of PGC-1α in Neurodegenerative Diseases: Molecular Mechanisms, Translational Challenges, and Therapeutic Potential."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Current findings indicate that PGC-1α supports mitochondrial biogenesis, oxidative phosphorylation, antioxidant defense, mitophagy, autophagy, protein quality control, and inflammatory balance."
      explanation: >
        Review evidence that antioxidant defense is part of the PGC-1alpha
        output program, which is the basis for the edge to Oxidative Stress.
  evidence:
  - reference: PMID:21376232
    reference_title: "PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PARIS is a KRAB and zinc finger protein that accumulates in models of parkin inactivation and in human PD brain."
    explanation: >
      Establishes that the repressor upstream of PGC-1alpha accumulates in
      human Parkinson disease brain, not only in experimental models.
  - reference: PMID:21376232
    reference_title: "PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Conditional knockout of parkin in adult animals leads to progressive loss of dopamine (DA) neurons in a PARIS-dependent manner."
    explanation: >
      Genetic epistasis in adult conditional parkin knockout mice shows the
      dopaminergic loss is routed through PARIS, the PPARGC1A repressor.
  - reference: PMID:20926834
    reference_title: "PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genes controlling cellular bioenergetics that are expressed in response to peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) are underexpressed in Parkinson's disease patients."
    explanation: >
      Direct human transcriptomic evidence that the PGC-1alpha-responsive
      program is underexpressed in Parkinson disease, which is the claim this
      node asserts.
  notes: >
    PPARGC1A is deliberately not added to the `genetic` section: it is not an
    established Mendelian Parkinson disease gene, but a downstream
    transcriptional node reached from PRKN (via PARIS/ZNF746) and, in
    sporadic disease, from as-yet-unresolved upstream regulation.
- name: MAPK Dysregulation
  description: >
    Dysregulation of mitogen-activated protein kinase (MAPK) signaling, particularly
    through overactivation of the JNK and p38 cascades, accelerates neurodegeneration
    and promotes alpha-synuclein accumulation and microglial activation. While basal
    MAPK activity is essential for neuroprotection and neuronal growth, pathological
    MAPK overactivation inhibits neuroprotective PI3K/AKT and PP2A pathways and
    activates detrimental GSK-3β and PTEN signaling, driving dopaminergic neurotoxicity.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: MAPK cascade
    term:
      id: GO:0000165
      label: MAPK cascade
    modifier: INCREASED
  - preferred_term: JNK cascade
    term:
      id: GO:0007254
      label: JNK cascade
    modifier: INCREASED
  - preferred_term: p38MAPK cascade
    term:
      id: GO:0038066
      label: p38MAPK cascade
    modifier: INCREASED
  downstream:
  - target: Alpha-Synuclein Aggregation
    description: MAPK dysregulation promotes alpha-synuclein accumulation.
    evidence:
    - reference: PMID:42320726
      reference_title: "Molecular crosstalk between MAPK signaling and neuroprotective pathways in Parkinson's disease: from pathogenesis to therapeutic potential."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "detailing how its dysregulation promotes the accumulation of alpha-synuclein and the activation of microglia"
      explanation: >
        The paper identifies MAPK dysregulation as promoting alpha-synuclein accumulation, supporting this downstream causal link.
  - target: Neuroinflammation
    description: MAPK overactivation drives microglial activation and pro-inflammatory cytokine release.
    evidence:
    - reference: PMID:42320726
      reference_title: "Molecular crosstalk between MAPK signaling and neuroprotective pathways in Parkinson's disease: from pathogenesis to therapeutic potential."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "detailing how its dysregulation promotes the accumulation of alpha-synuclein and the activation of microglia"
      explanation: >
        The paper identifies MAPK dysregulation as promoting microglial activation, a key driver of neuroinflammation in PD.
  - target: Dopaminergic Neuron Loss
    description: MAPK-driven oxidative stress, impaired neuroprotection, and neuroinflammation converge to promote dopaminergic neurotoxicity.
    evidence:
    - reference: PMID:42320726
      reference_title: "Molecular crosstalk between MAPK signaling and neuroprotective pathways in Parkinson's disease: from pathogenesis to therapeutic potential."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Preclinical evidence strongly supports the use of MAPK inhibitors to mitigate dopaminergic neurotoxicity and reduce proinflammatory cytokine release"
      explanation: >
        The paper's discussion of MAPK inhibitors as a strategy to reduce dopaminergic neurotoxicity indicates that MAPK dysregulation drives neuronal loss.
  evidence:
  - reference: PMID:42320726
    reference_title: "Molecular crosstalk between MAPK signaling and neuroprotective pathways in Parkinson's disease: from pathogenesis to therapeutic potential."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "While basal MAPK activity is essential for neuroprotection and neuronal growth, its overactivation, specifically via the JNK and p38 cascades, accelerates neurodegeneration."
    explanation: >
      This review establishes MAPK/JNK/p38 overactivation as a central driver of PD neurodegeneration, providing strong evidence for MAPK dysregulation as a distinct pathophysiological node.
  - reference: PMID:42320726
    reference_title: "Molecular crosstalk between MAPK signaling and neuroprotective pathways in Parkinson's disease: from pathogenesis to therapeutic potential."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "highlights critical crosstalk between MAPK and other vital pathways, including the inhibition of the neuroprotective PI3K/AKT and PP2A pathways and the detrimental activation of GSK-3β and PTEN signaling."
    explanation: >
      This describes the broader signaling context of MAPK dysregulation, including inhibition of neuroprotective and activation of pro-degenerative pathways.
- name: Neuroinflammation
  description: >
    Sustained glial activation in the PD brain, driven principally by microglia,
    with pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6), M1-like phenotype
    polarization, and complement cascade activation. Reactive astrocytes feed this
    state through their own release of inflammatory mediators; that arm is modeled
    separately as Reactive Astrogliosis.
  cell_types:
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: TNF-alpha production
    term:
      id: GO:0032640
      label: tumor necrosis factor production
    modifier: INCREASED
  - preferred_term: IL-1beta production
    term:
      id: GO:0032611
      label: interleukin-1 beta production
    modifier: INCREASED
  - preferred_term: IL-6 production
    term:
      id: GO:0032635
      label: interleukin-6 production
    modifier: INCREASED
  downstream:
  - target: Dopaminergic Neuron Loss
    evidence:
    - reference: PMID:37048085
      reference_title: "Microglia Mediated Neuroinflammation in Parkinson's Disease."
      supports: SUPPORT
      snippet: "Neuroinflammation has emerged as an involving mechanism at the initiation and development of PD."
      explanation: This indicates neuroinflammation contributes to PD progression, supporting dopaminergic neuron loss downstream.
  - target: Complement C3-C3aR Activation in Depression
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >
      Microglial neuroinflammation drives complement cascade activation (C3-C3aR axis) as part of
      the broader innate immune response, with convergent upregulation of complement and coagulation
      pathways in depression associated with PD. This complement-mediated branch contributes to
      depression-like behavior via microglial synaptic pruning, distinct from dopaminergic motor pathology.
    evidence:
    - reference: PMID:42263400
      reference_title: "The complement C3-microglial axis in depression of Parkinson's disease: from mechanism to therapeutic intervention."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In MPTP-treated male and female mice, hippocampal complement components (C1Q, C3, C3aR) and downstream signalling (p-STAT3, p-P65) were elevated, accompanied by microglial synapse phagocytosis and depressive-like behaviours."
      explanation: Mouse model demonstrates that neuroinflammatory upregulation of complement cascades drives hippocampal complement component elevation and microglial synaptic engulfment, manifesting as depressive-like behavior independent of motor phenotype.
  evidence:
  - reference: PMID:38245249
    reference_title: "The pathogenesis of Parkinson's disease."
    supports: SUPPORT
    snippet: "Recent work has also highlighted maladaptive immune and inflammatory responses, possibly triggered in the gut, that accelerate the pathogenesis of Parkinson's disease."
    explanation: This establishes that maladaptive immune and inflammatory responses play an active role in accelerating PD pathogenesis, supporting the neuroinflammation mechanism.
  - reference: PMID:37048085
    reference_title: "Microglia Mediated Neuroinflammation in Parkinson's Disease."
    supports: SUPPORT
    snippet: "Neuroinflammation has emerged as an involving mechanism at the initiation and development of PD. It is a complex network of interactions comprising immune and non-immune cells in addition to mediators of the immune response. Microglia, the resident macrophages in the CNS, take on the leading role in regulating neuroinflammation and maintaining homeostasis."
    explanation: This directly supports the role of microglia-mediated neuroinflammation in PD initiation and progression, confirming the importance of microglial activation in disease pathology.
  - reference: PMID:36598534
    reference_title: "Role of α-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson's disease."
    supports: SUPPORT
    snippet: "Neuroinflammation driven by microglia is an important pathological manifestation of PD. α-Syn is a crucial marker of PD, and its accumulation leads to microglia M1-like phenotype polarization, activation of NLRP3 inflammasomes, and impaired autophagy and phagocytosis in microglia."
    explanation: This links α-synuclein accumulation to microglial activation and pro-inflammatory M1 phenotype polarization, supporting the mechanism by which neuroinflammation contributes to neurodegeneration in PD.
- name: Reactive Astrogliosis
  biological_scale: CELLULAR
  description: >
    Conversion of astrocytes from a homeostatic, broadly neuroprotective state —
    neurotrophic factor secretion, blood-brain barrier regulation, and
    water-electrolyte and glutamate homeostasis — to a reactive state that releases
    inflammatory mediators, fails to clear synaptic glutamate, and triggers
    oxidative stress. Studies indicate that mutations in PD-associated genes may
    induce functional alterations in astrocytes; the cited review names no
    individual genes, so no per-gene claim is made here. Whether astrocytes protect
    or accelerate dopaminergic degeneration is regulated by bidirectional
    astrocyte-neuron and astrocyte-glia crosstalk.
  cell_types:
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Astrocyte activation
    term:
      id: GO:0048143
      label: astrocyte activation
    modifier: INCREASED
  - preferred_term: Astrocytic clearance of synaptic glutamate
    term:
      id: GO:0098712
      label: L-glutamate import across plasma membrane
    modifier: DECREASED
  downstream:
  - target: Dopaminergic Neuron Loss
    evidence:
    - reference: PMID:42599550
      reference_title: "Astrocytes orchestrate neuroprotection and pathogenesis via bidirectional neuronal interactions in Parkinson's disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Activated astrocytes accelerate neuronal degeneration by releasing inflammatory mediators, disrupting glutamate homeostasis, and triggering oxidative stress."
      explanation: States that reactive astrocytes accelerate neuronal degeneration, which is the edge this asserts.
  - target: Neuroinflammation
    description: >
      Reactive astrocytes release inflammatory mediators, adding an astrocytic arm
      to the glial inflammatory state that microglia principally drive.
    evidence:
    - reference: PMID:42599550
      reference_title: "Astrocytes orchestrate neuroprotection and pathogenesis via bidirectional neuronal interactions in Parkinson's disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Activated astrocytes accelerate neuronal degeneration by releasing inflammatory mediators, disrupting glutamate homeostasis, and triggering oxidative stress."
      explanation: Names release of inflammatory mediators as a mechanism of activated astrocytes, supporting the edge into the neuroinflammatory node.
  - target: Oxidative Stress
    evidence:
    - reference: PMID:42599550
      reference_title: "Astrocytes orchestrate neuroprotection and pathogenesis via bidirectional neuronal interactions in Parkinson's disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Activated astrocytes accelerate neuronal degeneration by releasing inflammatory mediators, disrupting glutamate homeostasis, and triggering oxidative stress."
      explanation: Names triggering of oxidative stress as a mechanism of activated astrocytes.
  - target: Blood-Brain Barrier Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >
      Astrocytes are one of the cell types regulating the blood-brain barrier, so
      loss of that homeostatic function on reactive conversion is a route into
      barrier breakdown. The cited review establishes the astrocytic BBB-regulatory
      role but does not itself report barrier breakdown caused by reactive
      astrocytes, so this edge is left uncited rather than over-claimed.
  evidence:
  - reference: PMID:42599550
    reference_title: "Astrocytes orchestrate neuroprotection and pathogenesis via bidirectional neuronal interactions in Parkinson's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Recent studies indicate that mutations in PD-associated genes may induce functional alterations in astrocytes."
    explanation: Supports a genetic contribution to astrocyte dysfunction in PD, hedged as "may induce functional alterations" and naming no individual gene.
  - reference: PMID:42599550
    reference_title: "Astrocytes orchestrate neuroprotection and pathogenesis via bidirectional neuronal interactions in Parkinson's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Furthermore, bidirectional regulatory interactions exist between astrocytes and both dopaminergic neurons and other glial cells in PD."
    explanation: Identifies bidirectional astrocyte-neuron and astrocyte-glia crosstalk as the regulator of which arm predominates.
- name: Complement C3-C3aR Activation in Depression
  description: >
    Elevated complement cascade activation, particularly the C3-C3aR signaling axis,
    drives microglial synaptic engulfment and loss. In depression associated with
    Parkinson disease, hippocampal complement components (C1Q, C3, C3aR) and downstream
    signaling (p-STAT3, p-P65) are upregulated, promoting microglial phagocytosis of
    synapses and contributing to depressive symptoms. This represents a distinct
    complement-mediated pathogenic pathway in depression, separable from canonical
    dopaminergic motor circuit involvement.
  cell_types:
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  locations:
  - preferred_term: hippocampal formation
    term:
      id: UBERON:0002421
      label: hippocampal formation
  biological_processes:
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
    modifier: INCREASED
  - preferred_term: synapse pruning
    term:
      id: GO:0098883
      label: synapse pruning
    modifier: INCREASED
  downstream:
  - target: Depression
    causal_link_type: DIRECT
    description: >
      Complement C3-C3aR-mediated microglial synaptic engulfment leads to hippocampal
      synaptic loss and dysfunction, manifesting as depression and mood disturbance
      in Parkinson disease.
    evidence:
    - reference: PMID:42263400
      reference_title: "The complement C3-microglial axis in depression of Parkinson's disease: from mechanism to therapeutic intervention."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In MPTP-treated male and female mice, hippocampal complement components (C1Q, C3, C3aR) and downstream signalling (p-STAT3, p-P65) were elevated, accompanied by microglial synapse phagocytosis and depressive-like behaviours. Genetic deletion of C3 rescued both MPTP-induced motor and depressive-like behavioural deficits and prevented hippocampal synaptic loss associated with microglial synaptic engulfment."
      explanation: >
        Elevation of hippocampal complement components strongly correlates with microglial
        synaptic phagocytosis and depressive-like behaviors in MPTP mice. C3 deletion
        rescued depressive deficits and prevented synaptic loss, demonstrating causal
        linkage of complement activation to depression in PD models.
  evidence:
  - reference: PMID:42263400
    reference_title: "The complement C3-microglial axis in depression of Parkinson's disease: from mechanism to therapeutic intervention."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In MPTP-treated male and female mice, hippocampal complement components (C1Q, C3, C3aR) and downstream signalling (p-STAT3, p-P65) were elevated, accompanied by microglial synapse phagocytosis and depressive-like behaviours."
    explanation: >
      MPTP mouse model demonstrates upregulation of complement cascade components in
      hippocampus alongside microglial synaptic phagocytosis and depression-like behaviors,
      establishing the complement pathway as a mechanism driving depression in PD.
  - reference: PMID:42263400
    reference_title: "The complement C3-microglial axis in depression of Parkinson's disease: from mechanism to therapeutic intervention."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DPD exhibits distinct sex-specific immune signatures, with convergent complement pathway activation driving microglial synaptic pruning and depressive symptoms."
    explanation: >
      Human plasma proteomic analysis from PPMI cohort reveals that depression in PD
      exhibits sex-specific complement pathway dysregulation, establishing complement
      activation as a mechanism contributing to depressive symptoms.
  - reference: PMID:42263400
    reference_title: "The complement C3-microglial axis in depression of Parkinson's disease: from mechanism to therapeutic intervention."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The antidepressant effect of BoNT/A is mediated through inhibition of the C3-C3aR signalling axis."
    explanation: >
      Mouse model studies demonstrate that complement pathway inhibition (via BoNT/A
      blocking C3-C3aR signaling) alleviates depressive-like symptoms and reduces
      microglial synaptic engulfment, providing mechanistic validation of C3-C3aR
      as a therapeutic target in depression.
- name: Autophagy-Lysosome Pathway Dysfunction
  biological_scale: CELLULAR
  conforms_to: "disabled_macroautophagy#Failure of Cytoplasmic Quality Control"
  description: >
    Impairment of the autophagy-lysosome pathway disrupts clearance of misfolded
    proteins including alpha-synuclein. Multiple PD genes (GBA, LRRK2, VPS35,
    ATP13A2) regulate lysosomal function, and their mutations impair protein
    degradation capacity leading to toxic protein accumulation.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Autophagy
    term:
      id: GO:0006914
      label: autophagy
  - preferred_term: Chaperone-mediated Autophagy
    term:
      id: GO:0061684
      label: chaperone-mediated autophagy
  downstream:
  - target: Alpha-Synuclein Aggregation
    evidence:
    - reference: PMID:31761667
      reference_title: "Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics."
      supports: SUPPORT
      snippet: "α-synuclein, encoded by the SNCA gene, is degraded mainly by the ALP, and mutations/multiplications in SNCA may lead to impairment of chaperone mediated autophagy or other ALP functions."
      explanation: This shows that autophagy-lysosome pathway dysfunction impairs α-synuclein clearance, supporting aggregation downstream.
  - target: Dopaminergic Neuron Loss
    evidence:
    - reference: PMID:31761667
      reference_title: "Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics."
      supports: SUPPORT
      snippet: "In recent years, multiple lines of evidence from human genetic and molecular studies have highlighted the importance of the autophagy lysosomal pathway (ALP) in Parkinson's disease (PD)."
      explanation: This supports ALP dysfunction as a key PD mechanism contributing to neuronal degeneration.
  evidence:
  - reference: PMID:31761667
    reference_title: "Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics."
    supports: SUPPORT
    snippet: "In recent years, multiple lines of evidence from human genetic and molecular studies have highlighted the importance of the autophagy lysosomal pathway (ALP) in Parkinson's disease (PD). Genes such as GBA and LRRK2, which harbor some of the most common mutations associated with PD, have essential roles in the ALP."
    explanation: This review establishes the genetic basis for autophagy-lysosome dysfunction in PD, identifying key genes and their mechanistic roles.
- name: LRRK2 GTPase Domain Dysregulation
  description: >
    Leucine-rich repeat kinase 2 (LRRK2) mutations disrupt the conformational dynamics of its ROC
    (Ras of complex proteins) G-domain, impairing GTPase activity and nucleotide (GTP/GDP) cycling.
    The arginine residue at position 1398 acts as a critical GTP-γ-phosphate sensor that regulates
    the ROC domain's active-to-inactive state transition. Pathogenic ROC/GTPase-domain mutations
    (e.g., R1441C/G/H) impair GTP hydrolysis, stabilize the constitutively active GTP-bound state,
    and enhance Rab29-dependent recruitment of LRRK2 to the trans-Golgi network. This dysregulation
    impairs vesicular trafficking, autophagosome-lysosome fusion, and clearance of alpha-synuclein
    aggregates, promoting neurodegeneration. Protective variants (e.g., R1398H) stabilize the
    GDP-bound inactive state and reduce disease risk, suggesting that GTPase domain normalization
    rather than kinase inhibition may be a disease-modifying therapeutic strategy.
  genes:
  - preferred_term: LRRK2
    term:
      id: hgnc:18618
      label: LRRK2
  cell_types:
  - preferred_term: Dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Autophagy
    term:
      id: GO:0006914
      label: autophagy
    modifier: DECREASED
  - preferred_term: Intracellular protein localization
    term:
      id: GO:0008104
      label: intracellular protein localization
    modifier: DYSREGULATED
  - preferred_term: Vesicle-mediated transport
    term:
      id: GO:0016192
      label: vesicle-mediated transport
    modifier: DECREASED
  downstream:
  - target: Autophagy-Lysosome Pathway Dysfunction
    description: Dysregulated LRRK2 GTPase activity impairs Rab29-dependent autophagosome-lysosome fusion and alpha-synuclein clearance.
  - target: Dopaminergic Neuron Loss
    description: Impaired protein clearance and autophagy promote accumulation of toxic protein aggregates and neuronal death.
  evidence:
  - reference: PPR:PPR1263597
    reference_title: "R1398 is the GTP-𝛾-phosphate sensor that drives the ROC G-domain switching mechanism unique to Parkinson's disease-associated LRRK2"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "A naturally occurring protective variant, R1398H, provides an alternative route for understanding how reduced disease risk may be achieved by tuning the regulatory GTPase domain rather than the kinase domain itself."
    explanation: Preprint demonstrates that GTPase domain tuning via protective R1398H variant may be a disease-modifying strategy, supporting the model that ROC domain conformational control is critical for LRRK2-related PD.
  - reference: PPR:PPR1263597
    reference_title: "R1398 is the GTP-𝛾-phosphate sensor that drives the ROC G-domain switching mechanism unique to Parkinson's disease-associated LRRK2"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Purified ROC carrying R1398H is folded but resolves as a stable homodimer corresponding to the GDP-bound off state previously defined for wild-type ROC."
    explanation: Biochemical analysis demonstrates that the protective R1398H variant stabilizes the inactive GDP-bound state, providing structural evidence for GTPase domain regulation as a disease-modifying mechanism.
  - reference: PPR:PPR1263597
    reference_title: "R1398 is the GTP-𝛾-phosphate sensor that drives the ROC G-domain switching mechanism unique to Parkinson's disease-associated LRRK2"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "R1398H reduces GTP hydrolysis, selectively weakens GTP-state stabilization while preserving GDP binding, and decreases Rab29-dependent trans-Golgi recruitment of full-length LRRK2."
    explanation: The protective variant reduces aberrant trans-Golgi recruitment, supporting the model that GTPase domain normalization may prevent pathological LRRK2 localization and consequent autophagy impairment.
- name: Gut Microbiome Dysbiosis
  conforms_to: "gut_dysbiosis#Age-Associated Gut Microbiota Alteration"
  description: >
    Parkinson disease cohorts show reproducible but modest gut microbiome
    shifts, including depletion of short-chain-fatty-acid-producing taxa and
    enrichment of genera linked to mucin or inflammatory biology. In the
    body-first model, dysbiosis is modeled as a plausible upstream trigger or
    modifier of intestinal inflammation and barrier dysfunction, not as an
    established direct cause of alpha-synuclein initiation.
  cell_types:
  - preferred_term: Enteroendocrine Cell
    term:
      id: CL:0000164
      label: enteroendocrine cell
  locations:
  - preferred_term: intestine
    term:
      id: UBERON:0000160
      label: intestine
  downstream:
  - target: Intestinal Inflammation and Barrier Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - body_first_enteric_alpha_synuclein_model
    description: >
      PD-associated dysbiosis may promote a pro-inflammatory intestinal state
      and barrier dysfunction, but the direction and necessity of this link
      remain unresolved in humans.
    evidence:
    - reference: PMID:33692356
      reference_title: "Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This dysbiosis might result in a pro-inflammatory status which could be linked to the recurrent gastrointestinal symptoms affecting PD patients."
      explanation: >
        Cross-cohort microbiome meta-analysis supports a dysbiosis-to-inflammation
        interpretation but phrases the causal link as a possibility.
    - reference: PMID:34220443
      reference_title: "Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A causal relationship has not been established, but gut dysbiosis is prevalent in PD and may lead to intestinal inflammation and barrier dysfunction."
      explanation: >
        Human marker data support modeling dysbiosis upstream of barrier and
        inflammatory changes while explicitly preserving causal uncertainty.
  evidence:
  - reference: PMID:33692356
    reference_title: "Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found significant alterations in the PD-associated microbiome, which are robust to study-specific technical heterogeneities, although differences in microbiome structure between PD and controls are small."
    explanation: >
      Meta-analysis across ten 16S datasets supports a reproducible
      PD-associated gut microbiome signature, while noting small effect sizes.
  - reference: PMID:36332796
    reference_title: "Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Alterations in the gut microbiome and associated metabolites may contribute to pathogenesis in PD."
    explanation: >
      Review-level evidence supports gut microbiome changes as plausible
      contributors to PD pathogenesis, but not as proven initiators.
- name: Intestinal Inflammation and Barrier Dysfunction
  conforms_to: "gut_dysbiosis#Intestinal Barrier Dysfunction and Microbial Translocation"
  description: >
    Sporadic Parkinson disease is associated with elevated intestinal
    inflammatory and permeability markers. These changes may create a local
    milieu that increases alpha-synuclein expression or exposes enteric neurons
    to amyloidogenic microbial or dietary compounds, but whether they initiate
    body-first PD or arise secondary to gut autonomic dysfunction remains open.
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Enteric Alpha-Synuclein Seeding
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - body_first_enteric_alpha_synuclein_model
    description: >
      Local gut inflammation and barrier leakiness may increase enteric
      alpha-synuclein expression or amyloidogenic exposure, providing a
      permissive setting for enteric alpha-synuclein seeding.
    evidence:
    - reference: PMID:34220443
      reference_title: "Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Gut dysbiosis is common in PD and can result in local inflammatory changes and barrier dysfunction/disruption, which may increase alpha-synuclein expression and facilitate its exposure to amyloidogenic compounds found in the gut, thus possibly contributing to key pathogenic events in PD; prospective evidence is nevertheless scarce"
      explanation: >
        Human marker study discussion supports a plausible route from
        dysbiosis/inflammation/barrier disruption to enteric alpha-synuclein
        seeding but explicitly notes scarce prospective evidence.
    - reference: PMID:42295088
      reference_title: "Peripheral Immune Challenge Drives Enteric α-Synuclein and Tau Pathology in LRRK2 G2019S Mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Overall, our findings demonstrate that chronic peripheral inflammation synergizes with LRRK2 G2019S to trigger early intestinal inflammation and α-synuclein/tau co-pathology in the absence of overt neurodegeneration."
      explanation: >-
        Supplies the missing directionality for this edge in a model system:
        chronic low-dose LPS exposure produces colonic immune infiltration and
        then enteric alpha-synuclein accumulation and phosphorylation. The
        effect is conditional on the LRRK2 G2019S genotype, so it does not show
        that inflammation alone seeds enteric alpha-synuclein in sporadic human
        disease.
    - reference: PMID:42327194
      reference_title: "Gut bacterial Infection drives Parkinsonian pathology in LRRK2 G2019S Knock-in Mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In parallel, recurrent infection induced pronounced intestinal p-αSyn accumulation and expansion of pathology beyond the epithelial layer in KI mice, supporting a gut-brain axis mechanism linking intestinal inflammation to neurodegeneration."
      explanation: >-
        Independent inflammatory trigger, same edge: recurrent Citrobacter
        rodentium infection drives colonic inflammation and barrier dysfunction
        followed by intestinal phosphorylated alpha-synuclein accumulation.
        Again genotype-conditional - wild-type mice were largely resistant - so
        it supports a gene-environment route into enteric seeding rather than a
        general one.
  evidence:
  - reference: PMID:34220443
    reference_title: "Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Calprotectin and zonulin are markers of intestinal inflammation and barrier permeability, respectively."
    explanation: >
      Establishes the measured marker interpretation for this intestinal
      inflammation and barrier dysfunction node.
  - reference: PMID:34220443
    reference_title: "Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mean calprotectin was higher in PD, both in serum (14.26 mcg/ml ± 4.50 vs. 5.94 mcg/ml ± 3.80, p = 0.0125) and stool (164.54 mcg/g ± 54.19 vs. 56.19 mcg/g ± 35.88, p = 0.0048)."
    explanation: >
      Case-control data support elevated intestinal inflammatory markers in PD.
- name: Enteric Alpha-Synuclein Seeding
  description: >
    In the body-first model, misfolded alpha-synuclein appears first in enteric
    or peripheral autonomic neural tissue and serves as the initiating seed for
    subsequent gut-to-brain spread. Direct causal support comes primarily from
    animal models that seed pathologic alpha-synuclein in the gastrointestinal
    wall.
  cell_types:
  - preferred_term: Enteric Neuron
    term:
      id: CL:0007011
      label: enteric neuron
  locations:
  - preferred_term: enteric nervous system
    term:
      id: UBERON:0002005
      label: enteric nervous system
  biological_processes:
  - preferred_term: inclusion body assembly
    term:
      id: GO:0070841
      label: inclusion body assembly
  downstream:
  - target: Vagal-Brainstem Alpha-Synuclein Propagation
    causal_link_type: DIRECT
    hypothesis_groups:
    - body_first_enteric_alpha_synuclein_model
    description: >
      Enteric alpha-synuclein seeds can propagate first to vagal brainstem
      nuclei and then to additional brain regions.
    evidence:
    - reference: PMID:31255487
      reference_title: "Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Spread of pathologic α-syn in brain, as assessed by phosphorylation of serine 129 of α-syn, was observed first in the dorsal motor nucleus, then in caudal portions of the hindbrain"
      explanation: >
        Gut-seeded mouse alpha-synuclein pathology first appears in vagal
        brainstem regions, supporting the enteric seeding to vagal propagation
        edge.
    - reference: PMID:39241780
      reference_title: "Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson's and Alzheimer's disease co-pathology and behavior impairments."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Gut pathology was initially observed, and α-Syn or Tau pathology was subsequently propagated into the DMV or NTS and then to other brain regions."
      explanation: >
        Independent gut-inducible mouse models support propagation from gut
        pathology to vagal brainstem nuclei and then broader brain regions.
  - target: Constipation
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - body_first_enteric_alpha_synuclein_model
    description: >
      Enteric or autonomic involvement is a plausible contributor to early
      constipation in body-first PD, but this edge remains clinically inferred.
    evidence:
    - reference: PMID:34220443
      reference_title: "Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "most people with sporadic PD develop gastrointestinal symptoms related to decreased transit time, constipation preceding the motor dysfunction with more than a decade in some cases"
      explanation: >
        Supports constipation as an early gastrointestinal manifestation
        compatible with body-first PD, without proving enteric seeding as its
        cause.
  evidence:
  - reference: PMID:31255487
    reference_title: "Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "fibrils were injected into the duodenal and pyloric muscularis layer"
    explanation: >
      The gut-to-brain transmission model experimentally seeds pathologic
      alpha-synuclein in the gastrointestinal wall.
  - reference: PMID:34220443
    reference_title: "Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The coexistence of an amyloidogenic gut microbiota with intestinal inflammation (leading to local overexpression of alpha-synuclein) and altered intestinal barrier permeability (exposing alpha-synuclein to the amyloidogenic xenobiotics) may play a key role in triggering the initial alpha-synuclein conformational changes in some people with sporadic PD"
    explanation: >
      Human review/discussion within the marker study supports enteric
      alpha-synuclein seeding as a plausible but not proven event in some
      sporadic PD cases.
- name: Vagal-Brainstem Alpha-Synuclein Propagation
  description: >
    Pathologic alpha-synuclein seeded in the gastrointestinal wall can propagate
    through vagal connections to the dorsal motor nucleus, nucleus tractus
    solitarius, caudal hindbrain, and ultimately midbrain and forebrain regions.
    Vagotomy experiments provide the strongest causal evidence for this
    body-first conduit.
  locations:
  - preferred_term: vagus nerve
    term:
      id: UBERON:0001759
      label: vagus nerve
  - preferred_term: midbrain
    term:
      id: UBERON:0001891
      label: midbrain
  downstream:
  - target: Alpha-Synuclein Aggregation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - body_first_enteric_alpha_synuclein_model
    intermediate_mechanisms:
    - dorsal motor nucleus and nucleus tractus solitarius involvement
    - caudal hindbrain and higher brain region propagation
    description: >
      Vagal-brainstem propagation links gut-origin pathology to the broader
      central alpha-synuclein aggregation cascade.
    evidence:
    - reference: PMID:31255487
      reference_title: "Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Truncal vagotomy and α-syn deficiency prevented the gut-to-brain spread of α-synucleinopathy and associated neurodegeneration and behavioral deficits."
      explanation: >
        Vagotomy rescue supports the vagus nerve as a required conduit for
        gut-origin alpha-synucleinopathy reaching the brain.
    - reference: PMID:39241780
      reference_title: "Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson's and Alzheimer's disease co-pathology and behavior impairments."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Truncal vagotomy and α-Syn deficiency significantly inhibited synucleinopathy or tauopathy spreading."
      explanation: >
        Independent gut-inducible mouse data support the same vagal conduit for
        inhibitable synucleinopathy spread.
  - target: Pontine Tegmental Alpha-Synuclein Pathology
    causal_link_type: DIRECT
    hypothesis_groups:
    - body_first_enteric_alpha_synuclein_model
    description: >
      As vagal-brainstem propagation continues rostrally, the pontine tegmentum
      - the site of the REM-atonia-generating circuit - is reached ahead of the
      nigrostriatal and cortical structures that define overt motor and
      cognitive disease.
    evidence:
    - reference: PMID:20187227
      reference_title: "Evidence in favor of Braak staging of Parkinson's disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "involvement of anterior olfactory nucleus, medulla, and pontine tegmentum occur earlier"
      explanation: >
        A large autopsy series confirms pontine tegmental Lewy pathology
        precedes substantia nigra involvement in the Braak sequence, the
        anatomical basis for this node sitting upstream of the nigrostriatal
        nodes in the pathograph.
  evidence:
  - reference: PMID:31255487
    reference_title: "Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Analysis of human pathology led Braak to postulate that α-synuclein (α-syn) pathology could spread from the gut to brain via the vagus nerve."
    explanation: >
      Establishes the gut-to-brain vagal propagation hypothesis tested by the
      mouse transmission model.
  - reference: PMID:39241780
    reference_title: "Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson's and Alzheimer's disease co-pathology and behavior impairments."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "α-Syn and Tau co-pathology can propagate from the gut to the brain, triggering behavioral disorders."
    explanation: >
      Supports gut-to-brain propagation in a gut-inducible transgenic mouse
      system.
- name: Pontine Tegmental Alpha-Synuclein Pathology
  description: >
    Braak staging places pontine tegmental involvement ahead of substantia
    nigra pathology in the same caudo-rostral progression that vagal-brainstem
    propagation follows. The pontine tegmentum houses the glutamatergic REM-on
    circuit whose descending limb generates REM sleep muscle atonia. In
    Parkinson disease the lesion at this site is degenerative rather than
    structural, narcoleptic, or drug-induced, and it arrives at a topographic
    stage that precedes the nigrostriatal degeneration defining overt motor
    disease.
  role: trigger
  biological_scale: CELLULAR
  conforms_to: "rem_sleep_atonia_control_failure#Lesion of the Pontine REM-Atonia Generator"
  biological_processes:
  - preferred_term: inclusion body assembly
    term:
      id: GO:0070841
      label: inclusion body assembly
  cell_types:
  - preferred_term: glutamatergic REM-on neuron of the sublaterodorsal nucleus
    term:
      id: CL:0000540
      label: neuron
    modifier: DECREASED
  locations:
  - preferred_term: sublaterodorsal nucleus
    term:
      id: UBERON:8440035
      label: sublaterodorsal nucleus
  - preferred_term: pons
    term:
      id: UBERON:0000988
      label: pons
  - preferred_term: brainstem
    term:
      id: UBERON:0002298
      label: brainstem
  downstream:
  - target: Loss of Descending Drive to Inhibitory Premotor Neurons
    causal_link_type: DIRECT
    hypothesis_groups:
    - body_first_enteric_alpha_synuclein_model
    description: >
      Pathology involving the pontine REM-on glutamatergic population removes
      the excitatory drive its descending axons carry to medullary and spinal
      inhibitory premotor neurons.
  evidence:
  - reference: PMID:20187227
    reference_title: "Evidence in favor of Braak staging of Parkinson's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proportion of cases that fit the PD staging scheme was 67% for incidental LBs; 86% for PSP with LBs; 86% for pure LBD; and 84% for LBD with AD"
    explanation: >
      Dickson's own autopsy series, rather than its statement of what Braak
      proposed: the caudo-rostral ordering that places pontine tegmental
      involvement before substantia nigra pathology holds in 84-86% of Lewy
      body disease cases. This is what licenses placing this node upstream of
      the nigrostriatal nodes in the pathograph.
  - reference: PMID:17412731
    reference_title: "Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The hypothesized pathophysiology of RBD is presented in relation to the Braak staging system for Parkinson's disease, in which the topography and temporal sequence of synuclein pathology in the brain could explain the evolution of parkinsonism and/or dementia well after the onset of RBD."
    explanation: >
      Ties the Braak sequence specifically to RBD pathophysiology rather than
      to brainstem involvement in general, which is the step that licenses
      placing this node upstream of the atonia nodes and that the staging paper
      alone does not make. Graded OTHER rather than HUMAN_CLINICAL because the
      quoted sentence states a hypothesis this Brain review advances, not a
      patient observation it reports - matching the grade
      `rem_sleep_atonia_control_failure.yaml` gives the comparable "is proposed
      as" sentence from the same paper.
  - reference: PMID:39577924
    reference_title: "Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In all participants, α-synuclein was found in the structures that regulate REM sleep atonia (eg, subcoeruleus nucleus, gigantocellular reticular nucleus, laterodorsal tegmentum, and amygdala)"
    explanation: >
      Places the pathology in the atonia-generating nuclei themselves, not
      merely somewhere in the pontine tegmentum. The pontine tegmentum is a
      large region and Braak stage 2 is classically locus coeruleus and caudal
      raphe, so without this the lesion claim would rest on the region-level
      ordering alone. Note the inferential step: this cohort is isolated RBD
      rather than diagnosed Parkinson disease, so it evidences the lesion
      topography rather than its presence in established PD.

- name: Loss of Descending Drive to Inhibitory Premotor Neurons
  description: >
    REM atonia is actively imposed rather than passively permitted: the
    glutamatergic REM-on population excites glycinergic and GABAergic premotor
    neurons in the ventromedial medulla and spinal cord, which hyperpolarise
    skeletal motor neurons. Losing the descending drive therefore releases
    motor neurons from an inhibition that should be present. This descending
    pathway is separate from the ascending pathway that generates the EEG
    features of REM sleep, so it can be lost while REM sleep itself proceeds
    normally - which is what polysomnography shows in Parkinson disease.
  role: amplifier
  biological_scale: CELLULAR
  conforms_to: "rem_sleep_atonia_control_failure#Loss of Descending Glutamatergic Drive to Inhibitory Premotor Neurons"
  biological_processes:
  - preferred_term: glutamatergic synaptic transmission
    term:
      id: GO:0035249
      label: synaptic transmission, glutamatergic
    modifier: DECREASED
  - preferred_term: inhibitory regulation of skeletal motor neuron output
    term:
      id: GO:0006937
      label: regulation of muscle contraction
    modifier: DECREASED
  locations:
  - preferred_term: brainstem
    term:
      id: UBERON:0002298
      label: brainstem
  downstream:
  - target: REM Sleep Muscle Atonia Loss
    causal_link_type: DIRECT
    hypothesis_groups:
    - body_first_enteric_alpha_synuclein_model
    description: >
      Without descending excitation of the inhibitory premotor pool, skeletal
      motor neurons are not hyperpolarised during REM sleep and muscle tone
      persists.
  evidence:
  - reference: PMID:17884926
    reference_title: "The pontine REM switch: past and present."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In the REM-on area are two populations of glutamatergic neurons, the
      first of which projects to the basal forebrain and regulates EEG
      components of REM sleep and the second of which projects to the
      ventromedial medulla and spinal cord and regulates atonia during REM
      sleep.
    explanation: >
      The two-population anatomy this node depends on: a descending atonia
      limb separable from the ascending EEG limb.
  - reference: PMID:17884926
    reference_title: "The pontine REM switch: past and present."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Our findings demonstrating independent pathways mediating atonia and
      the EEG components of REM provide a basis for their occasional
      dissociation in pathological states, e.g. REM sleep behaviour
      disorder.
    explanation: >
      States the dissociation explicitly and names RBD as its pathological
      instance, which is what permits atonia to fail here while REM sleep
      itself is preserved.

- name: REM Sleep Muscle Atonia Loss
  description: >
    Excess tonic or phasic electromyographic activity during scored REM sleep,
    the measurable abnormality that underlies dream enactment in Parkinson
    disease. Polysomnography confirms REM sleep
    without atonia in the majority of PD patients studied - more often than
    the clinical behavioural history alone identifies - so the
    electrophysiological finding runs ahead of, and is more sensitive than, a
    clinical diagnosis of REM sleep behavior disorder.
  role: central_effector
  biological_scale: ORGANISM
  conforms_to: "rem_sleep_atonia_control_failure#Failure of REM Sleep Skeletal Muscle Atonia"
  biological_processes:
  - preferred_term: REM sleep
    term:
      id: GO:0042747
      label: circadian sleep/wake cycle, REM sleep
    modifier: ABNORMAL
  - preferred_term: skeletal muscle contraction during REM sleep
    term:
      id: GO:0003009
      label: skeletal muscle contraction
    modifier: INCREASED
  downstream:
  - target: REM Sleep Behavior Disorder
    causal_link_type: DIRECT
    description: >
      Where atonia loss is accompanied by dream-enactment behaviour rather than
      remaining electrophysiologically silent, the released motor programmes
      generated during dreaming are enacted, producing the clinical phenotype.
    evidence:
    - reference: PMID:12196654
      reference_title: "REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Of these 19 patients with PD, 8 (42%) did not present with behavioral manifestations of RBD, and their cases may represent preclinical forms of RBD associated with PD."
      explanation: >
        Supports the conditional form this edge is written in rather than an
        unrestricted claim: 42% of PD patients with polysomnographic atonia
        loss have no behavioural enactment, so atonia loss is necessary but
        not sufficient for the clinical phenotype, and the two findings stay
        separable.
  evidence:
  - reference: PMID:12196654
    reference_title: "REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nineteen (58%) of 33 patients with PD but only 1 of 16 control subjects had REM sleep without atonia."
    explanation: >
      Direct polysomnographic quantification of REM sleep without atonia in a
      PD cohort versus controls - the measurement this node's conformance
      claim requires.
  - reference: PMID:12196654
    reference_title: "REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "One third of patients with PD met the diagnostic criteria of RBD based on PSG recordings."
    explanation: >
      Shows the polysomnographic finding is more prevalent than, and only
      partly overlaps with, a clinical RBD diagnosis - consistent with the
      module's requirement that the electrophysiological finding, not the
      behavioural history, is what satisfies conformance at this node.
- name: Central Alpha-Synuclein Initiation
  description: >
    In the brain-first model, the initial alpha-synuclein pathology begins in
    central sites such as the olfactory bulb or amygdala, then spreads through
    connected brain regions and later to peripheral autonomic structures. This
    node captures the competing central-origin route without asserting that it
    applies to all Parkinson disease.
  locations:
  - preferred_term: olfactory bulb
    term:
      id: UBERON:0002264
      label: olfactory bulb
  - preferred_term: amygdala
    term:
      id: UBERON:0001876
      label: amygdala
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: inclusion body assembly
    term:
      id: GO:0070841
      label: inclusion body assembly
  downstream:
  - target: Alpha-Synuclein Aggregation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - brain_first_central_alpha_synuclein_model
    intermediate_mechanisms:
    - central network propagation from olfactory bulb or amygdala
    description: >
      Central initiation feeds into the broader alpha-synuclein aggregation and
      propagation cascade through connected brain networks.
    evidence:
    - reference: PMID:38519273
      reference_title: "Brain-first vs. body-first Parkinson's disease: An update on recent evidence."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the initial pathology starts either in the olfactory bulb or amygdala leading to a brain-first subtype, or in the enteric nervous system leading to a body-first subtype."
      explanation: >
        Human subtype review supports olfactory bulb or amygdala origin as the
        central initiation route for the brain-first model.
  evidence:
  - reference: PMID:38519273
    reference_title: "Brain-first vs. body-first Parkinson's disease: An update on recent evidence."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Molecular imaging studies were generally in agreement with the model, whereas structural imaging studies, such as MRI volumetry, showed conflicting findings."
    explanation: >
      Review-level synthesis supports the brain-first/body-first model while
      noting that not all imaging modalities agree.
  - reference: PMID:32830221
    reference_title: "Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the PDRBD- data were compatible with a brain-first trajectory, characterized by primary loss of putaminal FDOPA uptake followed by a secondary loss of cardiac MIBG signal and 11C-donepezil signal."
    explanation: >
      Primary PET, MIBG, MRI, and gut-transit imaging evidence supports the
      central-first route by identifying a de novo PD subgroup with primary
      putaminal dopaminergic dysfunction followed by peripheral autonomic loss.
  - reference: PMID:40209563
    reference_title: "Amygdala neurodegeneration differentiates brain-first and body-first Parkinson's disease: An MRI study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'The degeneration of amygdala is distinctively pronounced in "brain-first" Parkinson''s disease, supporting differential disease progression patterns between subtypes.'
    explanation: >-
      Diffusion microstructure MRI gives the amygdala half of this node a
      human in vivo correlate: amygdala free interstitial fluid is higher in the
      brain-first group, matching the amygdala as a candidate central initiation
      site.
  - reference: PMID:40209563
    reference_title: "Amygdala neurodegeneration differentiates brain-first and body-first Parkinson's disease: An MRI study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "subtypes based on REM sleep behavior disorder history. Microstructural integrity was assessed using diffusion microstructure MRI."
    explanation: >-
      Bounds that result. The study is a retrospective cross-sectional analysis
      of 30 patients whose subtype labels come from REM-sleep-behavior-disorder
      history rather than from an observed origin site, so it supports an
      amygdala-differentiating pattern rather than amygdala initiation.
  - reference: PMID:33547846
    reference_title: "α-Synuclein Spread from Olfactory Bulb Causes Hyposmia, Anxiety, and Memory Loss in BAC-SNCA Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Severe α-Syn pathology in the transgenic mice injected with α-Syn preformed fibrils was initially observed along the olfactory pathway and later in the brain regions that are included in the limbic system and have connections with it."
    explanation: >-
      Rodent counterpart to the marmoset olfactory-bulb seeding result: an
      alpha-synuclein seed placed in the olfactory bulb spreads first along the
      olfactory pathway and then into connected limbic regions, supporting the
      anatomical possibility of the centrifugal route from a central site.
  - reference: PMID:33547846
    reference_title: "α-Synuclein Spread from Olfactory Bulb Causes Hyposmia, Anxiety, and Memory Loss in BAC-SNCA Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Behavioral analyses revealed hyposmia, followed by anxiety-like behavior and memory impairment, but not motor dysfunction, depression-like behavior, or circadian rhythm disturbance."
    explanation: >-
      Qualifies that model. Spread required an imposed preformed-fibril seed in
      mice overexpressing human SNCA, and produced no motor dysfunction, so it
      establishes anatomical possibility of olfactory-to-limbic propagation
      rather than spontaneous central initiation of a parkinsonian syndrome.
- name: Oxidative Stress
  description: >
    Excessive reactive oxygen species from dopamine metabolism and mitochondrial
    dysfunction causes lipid peroxidation, protein carbonylation, and DNA damage.
    Dopamine auto-oxidation generates toxic quinones that preferentially damage
    substantia nigra neurons.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Response to Oxidative Stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: ROS Metabolic Process
    term:
      id: GO:0072593
      label: reactive oxygen species metabolic process
  downstream:
  - target: Mitochondrial Dysfunction
  - target: Dopaminergic Neuron Loss
  - target: Alpha-Synuclein Aggregation
  evidence:
  - reference: PMID:37303175
    reference_title: "Oxidative Stress and Dopaminergic Metabolism: A Major PD Pathogenic Mechanism and Basis of Potential Antioxidant Therapies."
    supports: SUPPORT
    snippet: "Reactive oxygen species (ROS)-induced oxidative stress triggers the vicious cycle leading to the degeneration of dopaminergic neurons in the nigra pars compacta."
    explanation: This review directly describes the mechanism by which oxidative stress drives dopaminergic neurodegeneration.
- name: Calcium Dysregulation
  description: >
    Substantia nigra dopaminergic neurons rely on L-type calcium channels (CaV1.3)
    for autonomous pacemaking, making them uniquely vulnerable to calcium-mediated
    toxicity. Disrupted calcium homeostasis in mitochondria, ER, and lysosomes
    contributes to oxidative stress and cell death.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Calcium Ion Homeostasis
    term:
      id: GO:0055074
      label: calcium ion homeostasis
  - preferred_term: Calcium Ion Transport
    term:
      id: GO:0070588
      label: calcium ion transmembrane transport
  downstream:
  - target: Mitochondrial Dysfunction
  - target: Oxidative Stress
  - target: Dopaminergic Neuron Loss
  evidence:
  - reference: PMID:35339179
    reference_title: "The Role of Voltage-Gated Calcium Channels in Basal Ganglia Neurodegenerative Disorders."
    supports: SUPPORT
    snippet: "The dysregulation of VGCC activity has been reported in both Parkinson's disease (PD) and Huntington's (HD)."
    explanation: This review establishes the fundamental role of calcium channel dysregulation in PD pathogenesis.
- name: Endoplasmic Reticulum Stress
  description: >
    Accumulation of misfolded proteins in the ER activates the unfolded protein
    response (UPR). Chronic ER stress overwhelms protective mechanisms, triggering
    apoptotic pathways. Alpha-synuclein aggregates and GBA mutations directly
    impair ER function.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: ER Stress Response
    term:
      id: GO:0034976
      label: response to endoplasmic reticulum stress
  - preferred_term: Unfolded Protein Response
    term:
      id: GO:0030968
      label: endoplasmic reticulum unfolded protein response
  downstream:
  - target: Autophagy-Lysosome Pathway Dysfunction
  - target: Dopaminergic Neuron Loss
  evidence:
  - reference: PMID:38026955
    reference_title: "Strategies targeting endoplasmic reticulum stress to improve Parkinson's disease."
    supports: SUPPORT
    snippet: "Accumulating evidence shows that endoplasmic reticulum (ER) stress occurring in the SNpc DA neurons is an early event in the development of PD."
    explanation: This review establishes ER stress as an early and central event in PD pathogenesis.
- name: Synaptic Dysfunction
  description: >
    Impaired synaptic vesicle recycling, particularly defects in clathrin-mediated
    endocytosis, represents an early feature of PD. Multiple PD genes (DNAJC6,
    SYNJ1, LRRK2) regulate synaptic vesicle trafficking, and their dysfunction
    leads to synaptic failure before overt neurodegeneration.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Synaptic Vesicle Cycle
    term:
      id: GO:0099504
      label: synaptic vesicle cycle
  - preferred_term: Synaptic Vesicle Endocytosis
    term:
      id: GO:0048488
      label: synaptic vesicle endocytosis
  downstream:
  - target: Dopaminergic Neuron Loss
  - target: Alpha-Synuclein Aggregation
  evidence:
  - reference: PMID:38595283
    reference_title: "Dysfunction of synaptic endocytic trafficking in Parkinson's disease."
    supports: SUPPORT
    snippet: "Notably, several of these genes are linked to the synaptic vesicle recycling process, particularly the clathrin-mediated endocytosis pathway. This suggests that impaired synaptic vesicle recycling might represent an early feature of Parkinson's disease"
    explanation: Establishes synaptic vesicle endocytosis dysfunction as an early feature of PD.
- name: Iron Accumulation and Ferroptosis
  description: >
    Abnormal iron deposition in the substantia nigra promotes ferroptosis, an
    iron-dependent form of cell death characterized by lipid peroxidation. Iron
    catalyzes Fenton reactions generating hydroxyl radicals, and dysregulated
    iron metabolism contributes to oxidative damage.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Iron Ion Homeostasis
    term:
      id: GO:0006879
      label: intracellular iron ion homeostasis
  - preferred_term: Ferroptosis
    term:
      id: GO:0097707
      label: ferroptosis
  downstream:
  - target: Oxidative Stress
  - target: Dopaminergic Neuron Loss
  evidence:
  - reference: PMID:39218077
    reference_title: "Ferroptosis in Parkinson's disease -- The iron-related degenerative disease."
    supports: SUPPORT
    snippet: "Parkinson's disease (PD) is a prevalent and advancing age-related neurodegenerative disorder, distinguished by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Iron regional deposit in SNpc is a significant pathological characteristic of PD."
    explanation: This review establishes iron accumulation as a significant pathological characteristic and mechanistic driver of PD.
- name: Blood-Brain Barrier Dysfunction
  description: >
    Altered tight junction proteins, transporter dysfunction, and alpha-synuclein
    accumulation compromise BBB integrity. BBB breakdown allows infiltration of
    peripheral immune cells and blood-borne molecules, amplifying neuroinflammation.
  cell_types:
  - preferred_term: Brain Endothelial Cell
    term:
      id: CL:2000044
      label: brain microvascular endothelial cell
  - preferred_term: Pericyte
    term:
      id: CL:0000669
      label: pericyte
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: BBB Maintenance
    term:
      id: GO:0035633
      label: maintenance of blood-brain barrier
  - preferred_term: Vascular Permeability
    term:
      id: GO:0043114
      label: regulation of vascular permeability
  downstream:
  - target: Neuroinflammation
  - target: Dopaminergic Neuron Loss
  evidence:
  - reference: PMID:39075566
    reference_title: "Blood-brain barrier alterations and their impact on Parkinson's disease pathogenesis and therapy."
    supports: SUPPORT
    snippet: "There is increasing evidence for blood-brain barrier (BBB) alterations in Parkinson's disease (PD), the second most common neurodegenerative disorder with rapidly rising prevalence."
    explanation: This comprehensive 2024 review establishes BBB dysfunction as an emerging mechanism in PD pathogenesis.
  - reference: PMID:42599550
    reference_title: "Astrocytes orchestrate neuroprotection and pathogenesis via bidirectional neuronal interactions in Parkinson's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "As the most abundant glial cells in the central nervous system (CNS), astrocytes may exert neuroprotective effects through mechanisms including secretion of neurotrophic factors, regulation of the blood-brain barrier (BBB), and maintenance of water-electrolyte balance."
    explanation: Supports the astrocyte among the cell types regulating the barrier, which is why this node carries astrocyte as a cell type.
- name: Metabolic Dysfunction and Weight Loss
  description: >
    Parkinson disease is associated with progressive weight loss and metabolic dysregulation
    through multiple interacting mechanisms. Reduced metabolic rate, dysregulated appetite-regulating
    hormones (leptin, ghrelin, GLP-1), gastrointestinal dysfunction, cognitive decline affecting
    appetite awareness, dopaminergic-medication effects, and dopamine-dependent regulation of
    feeding behavior all contribute to systemic metabolic failure and weight loss. Weight loss
    occurs in a substantial fraction of PD patients and exerts significant morbidity and mortality,
    yet mechanistic understanding remains incomplete.
  biological_processes:
  - preferred_term: Metabolic process
    term:
      id: GO:0008152
      label: metabolic process
  downstream:
  - target: Weight Loss
    causal_link_type: DIRECT
    description: >
      Metabolic dysregulation, reduced energy expenditure, neuroendocrine hormone
      imbalances, and gastrointestinal dysfunction converge to cause progressive
      weight loss and nutritional decline in PD.
    evidence:
    - reference: PMID:41781031
      reference_title: "When the Scale Drops: Pathways to Weight Loss in Parkinson's Disease and Future Directions."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Emerging research highlights the role of metabolic regulation, neuroendocrine signaling, pharmacologic treatment, cognitive decline, gastrointestinal dysfunction, and brain stimulation in shaping weight trajectories in PD."
      explanation: >
        This review identifies multiple converging pathways that shape weight loss
        in PD, directly supporting metabolic dysfunction as a driver of weight loss.
  evidence:
  - reference: PMID:41781031
    reference_title: "When the Scale Drops: Pathways to Weight Loss in Parkinson's Disease and Future Directions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "weight loss has long been observed in PD and other neurodegenerative disorders, yet the mechanisms remain incompletely understood. This limited mechanistic insight has left few treatment options for weight loss in PD."
    explanation: >
      This 2026 review establishes weight loss as a significant, mechanistically
      complex, and undertreated symptom of Parkinson disease, establishing the
      rationale for a dedicated metabolic dysfunction mechanism node.
phenotypes:
- name: Resting Tremor
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Classic "pill-rolling" tremor at rest
  phenotype_term:
    preferred_term: Resting Tremor
    term:
      id: HP:0002322
      label: Resting tremor
  evidence:
  - reference: PMID:17955331
    reference_title: "The Rotterdam Study: objectives and design update."
    supports: SUPPORT
    snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
    explanation: This identifies resting tremor as a cardinal sign used to detect parkinsonism, supporting it as a core PD phenotype.
- name: Bradykinesia
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Slowness of movement, required for diagnosis
  phenotype_term:
    preferred_term: Bradykinesia
    term:
      id: HP:0002067
      label: Bradykinesia
  evidence:
  - reference: PMID:17955331
    reference_title: "The Rotterdam Study: objectives and design update."
    supports: SUPPORT
    snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
    explanation: This lists bradykinesia among the cardinal signs of parkinsonism, supporting its central role in PD.
- name: Rigidity
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Cogwheel or lead-pipe rigidity
  phenotype_term:
    preferred_term: Rigidity
    term:
      id: HP:0002063
      label: Rigidity
  evidence:
  - reference: PMID:17955331
    reference_title: "The Rotterdam Study: objectives and design update."
    supports: SUPPORT
    snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
    explanation: This confirms rigidity as a cardinal sign of parkinsonism relevant to PD.
- name: Postural Instability
  category: Neurological
  frequency: FREQUENT
  notes: Develops in later disease stages
  phenotype_term:
    preferred_term: Postural Instability
    term:
      id: HP:0002172
      label: Postural instability
  evidence:
  - reference: PMID:17955331
    reference_title: "The Rotterdam Study: objectives and design update."
    supports: SUPPORT
    snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
    explanation: This supports postural instability as a cardinal parkinsonian sign captured in PD assessments.
- name: Hyposmia
  category: Sensory
  frequency: FREQUENT
  notes: Often precedes motor symptoms by years
  phenotype_term:
    preferred_term: Hyposmia
    term:
      id: HP:0004409
      label: Hyposmia
  evidence:
  - reference: PMID:24136244
    reference_title: "Hyposmia: a possible biomarker of Parkinson's disease."
    supports: SUPPORT
    snippet: "Hyposmia, identified as reduced sensitivity to odor, is a common non-motor symptom of Parkinson's disease (PD) that antedates the typical motor symptoms by several years. It occurs in ∼90% of early-stage cases of PD."
    explanation: This establishes hyposmia as a highly prevalent prodromal symptom that precedes motor symptoms, supporting its importance as an early marker of PD.
- name: Constipation
  category: Gastrointestinal
  frequency: FREQUENT
  notes: Common non-motor symptom
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: PMID:7845407
    reference_title: "Anorectal manometry in the assessment of anorectal function in Parkinson's disease: a comparison with chronic idiopathic constipation."
    supports: SUPPORT
    snippet: "We investigated the role of anorectal manometry in evaluating constipation and anorectal function in 15 patients with Parkinson's disease (PD) and compared results with those of 9 patients with idiopathic constipation (IC) and 8 control (C) subjects."
    explanation: This study directly evaluates constipation in PD patients, supporting constipation as a common non-motor symptom.
- name: Depression
  category: Psychiatric
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:41301797
    reference_title: "Non-Motor Symptoms as Markers of Disease Severity in Parkinson's Disease: Associations Between Constipation, Depression, REM Sleep Behavior Disorder, and Motor Impairment."
    supports: SUPPORT
    snippet: "Depressive symptoms were similar across groups, but in prodromal PD, higher GDS scores were associated with worse UPDRS III scores (p = 0.02), as well as higher freezing and fall scores."
    explanation: This indicates depressive symptoms are present and clinically relevant in PD, supporting depression as a non-motor phenotype.
  - reference: PMID:42646502
    reference_title: "Parkinson's Disease: Pathophysiology, Treatment Strategies, Wellness Approaches, and Obstacles/Paths Forward."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "PD patients reported more depression, especially with sleep problems, which also worsened anxiety. Factors like age, motor symptoms, and sleep disturbances relate to depression, while sleep issues are linked to anxiety."
    explanation: >-
      Records the reported association between sleep disturbance and depression
      in PD. The quoted sentence is about sleep disturbance in general rather
      than REM sleep behavior disorder specifically, so it belongs on this
      phenotype; it makes no claim about cognition and recommends no therapy.
- name: REM Sleep Behavior Disorder
  category: Sleep
  notes: >-
    Prodromal non-motor feature that often precedes motor onset by years and
    correlates with greater motor severity. Results from dysfunction of brainstem
    motor inhibition circuits during REM sleep.
  phenotype_term:
    preferred_term: REM sleep behavior disorder
    term:
      id: HP:5200291
      label: REM sleep behavior disorder
  evidence:
  - reference: PMID:41301797
    reference_title: "Non-Motor Symptoms as Markers of Disease Severity in Parkinson's Disease: Associations Between Constipation, Depression, REM Sleep Behavior Disorder, and Motor Impairment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Constipation and REM sleep behavioral disorder were independent correlates of worse motor severity in prodromal and established PD"
    explanation: >-
      This PPMI-cohort study establishes REM sleep behavior disorder as a
      non-motor feature of both prodromal and established Parkinson disease that
      independently correlates with greater motor severity.
  - reference: PMID:42646502
    reference_title: "Parkinson's Disease: Pathophysiology, Treatment Strategies, Wellness Approaches, and Obstacles/Paths Forward."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It results from dysfunction of the subcoeruleus and magnocellularis nuclei in the brainstem"
    quote_role: REVIEW_SYNTHESIS
    explanation: >-
      Names the brainstem lesion behind RBD. These nuclei are glutamatergic and
      glycinergic respectively, not dopaminergic, which is the clinical point of
      RBD in PD: it reflects non-dopaminergic brainstem degeneration that
      precedes nigral loss, and so appears in the prodromal phase.
  - reference: PMID:42646502
    reference_title: "Parkinson's Disease: Pathophysiology, Treatment Strategies, Wellness Approaches, and Obstacles/Paths Forward."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dopamine influences motor and non-motor functions, including cognition, mood, sleep, sensory processes, and autonomic systems"
    quote_role: REVIEW_SYNTHESIS
    explanation: >-
      Records that sleep is among the non-motor functions dopamine influences.
      Kept deliberately narrow: the sentence states dopamine's range of
      influence, and does not assert depletion, a mechanism independent of
      motor circuits, or any claim specific to RBD.
- name: Cognitive Impairment
  category: Cognitive
  frequency: FREQUENT
  notes: >-
    Spans mild cognitive impairment (typically executive and visuospatial
    deficits) through to Parkinson disease dementia; the risk of dementia
    rises with disease duration.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:34210995
    reference_title: "Parkinson disease-associated cognitive impairment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition to the defining motor symptoms of PD, multiple non-motor symptoms occur; among them, cognitive impairment is common and can potentially occur at any disease stage."
    explanation: >-
      This Nature Reviews Disease Primers review establishes cognitive
      impairment as a common non-motor feature of PD that can occur at any
      disease stage.
  - reference: PMID:34210995
    reference_title: "Parkinson disease-associated cognitive impairment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "executive and visuospatial impairments are typical and can be accompanied by memory impairment, increasing the risk for early progression to dementia"
    explanation: >-
      Describes the mild-cognitive-impairment-to-dementia progression that
      underpins the progressive clinical course of cognitive impairment in PD.
- name: Dystonia
  category: Neurological
  notes: >
    Involuntary sustained or intermittent muscle contractions causing abnormal postures.
    When present in PD, dystonia is predominantly focal, most commonly affecting the lower
    limbs, followed by cervical involvement, and is associated with advanced Hoehn and Yahr
    stage (≥3), younger age at PD onset, and shorter disease duration. A population prevalence
    of dystonia in PD is not established by the cited case-control study, so no frequency band
    is asserted.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:42430982
    reference_title: "Dystonia in Parkinson's disease: Clinical characteristics and predictors of treatment response."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Focal dystonia was the predominant phenotype (75.0%), most commonly involving lower limbs, followed by cervical dystonia."
    explanation: >
      This clinical study characterizes the somatotopic distribution of dystonia in PD,
      showing that focal dystonia is the predominant form and lower-limb involvement is most common.
  - reference: PMID:42430982
    reference_title: "Dystonia in Parkinson's disease: Clinical characteristics and predictors of treatment response."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Data on 246 PD patients (164 with and 82 without dystonia) were analyzed."
    explanation: >
      Describes the case-control study composition (164 PD patients with dystonia versus 82
      without, drawn from the same source population). The 164:82 split is the study's
      case:control sampling ratio, not a population prevalence, and does not by itself
      quantify how frequently dystonia occurs in PD.
  - reference: PMID:42430982
    reference_title: "Dystonia in Parkinson's disease: Clinical characteristics and predictors of treatment response."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "advanced H&Y stage ≥3 (OR, 3.61; P = 0.002) was directly associated with it."
    explanation: >-
      Establishes association between dystonia and advanced Hoehn and Yahr stage,
      supporting dystonia as a clinical marker of disease progression.
  - reference: PMID:42430982
    reference_title: "Dystonia in Parkinson's disease: Clinical characteristics and predictors of treatment response."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Levodopa dose increases improved dystonia in 51.6% of patients, and botulinum neurotoxin (BoNT) improved dystonia (OR, 3.01; P = 0.05)."
    explanation: >-
      Documents treatment response patterns for PD-associated dystonia, including
      efficacy of levodopa dose optimization and botulinum neurotoxin injection.
- name: Weight Loss
  category: Constitutional
  notes: >-
    Progressive unintentional weight loss is a well-recognized non-motor feature
    of Parkinson disease, arising from multiple interacting mechanisms (metabolic
    dysregulation, neuroendocrine/appetite-hormone disruption, gastrointestinal
    dysfunction, cognitive decline, and medication effects). It carries
    substantial morbidity and mortality.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:41781031
    reference_title: "When the Scale Drops: Pathways to Weight Loss in Parkinson's Disease and Future Directions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "weight loss has long been observed in PD and other neurodegenerative disorders, yet the mechanisms remain incompletely understood. This limited mechanistic insight has left few treatment options for weight loss in PD."
    explanation: >-
      Establishes weight loss as a long-recognized non-motor symptom of Parkinson
      disease with substantial clinical impact.
- name: Impulse Control Behaviors
  category: Psychiatric
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Impulse control behaviors
    term:
      id: HP:0100710
      label: Impulsivity
  notes: >-
    Reward-seeking impulse control behaviors (gambling, hypersexuality, compulsive shopping,
    binge eating) represent a major behavioral comorbidity in PD, particularly in patients
    receiving dopamine agonist therapy. These behaviors arise from dopaminergic sensitization
    of reward-processing circuits and are distinct from classic obsessive-compulsive
    compulsions. Bound to HP:0100710 Impulsivity, which is the closest available HP term;
    preferred_term carries the more specific clinical concept. What HP lacks is a term for
    the dopaminergic-therapy-related ICB syndrome as such - one that distinguishes it from
    trait impulsivity and from HP:0000722 Compulsive behaviors - not a term for impulsivity.
    The frequency band is OCCASIONAL (5-29%): the meta-analytic point estimate is 19%
    (95% CI 15-24%) and the DOMINION cross-sectional estimate is 13.6%, so both the pooled
    estimate and its confidence interval sit inside that band.
  evidence:
  - reference: PMID:20457959
    reference_title: "Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An ICD was identified in 13.6% of patients (gambling in 5.0%, compulsive sexual behavior in 3.5%, compulsive buying in 5.7%, and binge-eating disorder in 4.3%), and 3.9% had 2 or more ICDs."
    explanation: >-
      Peer-reviewed point-prevalence estimate from 3090 patients at 46 movement disorder
      centres, with the four constituent behaviors counted separately. Corroborates the
      preprint meta-analysis and independently places the frequency in the OCCASIONAL band.
  - reference: PPR:PPR1298507
    reference_title: "Prevalence and Treatment of Impulse Control Behaviours in Parkinson's Disease: A Meta-Analysis and Systematic Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A random-effects meta-analysis of 27 studies (n = 17,906) found a mean event rate for at least one ICB in PD of 0.19 [95% CI = 0.15, 0.24]"
    explanation: >-
      Pooled event rate across 27 studies, giving the 19% (95% CI 15-24%) estimate behind the
      OCCASIONAL band. A non-peer-reviewed preprint, cited alongside the peer-reviewed
      DOMINION prevalence above rather than as sole support.
  - reference: PMID:20457959
    reference_title: "Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Impulse control disorders were more common in patients treated with a dopamine agonist than in patients not taking a dopamine agonist (17.1% vs 6.9%; odds ratio [OR], 2.72; 95% confidence interval [CI], 2.08-3.54; P < .001)."
    explanation: >-
      Quantifies dopamine agonist exposure as a risk factor for this phenotype, which is the
      peer-reviewed counterpart of the preprint's qualitative statement below.
  - reference: PPR:PPR1298507
    reference_title: "Prevalence and Treatment of Impulse Control Behaviours in Parkinson's Disease: A Meta-Analysis and Systematic Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mean event rate for at least one ICB in PD of 0.19 [95% CI = 0.15, 0.24], with evidence suggesting higher rates in patients taking dopamine agonists"
    explanation: >-
      The meta-analysis reports the same direction of effect for dopamine agonist exposure,
      qualitatively rather than as an effect size.
stages:
- name: "Stage 1: Unilateral Disease"
  description: >
    Symptoms are present on one side of the body only. Mild unilateral involvement
    with minimal or no functional impairment. Patients may exhibit resting tremor,
    rigidity, or bradykinesia on one limb or side. Daily activities are not
    significantly affected.
  evidence:
  - reference: PMID:27918765
    reference_title: "Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid."
    supports: SUPPORT
    snippet: "the Hoehn and Yahr scale, with the lowest grade indicating unilateral involvement with minimal or no functional impairment"
    explanation: This describes Stage 1 (the lowest grade) as unilateral involvement with minimal or no functional impairment.
  - reference: PMID:34461264
    reference_title: "The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Clinical findings indicate that LID typically only occurs following the progression of PD motor symptoms from the unilateral (Hoehn and Yahr (HY) Stage I) to the bilateral stage (HY Stage II)."
    explanation: This identifies Stage I as the unilateral phase of PD motor symptoms.
  notes: >
    Original Hoehn and Yahr staging scale from 1967 (PMID:6067254). A modified
    scale with 0.5 increments (Stages 1.5, 2.5) has been widely adopted but
    lacks formal clinimetric validation.
- name: "Stage 2: Bilateral Disease Without Balance Impairment"
  description: >
    Symptoms are present on both sides of the body or at the midline. Bilateral
    involvement without impairment of balance. Patients show bilateral tremor,
    rigidity, and bradykinesia but maintain normal postural reflexes and physical
    independence.
  evidence:
  - reference: PMID:34461264
    reference_title: "The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Clinical findings indicate that LID typically only occurs following the progression of PD motor symptoms from the unilateral (Hoehn and Yahr (HY) Stage I) to the bilateral stage (HY Stage II)."
    explanation: This identifies Stage II as the bilateral stage of PD motor symptom progression.
  - reference: PMID:15372591
    reference_title: "Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations."
    supports: SUPPORT
    snippet: "the scale fulfills at least some criteria for reliability and validity, especially for the midranges of the scale (Stages 2-4)."
    explanation: The MDS Task Force report validates the reliability of midrange stages (2-4) of the Hoehn and Yahr scale.
- name: "Stage 3: Bilateral Disease With Postural Instability"
  description: >
    Mild to moderate bilateral disease with early postural instability. The first
    sign of impaired righting reflexes appears. Patients remain physically
    independent in daily activities but have clinically evident balance impairment.
  evidence:
  - reference: PMID:20181069
    reference_title: "Depression, extrapyramidal symptoms, dementia and an unexpected outcome: a case report."
    supports: SUPPORT
    snippet: "The modified Hoehn and Yahr scale was 3: mild to moderate bilateral disease; some postural instability; physically independent."
    explanation: This directly defines Stage 3 as mild to moderate bilateral disease with some postural instability while remaining physically independent.
  - reference: PMID:15372591
    reference_title: "Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations."
    supports: SUPPORT
    snippet: "Because the HY scale is weighted heavily toward postural instability as the primary index of disease severity, it does not capture completely impairments or disability from other motor features of PD and gives no information on nonmotor problems."
    explanation: This highlights that the Hoehn and Yahr scale weights postural instability as a primary severity index, providing context for why balance impairment becomes central at Stage 3.
- name: "Stage 4: Severe Disability, Still Ambulatory"
  description: >
    Fully developed, severely disabling disease. Patients remain ambulatory but
    have marked loss of independence in daily activities. More than half require
    assistance with most activities of daily living, despite retained ability to
    complete walk-based assessments.
  evidence:
  - reference: PMID:34125001
    reference_title: "Effect of Lee Silverman Voice Treatment (LSVT)® BIG on motor symptoms in a patient with severe Parkinson's disease: a case report."
    supports: SUPPORT
    snippet: "Her disease severity was classified as Hoehn and Yahr stage 4. The unified Parkinson's disease rating scale (UPDRS) part 3, 10-m walk test (10MWT), timed up-and-go test (TUG), Berg balance scale (BBS), and 30-s chair stand test (30-s CST) were used for assessment before and after intervention."
    explanation: This stage 4 case report shows that advanced patients can remain ambulatory enough to perform walk-based assessments despite severe motor impairment.
  - reference: PMID:40162911
    reference_title: "Profile of Independence in Activities of Daily Living Among Patients With Parkinson's Disease: A Retrospective Observational Study."
    supports: SUPPORT
    snippet: "In the H-Y Stage 4 group, more than half of the patients required assistance with most ADLs, except feeding and bowel control."
    explanation: This directly supports substantial dependence in daily activities as a defining functional feature of Stage 4 disease.
- name: "Stage 5: Wheelchair-Bound or Bedridden"
  description: >
    Patient is confined to wheelchair or bedridden unless aided. Complete
    dependence on caregivers for all activities. Represents the most severe
    stage of motor disability in Parkinson's disease.
  evidence:
  - reference: PMID:27918765
    reference_title: "Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid."
    supports: SUPPORT
    snippet: "the highest grade defining patients with complete confinement to wheelchair or bed."
    explanation: This directly defines Stage 5 (the highest grade) as complete confinement to wheelchair or bed.
genetic:
- name: SNCA
  gene_term:
    preferred_term: SNCA
    term:
      id: hgnc:11138
      label: SNCA
  association: Causative
  relationship_type: CAUSATIVE
  notes: Alpha-synuclein gene, autosomal dominant forms
  evidence:
  - reference: PMID:9197268
    reference_title: "Mutation in the alpha-synuclein gene identified in families with Parkinson's disease."
    supports: SUPPORT
    snippet: "A mutation was identified in the alpha-synuclein gene, which codes for a presynaptic protein thought to be involved in neuronal plasticity, in the Italian kindred and in three unrelated families of Greek origin with autosomal dominant inheritance for the PD phenotype."
    explanation: This landmark 1997 Science paper identified the first SNCA mutations in familial PD with autosomal dominant inheritance, establishing SNCA as a causative gene for Parkinson's disease.
  - reference: CGGV:assertion_d21593ae-ed10-4442-8167-24f96f917302-2022-05-03T134931.425Z
    reference_title: "SNCA / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SNCA | HGNC:11138 | Parkinson disease | MONDO:0005180 | AD | Definitive"
    explanation: ClinGen classifies the SNCA-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.
- name: LRRK2
  gene_term:
    preferred_term: LRRK2
    term:
      id: hgnc:18618
      label: LRRK2
  association: Risk Factor
  relationship_type: CAUSATIVE
  notes: >-
    Most common genetic cause of late-onset PD; G2019S acts as an
    autosomal-dominant causative allele with reduced (age-dependent)
    penetrance, so it is often described clinically as a risk factor.
  evidence:
  - reference: PMID:19945904
    reference_title: "Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review."
    supports: SUPPORT
    snippet: "The LRRK2 G2019S mutation is the most frequent known cause of familial and sporadic Parkinson's disease."
    explanation: This systematic review establishes that LRRK2 G2019S is the most common genetic cause of both familial and sporadic PD, supporting its role as the major genetic risk factor.
  - reference: CGGV:assertion_2728e13a-b95a-4c55-8cba-082260094ecd-2021-05-03T160000.000Z
    reference_title: "LRRK2 / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "LRRK2 | HGNC:18618 | Parkinson disease | MONDO:0005180 | AD | Definitive"
    explanation: ClinGen classifies the LRRK2-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.
  - reference: PMID:38750146
    reference_title: "Sex-dependent interactions between prodromal intestinal inflammation and LRRK2 G2019S in mice promote endophenotypes of Parkinson's disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Chronic intestinal damage in genetically predisposed male mice promotes α-synuclein aggregation in the substantia nigra, loss of dopaminergic neurons and motor impairment."
    explanation: >-
      Offers a candidate explanation for the incomplete, age-dependent
      penetrance recorded in the notes above: in human LRRK2 G2019S transgenic
      mice a prodromal gut-inflammatory insult is what converts the genotype
      into nigral alpha-synuclein aggregation, dopaminergic loss, and motor
      impairment, and the effect is restricted to males. Whether the same
      gene-environment interaction modifies penetrance in human carriers is
      untested.
- name: PINK1
  gene_term:
    preferred_term: PINK1
    term:
      id: hgnc:14581
      label: PINK1
  association: Causative
  relationship_type: CAUSATIVE
  notes: Mitochondrial kinase, autosomal recessive
  evidence:
  - reference: PMID:25611507
    reference_title: "The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease."
    supports: SUPPORT
    snippet: "Biochemical and genetic studies reveal that the products of two genes that are mutated in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together in the same pathway to govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved in Parkinson's disease."
    explanation: This identifies PINK1 mutations in autosomal recessive parkinsonism, supporting its causative role in PD.
  - reference: CGGV:assertion_1999e6c4-eb15-438a-a4ea-98989112dcbb-2023-01-18T190000.000Z
    reference_title: "PINK1 / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PINK1 | HGNC:14581 | Parkinson disease | MONDO:0005180 | AR | Definitive"
    explanation: ClinGen classifies the PINK1-Parkinson disease gene-disease relationship as definitive with autosomal recessive inheritance.
- name: GBA1
  gene_term:
    preferred_term: GBA1
    term:
      id: hgnc:4177
      label: GBA
  association: Risk Factor
  relationship_type: RISK_FACTOR
  notes: >-
    Glucocerebrosidase (GBA1); the single most common genetic risk factor for
    PD. Heterozygous variants confer risk with reduced penetrance (ClinGen
    reports the assertion under an autosomal-dominant MOI).
  evidence:
  - reference: PMID:30097731
    reference_title: "The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions."
    supports: SUPPORT
    snippet: "DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation at GBA and SNCA."
    explanation: This identifies GBA as a genetic risk locus shared with PD, supporting its role as a PD risk factor.
  - reference: CGGV:assertion_9201c03f-10de-447c-9b84-194f14b549b6-2022-05-03T134810.206Z
    reference_title: "GBA1 / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GBA1 | HGNC:4177 | Parkinson disease | MONDO:0005180 | AD | Definitive"
    explanation: ClinGen classifies the GBA1-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.
- name: PARK7
  gene_term:
    preferred_term: PARK7
    term:
      id: hgnc:16369
      label: PARK7
  association: Causative
  relationship_type: CAUSATIVE
  notes: DJ-1 (PARK7); biallelic variants cause early-onset autosomal-recessive PD.
  evidence:
  - reference: CGGV:assertion_d79439d2-844b-4ba6-aceb-e6b179eaaa01-2022-06-27T160000.000Z
    reference_title: "PARK7 / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PARK7 | HGNC:16369 | Parkinson disease | MONDO:0005180 | AR | Definitive"
    explanation: ClinGen classifies the PARK7-Parkinson disease gene-disease relationship as definitive with autosomal recessive inheritance.
- name: PRKN
  gene_term:
    preferred_term: PRKN
    term:
      id: hgnc:8607
      label: PRKN
  association: Causative
  relationship_type: CAUSATIVE
  notes: >-
    Parkin (PRKN; formerly PARK2). Biallelic loss-of-function variants cause
    early-onset autosomal-recessive PD.
  evidence:
  - reference: PMID:25611507
    reference_title: "The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease."
    supports: SUPPORT
    snippet: "Biochemical and genetic studies reveal that the products of two genes that are mutated in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together in the same pathway to govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved in Parkinson's disease."
    explanation: This establishes Parkin (PRKN, formerly PARK2) as a gene mutated in autosomal recessive parkinsonism, supporting its causative role.
  - reference: CGGV:assertion_6b39c4a0-f6bd-4afc-b2a7-f234eab5a667-2023-01-18T190000.000Z
    reference_title: "PRKN / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PRKN | HGNC:8607 | Parkinson disease | MONDO:0005180 | AR | Definitive"
    explanation: ClinGen classifies the PRKN-Parkinson disease gene-disease relationship as definitive with autosomal recessive inheritance.
- name: VPS35
  gene_term:
    preferred_term: VPS35
    term:
      id: hgnc:13487
      label: VPS35
  association: Causative
  relationship_type: CAUSATIVE
  notes: >-
    Retromer component VPS35 (D620N); autosomal-dominant late-onset PD.
  evidence:
  - reference: CGGV:assertion_b0e546d6-8a44-4e9d-83aa-f781ec4ec166-2021-11-03T134517.796Z
    reference_title: "VPS35 / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "VPS35 | HGNC:13487 | Parkinson disease | MONDO:0005180 | AD | Definitive"
    explanation: ClinGen classifies the VPS35-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.
environmental:
- name: Pesticide Exposure
  exposure_term:
    preferred_term: exposure to pesticide
    term:
      id: ECTO:0000530
      label: exposure to pesticide
  influences_mechanisms:
  - target: Mitochondrial Dysfunction
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Rotenone is a complex I inhibitor, and complex I deficiency is what this
      node is built around, so in the animal model the exposure acts on the
      node with nothing in between. The directness is taken from that model
      and not from the human data, which is worth stating rather than leaving
      to inference: the human evidence here reaches only the association
      between pesticide exposure and developing the disease, and both items
      are graded partial for that reason. The same rat study also reproduced
      alpha-synuclein-containing nigral inclusions, which would support an
      edge into the aggregation node, but that arm is not drawn because rodent
      inclusion pathology would then be its only support.
    evidence:
    - reference: PMID:11100151
      reference_title: "Chronic systemic pesticide exposure reproduces features of Parkinson's disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We report that chronic, systemic inhibition of complex I by the lipophilic pesticide, rotenone, causes highly selective nigrostriatal dopaminergic degeneration that is associated behaviorally with hypokinesia and rigidity"
      explanation: >-
        Names the pesticide, the complex I inhibition this node holds, and the
        nigrostriatal degeneration downstream of it. Rat work, so it carries
        the mechanism without establishing it in human disease.
    - reference: PMID:15177059
      reference_title: "Occupational and environmental risk factors for Parkinson's disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "there is general agreement that smoking and exposure to pesticides affect the probability of developing PD."
      explanation: >-
        Review reporting general agreement that pesticide exposure affects the
        probability of developing the disease. It establishes the exposure at
        the level of the disease and says nothing about mitochondria.
  notes: Rotenone and paraquat linked to increased risk
  evidence:
  - reference: PMID:15177059
    reference_title: "Occupational and environmental risk factors for Parkinson's disease."
    supports: SUPPORT
    snippet: "there is general agreement that smoking and exposure to pesticides affect the probability of developing PD."
    explanation: This review supports pesticide exposure as an environmental factor influencing PD risk.
- name: Rural Living
  notes: Associated with pesticide/herbicide exposure
  evidence:
  - reference: PMID:15177059
    reference_title: "Occupational and environmental risk factors for Parkinson's disease."
    supports: SUPPORT
    snippet: "While clear links to rural living, dietary factors, exposure to metals, head injury, and exposure to infectious diseases during childhood have not been established, there is general agreement that smoking and exposure to pesticides affect the probability of developing PD."
    explanation: This review notes that clear links to rural living are not established, indicating mixed evidence for this risk factor.
- name: Head Trauma
  influences_mechanisms:
  - target: Dopaminergic Neuron Loss
    environmental_effect: PREDISPOSES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Traumatic brain injury raises later risk of the disease by about half
      again. Pointed at the core neuropathological lesion rather than at a
      mechanism node because no cited sentence follows the injury to any
      particular step: neuroinflammation is the usual proposal and this entry
      holds a node for it, but nothing here measures that route, so the
      intermediates stay unknown.
    evidence:
    - reference: PMID:36781627
      reference_title: "Traumatic brain injury and risk of Parkinson's disease: a meta-analysis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The risk ratio of TBI among PD and controls by a combination of 15 studies using a random-effect model was 1.48 (95% CI 1.22-1.74)."
      explanation: >-
        Meta-analysis of 15 studies giving a risk ratio of 1.48 for traumatic
        brain injury. It quantifies the exposure-disease association and not
        the neuronal loss this link targets.
  notes: Possible risk factor
  evidence:
  - reference: PMID:36781627
    reference_title: "Traumatic brain injury and risk of Parkinson's disease: a meta-analysis."
    supports: SUPPORT
    snippet: "The risk ratio of TBI among PD and controls by a combination of 15 studies using a random-effect model was 1.48 (95% CI 1.22-1.74)."
    explanation: This meta-analysis supports head trauma (TBI) as a risk factor for developing PD.
prevalence:
- population: Population aged 65 years and older (worldwide)
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 2500.0
  rate_low: 2000.0
  rate_high: 3000.0
  notes: >-
    Parkinson disease affects 2-3% of the population aged 65 years and older,
    making it the second-most common neurodegenerative disorder. Prevalence
    rises steeply with age.
  evidence:
  - reference: PMID:28332488
    reference_title: "Parkinson disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Parkinson disease is the second-most common neurodegenerative disorder that affects 2-3% of the population ≥65 years of age."
    explanation: >-
      This Nature Reviews Disease Primers review states that PD affects 2-3% of
      people aged 65 and older, supporting the point-prevalence estimate.
treatments:
- name: Levodopa/Carbidopa
  description: Gold standard treatment, replaces dopamine precursor.
  evidence:
  - reference: PMID:27577098
    reference_title: "Current and experimental treatments of Parkinson disease: A guide for neuroscientists."
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review identifies L-Dopa as a core pharmacotherapy for PD motor symptoms.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: levodopa
      term:
        id: CHEBI:15765
        label: L-dopa
    - preferred_term: carbidopa
      term:
        id: CHEBI:3395
        label: carbidopa
  target_mechanisms:
  - target: Striatal Dopamine Deficiency
    treatment_effect: RESTORES
    description: Levodopa supplies dopamine precursor to partially restore dopaminergic signaling in dopamine-depleted striatal circuits.
- name: Dopamine Agonists
  description: >-
    Directly stimulate dopamine receptors. Carries a class-level risk of impulse control
    behaviors: dopamine agonist exposure raises the odds of an ICD roughly 2- to 3.5-fold,
    and the association holds across pramipexole and ropinirole rather than being specific
    to one agent. See the Impulse Control Behaviors phenotype.
  evidence:
  - reference: PMID:27577098
    reference_title: "Current and experimental treatments of Parkinson disease: A guide for neuroscientists."
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review identifies dopamine agonists as part of standard pharmacotherapy for PD.
  - reference: PMID:20457959
    reference_title: "Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dopamine agonist treatment in PD is associated with 2- to 3.5-fold increased odds of having an ICD. This association represents a drug class relationship across ICDs."
    explanation: >-
      Establishes the impulse-control adverse effect as a property of the dopamine agonist
      drug class rather than of an individual agent, which is why it is recorded on this
      treatment entry and not only on the phenotype.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Striatal Dopamine Deficiency
    treatment_effect: BYPASSES
    description: Dopamine agonists bypass reduced endogenous dopamine by directly stimulating dopamine receptors in downstream circuits.
- name: Impulse Control Behavior Management
  description: >-
    Management of dopaminergic-therapy-related impulse control behaviors. The first-line step
    in practice is reduction or withdrawal of the dopamine agonist; the interventions studied
    beyond that are cognitive behavioural therapy, levodopa infusion, atomoxetine, naltrexone,
    valproic acid, and deep brain stimulation. The evidence base is small and preliminary - a
    narrative synthesis of 10 studies totalling 283 patients - so this is recorded as a
    treatable target rather than as established therapy.
  evidence:
  - reference: PPR:PPR1298507
    reference_title: "Prevalence and Treatment of Impulse Control Behaviours in Parkinson's Disease: A Meta-Analysis and Systematic Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A narrative synthesis of 10 studies (n = 283) found preliminary evidence for the effectiveness of cognitive behavioural therapy, levodopa infusion, atomoxetine, naltrexone, valproic acid, and deep brain stimulation in supporting ICB reduction."
    explanation: >-
      The source for the intervention list and for the strength of the claim - preliminary
      evidence from a narrative synthesis, not pooled effect estimates.
  treatment_term:
    preferred_term: Therapeutic Procedure
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  target_mechanisms:
  - target: Impulse Control Behaviors
    treatment_effect: INHIBITS
    description: >-
      These interventions are studied as ways to reduce impulse control behaviors themselves,
      which is what connects this phenotype to the treatment graph.
- name: MAO-B Inhibitors
  description: Prevent dopamine breakdown (selegiline, rasagiline).
  evidence:
  - reference: PMID:27577098
    reference_title: "Current and experimental treatments of Parkinson disease: A guide for neuroscientists."
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review lists MAO-B inhibitors among standard PD pharmacotherapies.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Striatal Dopamine Deficiency
    treatment_effect: MODULATES
    description: MAO-B inhibitors prolong dopamine signaling by reducing dopamine breakdown.
- name: COMT Inhibitors
  description: Extend levodopa duration (entacapone).
  evidence:
  - reference: PMID:27577098
    reference_title: "Current and experimental treatments of Parkinson disease: A guide for neuroscientists."
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review lists COMT inhibitors among standard PD pharmacotherapies.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Striatal Dopamine Deficiency
    treatment_effect: MODULATES
    description: COMT inhibitors extend levodopa-derived dopaminergic signaling and indirectly modulate striatal dopamine deficiency.
- name: Deep Brain Stimulation
  description: Surgical therapy for advanced motor fluctuations.
  evidence:
  - reference: PMID:27577098
    reference_title: "Current and experimental treatments of Parkinson disease: A guide for neuroscientists."
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review identifies deep brain stimulation as a standard symptomatic therapy for PD.
  treatment_term:
    preferred_term: deep brain stimulation
    term:
      id: NCIT:C21024
      label: Deep Brain Stimulation
  target_mechanisms:
  - target: Basal Ganglia Circuit Dysfunction
    treatment_effect: MODULATES
    description: DBS modulates abnormal basal ganglia motor circuit activity rather than acting upstream on dopaminergic neuron loss.
- name: Physical Therapy
  description: Maintains mobility and reduces fall risk. Exercise programs including PWR!Moves, Rock Steady Boxing, Dance for Parkinson's, yoga, and tai chi are evidence-based approaches that specifically reduce rigidity, improve postural stability, and enhance motor fluidity through rebalancing of basal ganglia circuits.
  evidence:
  - reference: PMID:27577098
    reference_title: "Current and experimental treatments of Parkinson disease: A guide for neuroscientists."
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review lists physiotherapy as part of symptomatic treatment for PD.
  - reference: PMID:42646502
    reference_title: "Parkinson's Disease: Pathophysiology, Treatment Strategies, Wellness Approaches, and Obstacles/Paths Forward."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Stretching and range-of-motion exercises (e.g., PWR!Moves), strengthening exercises (e.g., Rock Steady Boxing), dancing (e.g., Dance for Parkinson's Disease), and yoga and tai chi help reduce stiffness"
    explanation: Comprehensive review identifies multiple evidence-based exercise modalities that effectively reduce rigidity and motor stiffness in PD.
  - reference: PMID:42646502
    reference_title: "Parkinson's Disease: Pathophysiology, Treatment Strategies, Wellness Approaches, and Obstacles/Paths Forward."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tai Chi was found to be effective, alongside resistance and stretching, for improving motor symptoms, physical abilities, and quality of life in early to mid-stage PD"
    explanation: Tai Chi demonstrates measurable benefit for multiple motor domains including endurance, control, and postural stability in PD.
  - reference: PMID:42646502
    reference_title: "Parkinson's Disease: Pathophysiology, Treatment Strategies, Wellness Approaches, and Obstacles/Paths Forward."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A study measured motor and non-motor symptom changes in PD participants after the 8-week ‘PWR!Moves’ program, a multidisciplinary wellness course"
    quote_role: REVIEW_SYNTHESIS
    explanation: >-
      Supports structured exercise as a management component. The snippet was
      moved to the sentence that names the study and its 8-week PWR!Moves
      intervention, so it is self-describing; the adjacent result sentence
      ("Most improved in three of four UPDRS areas") could not be quoted
      together with it, because the citation marker between the two is stripped
      before substring matching. Graded REVIEW_SYNTHESIS: this review is
      reporting study [352] rather than presenting its own result.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Physical Therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  target_mechanisms:
  - target: Basal Ganglia Circuit Dysfunction
    treatment_effect: MODULATES
    description: >-
      Structured exercise is reported to shift the excitatory/inhibitory balance
      within the basal ganglia rather than route around it. Cueing and
      compensation strategies, which do work around the circuit, are delivered
      alongside it; MODULATES records the claim this entry actually cites
      evidence for.
    evidence:
    - reference: PMID:42646502
      reference_title: "Parkinson's Disease: Pathophysiology, Treatment Strategies, Wellness Approaches, and Obstacles/Paths Forward."
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: "Exercise helps reestablish the balance between excitatory and inhibitory signals in the basal ganglia, decreasing excitotoxicity and enhancing movement"
      explanation: >-
        Link-level evidence for the mechanism of action asserted by this edge.
        Graded OTHER with quote_role REVIEW_SYNTHESIS: the sentence is the
        review's synthesis of its references [305-308] under the heading
        "Modulation of glutamate and motor circuits", not a result this
        publication reports.
- name: Botulinum Neurotoxin A (BoNT/A) for Depression
  description: >
    Botulinum toxin type A alleviates depression in Parkinson's disease by inhibiting
    the complement C3-C3aR signaling axis and reducing microglial synaptic phagocytosis.
    This represents a novel complement-targeted approach to managing depression as a
    non-motor symptom in PD, distinct from BoNT/A's canonical motor symptom applications.
  evidence:
  - reference: PMID:42263400
    reference_title: "The complement C3-microglial axis in depression of Parkinson's disease: from mechanism to therapeutic intervention."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "BoNT/A treatment alleviated depressive-like behaviours and reduced microglial synaptic engulfment in an MPTP model; these therapeutic effects were abolished in C3-/- and C3aR-/- mice."
    explanation: >
      Mouse PD model demonstrates that BoNT/A alleviates depression-like behavior through
      inhibition of the C3-C3aR complement axis, preventing microglial synaptic engulfment
      and protecting against synapse loss in the hippocampus.
  treatment_term:
    preferred_term: botulinum toxin type A therapy
    term:
      id: NCIT:C157775
      label: Botulinum Toxin Therapy
  target_mechanisms:
  - target: Complement C3-C3aR Activation in Depression
    treatment_effect: INHIBITS
    description: >
      BoNT/A suppresses complement C3-C3aR signaling through modulation of microglial
      phagocytosis-related functions, reducing microglial activation and synaptic
      phagocytosis, thereby alleviating depression-like symptoms in PD models.
datasets:
# Parkinson's Disease Gut Microbiome Studies
- accession: bioproject:PRJNA834801
  title: Large-scale metagenomics of Parkinson's disease gut microbiome
  description: >-
    Shotgun metagenomics from the NeuroGenetics Research Consortium (NGRC)
    with over 30% of species, genes and pathways showing altered abundances
    in PD. Identified polymicrobial clusters and competitive relationships.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  data_type: WGS
  sample_types:
  - preferred_term: fecal sample
    term:
      id: OBI:0002503
      label: feces specimen
    tissue_term:
      preferred_term: feces
      term:
        id: UBERON:0001988
        label: feces
  conditions:
  - Parkinson's disease
  - healthy controls
  publication: PMID:36357667
  notes: Nature Communications 2022 - largest PD metagenomics to date
  evidence:
  - reference: PMID:37449597
    reference_title: "Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson's disease."
    supports: SUPPORT
    snippet: "This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."
    explanation: This supports the relevance of gut microbiome datasets to PD mechanisms.

- accession: bioproject:PRJNA782492
  title: Multi-omics analysis of PD gut microbiome gene expression
  description: >-
    Integrated metagenomics and metatranscriptomics analyzing microbiome gene
    co-expression networks in Parkinson's disease. Observed significant
    depletion of hub genes in PD patients.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  data_type: WGS
  sample_types:
  - preferred_term: fecal sample
    term:
      id: OBI:0002503
      label: feces specimen
    tissue_term:
      preferred_term: feces
      term:
        id: UBERON:0001988
        label: feces
  conditions:
  - Parkinson's disease
  - healthy controls
  notes: npj Biofilms and Microbiomes 2025 - multi-omics approach
  evidence:
  - reference: PMID:37449597
    reference_title: "Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson's disease."
    supports: SUPPORT
    snippet: "This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."
    explanation: This supports the relevance of gut microbiome datasets to PD mechanisms.

- accession: bioproject:PRJNA808166
  title: Longitudinal gut microbiome in Parkinson's disease
  description: >-
    Longitudinal study investigating gut microbiome changes in PD patients
    and impact of device-assisted therapies. Tracks microbiome alterations
    with disease progression.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  sample_types:
  - preferred_term: fecal sample
    term:
      id: OBI:0002503
      label: feces specimen
    tissue_term:
      preferred_term: feces
      term:
        id: UBERON:0001988
        label: feces
  conditions:
  - Parkinson's disease baseline
  - Parkinson's disease follow-up
  notes: Frontiers Aging Neuroscience 2022 - longitudinal design
  evidence:
  - reference: PMID:37449597
    reference_title: "Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson's disease."
    supports: SUPPORT
    snippet: "This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."
    explanation: This supports the relevance of gut microbiome datasets to PD mechanisms.

- accession: bioproject:PRJNA530401
  title: PD gut microbiome meta-analysis cohort
  description: >-
    Metagenomic sequencing data from PD patients and controls contributing
    to cross-cohort meta-analyses. Identified alterations linked to
    intestinal inflammation including reduced butyrate producers.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  data_type: WGS
  sample_types:
  - preferred_term: fecal sample
    term:
      id: OBI:0002503
      label: feces specimen
    tissue_term:
      preferred_term: feces
      term:
        id: UBERON:0001988
        label: feces
  conditions:
  - Parkinson's disease
  - healthy controls
  notes: npj Parkinson's Disease 2021 - meta-analysis contributing cohort
  evidence:
  - reference: PMID:37449597
    reference_title: "Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson's disease."
    supports: SUPPORT
    snippet: "This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."
    explanation: This supports the relevance of gut microbiome datasets to PD mechanisms.

- accession: metabolights:MTBLS2266
  title: Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease
  description: >-
    LC-MS sebum metabolomics in Parkinson's disease, including drug-naive and
    medicated cohorts, compared with well-matched controls to identify lipid
    pathway alterations.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: METABOLOMICS
  sample_count: 274
  conditions:
  - Parkinson's disease
  - drug-naive Parkinson's disease
  - medicated Parkinson's disease
  - healthy controls
  publication: PMID:33707447
  findings:
  - statement: Sebum metabolomics in PD shows alterations in lipid metabolism pathways, including the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis.
    evidence:
    - reference: metabolights:MTBLS2266
      reference_title: "Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease"
      supports: SUPPORT
      snippet: "Pathway enrichment analysis shows alterations in lipid metabolism related to the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis."
      explanation: The dataset description reports lipid pathway alterations detected in sebum metabolomics for PD.
  - statement: LC-MS profiling of 274 participants detected metabolites predictive of PD phenotype.
    evidence:
    - reference: metabolights:MTBLS2266
      reference_title: "Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease"
      supports: SUPPORT
      snippet: "We used liquid chromatography-mass spectrometry (LC-MS) to analyse 274 samples from participants (80 drug naïve PD, 138 medicated PD and 56 well matched control subjects) and detected metabolites that could predict PD phenotype."
      explanation: The dataset description specifies LC-MS profiling and the PD/control cohort sizes.
  evidence:
  - reference: metabolights:MTBLS2266
    reference_title: "Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease"
    supports: SUPPORT
    snippet: "Here, we use a metabolomics profiling approach to identify changes to lipids in PD observed in sebum, a non-invasively available biofluid."
    explanation: Establishes that the dataset focuses on PD sebum metabolomics.
  notes: Metabolomics profiling of sebum as a non-invasive biofluid for PD.

- accession: metabolights:MTBLS10743
  title: Metabolomic Changes in Idiopathic and GBA1 Parkinson’s Disease
  description: >-
    Mass spectrometry metabolomics comparing idiopathic Parkinson's disease and
    GBA1-associated Parkinson's disease cohorts with controls.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: METABOLOMICS
  conditions:
  - idiopathic Parkinson's disease
  - GBA1-associated Parkinson's disease
  - healthy controls
  findings:
  - statement: Metabolomic signatures differ between GBA1-PD and idiopathic PD in sebum and serum with good specificity and sensitivity.
    evidence:
    - reference: metabolights:MTBLS10743
      reference_title: "Metabolomic Changes in Idiopathic and GBA1 Parkinson's Disease"
      supports: SUPPORT
      snippet: "Differences in metabolomic signatures were seen between ... GBA1-PD and iPD in sebum and serum with good specificity and sensitivity."
      explanation: The dataset description reports discriminative metabolomic signatures between GBA1-PD and idiopathic PD.
  - statement: Serum pathways implicated include sphingolipid metabolism, amino sugar metabolism and amino acid pathways, while sebum features are hypothesised to be lipid degradation products.
    evidence:
    - reference: metabolights:MTBLS10743
      reference_title: "Metabolomic Changes in Idiopathic and GBA1 Parkinson's Disease"
      supports: SUPPORT
      snippet: "Significant pathways in serum included sphingolipid metabolism, amino sugar metabolism and amino acid pathways, whereas significant features between groups in sebum are hypothesised to be lipid degradation products."
      explanation: The dataset description lists pathway-level differences in serum and hypothesized lipid degradation products in sebum.
  evidence:
  - reference: metabolights:MTBLS10743
    reference_title: "Metabolomic Changes in Idiopathic and GBA1 Parkinson's Disease"
    supports: SUPPORT
    snippet: "Here, we use mass spectrometry based metabolomics to analyse serum and sebum samples from 50 genotyped participants and find differences in lipid and sugar regulation, oxidative stress and the production of amino acids and neurotransmitters which distinguish ... GBA1-PD from iPD."
    explanation: Establishes the dataset's serum and sebum metabolomics design distinguishing GBA1-PD from idiopathic PD.
  notes: Preprint dataset describing metabolic changes in idiopathic vs GBA1 PD.

# CELLxGENE - Multi-region single nucleus PD atlas
- accession: "cellxgene:d5d0df8f-4eee-49d8-a221-a288f50a1590"
  title: A multi-region single nucleus transcriptomic atlas of Parkinson's disease
  description: >-
    Single-nucleus RNA-seq atlas of Parkinson's disease spanning multiple brain
    regions, providing cell-type-resolved transcriptomic profiles of dopaminergic
    neurons and glial populations in PD and healthy controls.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  sample_types:
  - preferred_term: brain tissue
    tissue_term:
      preferred_term: brain
      term:
        id: UBERON:0000955
        label: brain
  conditions:
  - Parkinson's disease
  - healthy controls
  publication: PMID:39317733
  notes: CZI CELLxGENE collection. DOI 10.1038/s41597-024-04117-y. Multi-region snRNA-seq atlas enabling virtual cell model training on PD-relevant cell states.

discussions:
- discussion_id: pd_pgc1a_therapeutic_window
  prompt: >-
    Does restoring PGC-1alpha signaling protect nigral dopaminergic neurons in
    human Parkinson disease, given that rescue is seen in cellular models while
    sustained supraphysiological expression in the adult rat nigrostriatal
    system is itself dopaminergic-toxic?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#PGC-1alpha Transcriptional Program Repression
  - pathophysiology#Mitochondrial Dysfunction
  rationale: >-
    The direction of the human observation is not in doubt: PGC-1alpha-responsive
    bioenergetic genes are underexpressed in laser-captured human nigral neurons
    early in disease, and the repressor PARIS accumulates in human Parkinson
    disease brain. What does not transfer cleanly from model to patient is the
    therapeutic inverse. Cellular models show that activating PGC-1alpha blocks
    alpha-synuclein- and rotenone-induced dopaminergic loss, but AAV-mediated
    sustained overexpression in the adult rat nigrostriatal system selectively
    impairs dopaminergic function and, at higher levels, causes overt
    degeneration - and it does not rescue alpha-synuclein-induced degeneration.
    PGC-1alpha therefore behaves as a rheostat with an activation-level, cell-type,
    isoform and disease-stage dependence rather than as a monotonic neuroprotective
    switch, so a positive result in one model system cannot be read as evidence
    that pathway activation is protective in patients. Recording this as a
    HUMAN_MODEL_MISMATCH rather than a plain KNOWLEDGE_GAP is deliberate: the
    model evidence exists and is abundant on both sides; it is its translational
    validity, and specifically the existence and width of a therapeutic window,
    that is unresolved. This gap is shared with other neurodegenerative entries
    (Huntington disease, Alzheimer disease, amyotrophic lateral sclerosis) in
    which the same coactivator is implicated.
  proposed_experiments:
  - experiment_id: exp_pd_pgc1a_dose_response_nigrostriatal
    name: Dose-graded PGC-1alpha activation in nigrostriatal models
    description: >-
      Titrate PGC-1alpha activity across a graded range - from partial
      restoration toward physiological levels up to the supraphysiological
      levels used in the AAV overexpression studies - in human iPSC-derived
      midbrain dopaminergic neurons and in an in vivo nigrostriatal model,
      reading out respiratory-chain subunit expression, mitochondrial membrane
      potential, dopamine content and dopaminergic survival at each level.
    experiment_type:
      preferred_term: dose-response perturbation study
    decision_criterion: >-
      A therapeutic window exists if there is a contiguous range of PGC-1alpha
      activity in which bioenergetic readouts improve without loss of
      dopaminergic markers or dopamine content; the rheostat model predicts an
      inverted-U with toxicity at the high end, whereas a simple neuroprotective
      model predicts monotonic benefit.
  - experiment_id: exp_pd_pgc1a_target_engagement_biomarker
    name: Human target-engagement biomarker for PGC-1alpha modulation
    description: >-
      Establish and validate a measurable readout of PGC-1alpha pathway
      engagement in living patients - for example a peripheral or CSF
      transcriptional signature of the PGC-1alpha-responsive gene set benchmarked
      against the postmortem nigral signature - so that a trial of any
      PGC-1alpha-directed agent can distinguish target-engagement failure from
      mechanism failure.
    experiment_type:
      preferred_term: biomarker validation study
    decision_criterion: >-
      The biomarker is usable if it shifts dose-dependently with a known
      PGC-1alpha modulator and correlates with the nigral PGC-1alpha-responsive
      gene-set deficit; absent such a readout, a negative clinical trial cannot
      be interpreted as refuting the mechanism.
  evidence:
  - reference: PMID:22246294
    reference_title: "Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In the adult rat nigrostriatal system, adeno-associated virus (AAV)-mediated overexpression of PGC-1α induces the selective loss of dopaminergic markers and increases dopamine (DA) catabolism, leading to a reduction in striatal DA content."
    explanation: >-
      The in vivo counterexample to the cellular rescue result: sustained
      pathway activation is itself dopaminergic-toxic, which is what creates the
      translational uncertainty.
  - reference: PMID:22246294
    reference_title: "Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These results highlight the central role of PGC-1α in the function and survival of dopaminergic neurons and the critical need for maintaining physiological levels of PGC-1α activity."
    explanation: >-
      States the therapeutic-window requirement directly - benefit is
      conditional on activity level, not on activation per se.
  - reference: PMID:42430091
    reference_title: "The Role of PGC-1α in Neurodegenerative Diseases: Molecular Mechanisms, Translational Challenges, and Therapeutic Potential."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "These observations suggest that PGC-1α is not a simple neuroprotective switch, but a flexible regulatory hub whose therapeutic value depends on cell type, isoform profile, disease stage, and activation level."
    explanation: >-
      Cross-disease review framing that generalizes the mismatch beyond
      Parkinson disease and names the four context variables that determine
      whether modulation helps.
  notes: >-
    Raised from dismech issue #6114 ([kgap-scan:scope] PGC-1alpha-mediated
    neuroprotection), which asked whether the Parkinson, Alzheimer and
    amyotrophic lateral sclerosis entries should carry a PGC-1alpha node. The
    Huntington disease entry already curates the mHTT-driven PGC-1alpha
    repression chain; Alzheimer disease and amyotrophic lateral sclerosis remain
    uncurated for this mechanism.
- discussion_id: gap_pd_microbiome_causal_direction_body_first
  prompt: >-
    In body-first Parkinson disease, are gut microbiome dysbiosis and
    intestinal barrier/inflammatory changes causal triggers for enteric
    alpha-synuclein seeding, modifiers that amplify an already initiated
    synucleinopathy, or secondary consequences of autonomic gut dysfunction?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Gut Microbiome Dysbiosis
  - pathophysiology#Intestinal Inflammation and Barrier Dysfunction
  - pathophysiology#Enteric Alpha-Synuclein Seeding
  - pathophysiology#Vagal-Brainstem Alpha-Synuclein Propagation
  rationale: >-
    Cross-sectional human studies support PD-associated dysbiosis and elevated
    intestinal inflammatory/permeability markers, while animal studies support
    gut-to-brain alpha-synuclein propagation through the vagus nerve. The
    unresolved step is temporal and causal: whether dysbiosis or barrier
    dysfunction initiates enteric alpha-synuclein misfolding in humans, merely
    accelerates propagation, or appears after autonomic denervation has already
    altered gut physiology.
  proposed_experiments:
  - experiment_id: exp_pd_prodromal_microbiome_barrier_alpha_syn_longitudinal_cohort
    name: Prodromal microbiome-barrier alpha-synuclein longitudinal cohort
    description: >-
      Follow iRBD-, constipation-, and hyposmia-enriched prodromal cohorts with
      serial stool metagenomics, SCFA/metabolite profiling, fecal and serum
      calprotectin/zonulin, autonomic imaging, and standardized enteric
      alpha-synuclein biopsy assays before motor conversion.
    experiment_type:
      preferred_term: longitudinal prodromal multi-omics cohort study
    readouts:
    - name: Microbiome dysbiosis trajectory
      target: pathophysiology#Gut Microbiome Dysbiosis
      description: >
        Determine whether reproducible microbiome shifts precede, track with,
        or follow enteric alpha-synuclein and autonomic biomarker changes.
      assays:
      - preferred_term: shotgun metagenomic sequencing
      - preferred_term: fecal metabolomics
      direction: POSITIVE
    - name: Intestinal inflammation and barrier trajectory
      target: pathophysiology#Intestinal Inflammation and Barrier Dysfunction
      description: >
        Measure whether inflammatory and permeability markers rise before
        enteric alpha-synuclein detection and clinical conversion.
      assays:
      - preferred_term: calprotectin assay
      - preferred_term: zonulin assay
      direction: POSITIVE
    - name: Enteric alpha-synuclein seeding
      target: pathophysiology#Enteric Alpha-Synuclein Seeding
      description: >
        Track phosphorylated or aggregated alpha-synuclein in standardized
        enteric biopsies as a candidate initiating event.
      assays:
      - preferred_term: immunohistochemistry
      - preferred_term: alpha-synuclein seed amplification assay
      direction: POSITIVE
    decision_criterion: >-
      Microbiome and barrier changes would support a trigger model only if they
      reproducibly precede enteric alpha-synuclein positivity and autonomic
      denervation in converters; changes that follow autonomic dysfunction would
      support a consequence or modifier model.
    would_support:
    - pathophysiology#Gut Microbiome Dysbiosis
    - pathophysiology#Intestinal Inflammation and Barrier Dysfunction
    - pathophysiology#Enteric Alpha-Synuclein Seeding
  evidence:
  - reference: PMID:34220443
    reference_title: "Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A causal relationship has not been established, but gut dysbiosis is prevalent in PD and may lead to intestinal inflammation and barrier dysfunction."
    explanation: >-
      The human marker study states the core causal-direction uncertainty
      motivating this knowledge gap.
  - reference: PMID:36332796
    reference_title: "Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, it remains unclear how these mechanisms relate to sporadic PD, a more common form of PD."
    explanation: >-
      Review-level synthesis highlights uncertainty about how gut-related
      mechanisms map onto sporadic PD pathogenesis.
  - reference: PMID:41826284
    reference_title: "Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson's disease: a randomized phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Microbiome profiling revealed greater similarity to donor composition and a marked reduction in Escherichia-Shigella, correlating with decreased colonic α-synuclein aggregation"
    explanation: >-
      The strongest interventional human evidence bearing on this gap: in a
      72-patient phase 2 trial of repeated donor fecal transplantation the
      induced microbiome shift correlated with reduced colonic alpha-synuclein
      aggregation. A correlation between two changes measured after treatment
      does not order dysbiosis before enteric alpha-synuclein misfolding, which
      is the question this gap asks.
  - reference: PMID:41674471
    reference_title: "Safety and Efficacy of Fecal Microbiota Transplantation in Alleviating Symptoms of Parkinson's Disease: A Randomized, Placebo-Controlled, Double-Blinded Study."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "A single FMT does not influence motor symptoms manifestation in patients with PD but could improve non-motor functioning via gut-brain axis."
    explanation: >-
      The counterweight that keeps this gap open. A 59-patient randomized
      placebo-controlled trial of single colonoscopic transplantation found no
      motor effect at 12 months. Read with the positive repeated-dosing trial
      above, microbiota manipulation has inconsistent clinical effects, which is
      not what a straightforward causal-trigger model would predict.
- discussion_id: gap_pd_variant_specific_isogenic_hpsc_mechanisms
  prompt: >-
    Which Parkinson disease risk and causal variants produce convergent
    dopaminergic-neuron mechanisms in a controlled human genetic background,
    and which phenotypes are variant-specific, modifier-dependent, or culture
    artifacts?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Dopaminergic Neuron Loss
  - pathophysiology#Alpha-Synuclein Aggregation
  - pathophysiology#Mitochondrial Dysfunction
  - pathophysiology#Autophagy-Lysosome Pathway Dysfunction
  rationale: >-
    Patient-derived iPSC comparisons are powerful but confounded by background
    genetic variation. Large WGS-QC'd isogenic hPSC panels, differentiated into
    midbrain dopaminergic neurons and phenotyped with imaging and sequencing,
    can separate variant-specific causal mechanisms from shared downstream
    neurodegenerative states.
  proposed_experiments:
  - experiment_id: exp_pd_automated_isogenic_hpsc_variant_panel
    name: Automated isogenic hPSC Parkinson variant panel
    description: >-
      Generate or extend a WGS-QC'd isogenic hPSC panel carrying high-risk or
      causal Parkinson disease alleles, differentiate lines into midbrain
      dopaminergic neurons, and benchmark variant-specific effects on
      alpha-synuclein handling, mitochondrial state, lysosomal function, and
      dopaminergic-neuron survival.
    experiment_type:
      preferred_term: high-throughput isogenic stem-cell perturbation experiment
    model_systems:
    - name: Genome-edited hPSC-derived midbrain dopaminergic neuron panel
      description: >-
        Isogenic human pluripotent stem cell collection carrying Parkinson
        disease variants, differentiated into disease-relevant dopaminergic
        neurons for mechanism-resolved phenotyping.
      experimental_model_type: IPSC_DERIVED_MODEL
      organism:
        preferred_term: human
        term:
          id: NCBITaxon:9606
          label: Homo sapiens
      cell_types:
      - preferred_term: midbrain dopaminergic neuron
        term:
          id: CL:0000700
          label: dopaminergic neuron
      publication: PMID:38405931
      notes: >-
        Designed to be compatible with automated hPSC genome-engineering and
        clonal QC workflows such as ATTIS-style high-throughput line generation.
    perturbations:
    - name: Parkinson disease variant editing
      target: pathophysiology#Dopaminergic Neuron Loss
      description: >
        Introduce or compare causal and high-risk Parkinson alleles in a shared
        genetic background.
      genes:
      - preferred_term: SNCA
        term:
          id: hgnc:11138
          label: SNCA
      - preferred_term: LRRK2
        term:
          id: hgnc:18618
          label: LRRK2
      - preferred_term: GBA1
        term:
          id: hgnc:4177
          label: GBA
      - preferred_term: PINK1
        term:
          id: hgnc:14581
          label: PINK1
      - preferred_term: PRKN
        term:
          id: hgnc:8607
          label: PRKN
    - name: Prime-editing generation or correction
      target: gene#LRRK2
      description: >
        Use prime editing or correction to create reciprocal disease and rescue
        alleles where feasible.
      genes:
      - preferred_term: LRRK2
        term:
          id: hgnc:18618
          label: LRRK2
    readouts:
    - name: Alpha-synuclein aggregation burden
      target: pathophysiology#Alpha-Synuclein Aggregation
      description: >
        High-content imaging and biochemical readouts of alpha-synuclein
        accumulation in differentiated dopaminergic neurons.
      assays:
      - preferred_term: high-content imaging
      - preferred_term: immunocytochemistry
      direction: POSITIVE
    - name: Mitochondrial dysfunction
      target: pathophysiology#Mitochondrial Dysfunction
      description: >
        Mitochondrial respiration, membrane-potential, and stress-state
        measurements across edited variants and corrected controls.
      biological_processes:
      - preferred_term: mitochondrial organization
        term:
          id: GO:0007005
          label: mitochondrion organization
      assays:
      - preferred_term: mitochondrial respiration assay
      direction: NEGATIVE
    - name: Autophagy-lysosome pathway dysfunction
      target: pathophysiology#Autophagy-Lysosome Pathway Dysfunction
      description: >
        Lysosomal function, autophagic flux, and transcriptomic readouts
        stratified by causal allele and rescue status.
      biological_processes:
      - preferred_term: autophagy
        term:
          id: GO:0006914
          label: autophagy
      assays:
      - preferred_term: lysosomal function assay
      - preferred_term: single-cell transcriptomic profiling
      direction: NEGATIVE
    - name: Dopaminergic neuron survival and identity
      target: pathophysiology#Dopaminergic Neuron Loss
      description: >
        Cell survival, dopaminergic identity, and dopamine biosynthesis readouts
        after differentiation.
      biological_processes:
      - preferred_term: dopamine biosynthetic process
        term:
          id: GO:0042416
          label: dopamine biosynthetic process
      assays:
      - preferred_term: high-content imaging
      - preferred_term: targeted transcriptomic profiling
      direction: NEGATIVE
    controls:
    - name: Isogenic unedited parental hPSC line
      description: Same genetic background without Parkinson-associated edits.
    - name: Corrected rescue alleles
      description: Reciprocal correction of disease alleles where editing design allows.
    decision_criterion: >-
      A mechanism is prioritized when multiple independently edited clones for
      the same variant show a reproducible phenotype that is attenuated by
      isogenic correction and maps to a declared pathophysiology node.
    would_support:
    - pathophysiology#Alpha-Synuclein Aggregation
    - pathophysiology#Mitochondrial Dysfunction
    - pathophysiology#Autophagy-Lysosome Pathway Dysfunction
    - pathophysiology#Dopaminergic Neuron Loss
    would_refute:
    - pathophysiology#Alpha-Synuclein Aggregation
    - pathophysiology#Mitochondrial Dysfunction
    - pathophysiology#Autophagy-Lysosome Pathway Dysfunction
    evidence:
    - reference: PMID:38405931
      reference_title: "iSCORE-PD: an isogenic stem cell collection to research Parkinson's Disease."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "we generated a collection of 65 human stem cell lines genetically engineered to harbor high risk or causal variants in genes associated with PD"
      explanation: >-
        Demonstrates the feasibility of a large isogenic hPSC Parkinson variant
        collection for mechanism-resolved experiments.
    - reference: PMID:38405931
      reference_title: "iSCORE-PD: an isogenic stem cell collection to research Parkinson's Disease."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "rigorous quality controls, including whole-genome sequencing of each line."
      explanation: Supports WGS-QC as a design requirement for the proposed panel.
    - reference: PMID:36069759
      reference_title: "Highly efficient generation of isogenic pluripotent stem cell models using prime editing."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Finally, we demonstrated that this mRNA-based delivery approach can be used repeatedly to yield editing efficiencies exceeding 60% and to correct or introduce familial mutations causing Parkinson's disease in hPSCs."
      explanation: >-
        Supports prime editing as a practical modality for generating and
        correcting Parkinson disease mutations in hPSCs.
  evidence:
  - reference: PMID:38405931
    reference_title: "iSCORE-PD: an isogenic stem cell collection to research Parkinson's Disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our iSCORE-PD collection represents an easily accessible and valuable platform to study PD, which can be used by investigators to understand the molecular pathophysiology of PD in a human cellular setting."
    explanation: >-
      Establishes the existence of a human isogenic hPSC resource for studying
      Parkinson molecular pathophysiology, while the specific knowledge gap
      remains the standardized phenotype-to-mechanism adjudication.
- discussion_id: gap_pd_weight_loss_multifactorial_mechanisms
  prompt: >-
    Weight loss is a long-observed non-motor symptom of Parkinson disease, yet
    its mechanisms remain incompletely understood. Which of the proposed pathways
    — metabolic dysregulation, neuroendocrine disruption, gastrointestinal
    dysfunction, cognitive decline, and pharmacologic effects — are primary drivers
    versus secondary consequences, and how do they interact across the disease course?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Dopaminergic Neuron Loss
  - pathophysiology#Intestinal Inflammation and Barrier Dysfunction
  - pathophysiology#Basal Ganglia Circuit Dysfunction
  rationale: >-
    Weight loss exerts substantial morbidity and mortality in PD, yet limited
    mechanistic understanding constrains treatment options. The Gabriel et al.
    (2026) review identifies six interacting pathways: (1) metabolic
    dysregulation (altered energy expenditure or intake), (2) neuroendocrine
    disruption (leptin/ghrelin/GLP-1 signaling), (3) gastrointestinal
    dysfunction (dysmotility, malabsorption, barrier dysfunction), (4) cognitive
    decline (reduced appetite awareness), (5) dopaminergic-medication effects
    (appetite suppression), and (6) brain stimulation paradoxes (DBS-induced
    weight changes). The relative contribution and temporal ordering of these
    mechanisms remain unknown. Resolving cross-mechanism interactions would
    enable targeted metabolic interventions in PD.
  proposed_experiments:
  - experiment_id: exp_pd_weight_loss_longitudinal_mechanisms
    name: Longitudinal weight loss phenotype stratification with multi-mechanism readouts
    description: >-
      Follow a large PD cohort with serial body composition (DXA, bioimpedance),
      resting metabolic rate, circulating metabolic hormones (leptin, adiponectin,
      GLP-1, ghrelin), dopamine-agonist doses and appetite-affecting medications,
      cognitive testing, gastrointestinal symptom questionnaires, and GI transit
      imaging. Stratify the cohort into weight-loss phenotypes (progressive vs.
      stable) and identify mechanistic signatures.
    experiment_type:
      preferred_term: longitudinal multi-omics observational cohort study
    readouts:
    - name: Metabolic rate and body composition trajectories
      target: pathophysiology#Dopaminergic Neuron Loss
      description: >
        Measure resting metabolic rate, energy expenditure, and changes in
        lean vs. fat mass to distinguish metabolic dysregulation from
        reduced intake.
      assays:
      - preferred_term: indirect calorimetry
      - preferred_term: dual-energy X-ray absorptiometry
      direction: NEGATIVE
    - name: Circulating neuroendocrine hormone patterns
      target: pathophysiology#Dopaminergic Neuron Loss
      description: >
        Quantify leptin, ghrelin, adiponectin, GLP-1, and other appetite-regulating
        hormones to identify dysregulation of satiety/hunger signaling.
      assays:
      - preferred_term: serum hormone quantification
      direction: NEGATIVE
    - name: Gastrointestinal function and symptoms
      target: pathophysiology#Intestinal Inflammation and Barrier Dysfunction
      description: >
        Assess gastric emptying (breath test), small-bowel transit, colonic
        function, permeability markers (zonulin, calprotectin), and GI symptom
        severity to establish causal vs. consequential GI involvement.
      assays:
      - preferred_term: gastric-emptying scintigraphy
      - preferred_term: fecal calprotectin assay
      direction: NEGATIVE
    - name: Cognitive decline severity
      target: pathophysiology#Basal Ganglia Circuit Dysfunction
      description: >
        Administer validated cognitive batteries (MoCA, MMSE) and assess
        appetite awareness to test the cognitive-suppression hypothesis.
      assays:
      - preferred_term: cognitive assessment battery
      direction: NEGATIVE
    decision_criterion: >-
      Mechanistic dominance is supported by: (1) trajectories preceding or
      independent of weight loss (dysmetabolism, hormone changes, GI dysfunction);
      (2) stratification of the cohort into mechanistically distinct weight-loss
      phenotypes; (3) reproducible associations between mechanism-specific markers
      and subsequent weight-loss progression in converters.
    would_support:
    - pathophysiology#Dopaminergic Neuron Loss
    - pathophysiology#Intestinal Inflammation and Barrier Dysfunction
    - pathophysiology#Basal Ganglia Circuit Dysfunction
  evidence:
  - reference: PMID:41781031
    reference_title: "When the Scale Drops: Pathways to Weight Loss in Parkinson's Disease and Future Directions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "weight loss has long been observed in PD and other neurodegenerative disorders, yet the mechanisms remain incompletely understood. This limited mechanistic insight has left few treatment options for weight loss in PD."
    explanation: >-
      The Gabriel et al. review establishes weight loss as a significant yet
      mechanistically unexplained PD symptom, directly motivating this knowledge gap.
  - reference: PMID:41781031
    reference_title: "When the Scale Drops: Pathways to Weight Loss in Parkinson's Disease and Future Directions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Emerging research highlights the role of metabolic regulation, neuroendocrine signaling, pharmacologic treatment, cognitive decline, gastrointestinal dysfunction, and brain stimulation in shaping weight trajectories in PD."
    explanation: >-
      This enumerates the six candidate mechanisms for weight loss in PD,
      supporting the multi-pathway framing of the gap.
- discussion_id: gap_pd_origin_site_operationalization
  prompt: >-
    Can brain-first versus body-first origin site be operationalized as a
    measurable layer of the biological staging frameworks for Parkinson
    disease, and does origin-site stratification carry mechanistic or
    prognostic information that the existing anchors and data-driven subtypes
    do not already capture?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - mechanistic_hypotheses#body_first_enteric_alpha_synuclein_model
  - mechanistic_hypotheses#brain_first_central_alpha_synuclein_model
  rationale: >-
    Both origin-site hypotheses in this entry are curated as ALTERNATIVE, and
    both are assigned in practice from proxies - premotor REM-sleep behavior
    disorder, autonomic markers, imaging asymmetry - rather than from an
    observed first site of alpha-synuclein pathology. Two current biological
    definitions of the disease, the neuronal alpha-synuclein disease integrated
    staging system and SynNeurGe, are built on alpha-synuclein seeding,
    neurodegeneration, genetics, and functional impairment; neither carries an
    origin-site axis. That is an implementation gap rather than evidence against
    either model, and it should not be read as a scientific qualification of the
    mechanism. But it leaves the practical question unanswered: no consensus
    operational definition of origin site exists, so origin-site subtype
    membership is not portable between cohorts, and there is no agreed way to
    record it alongside a biological stage. The prognostic side of the question
    is not favorable either - a 10-year PPMI comparison found that data-driven
    subtypes separate rapid progressors more efficiently than the pathological
    brain-first/body-first labels do. That comparison measures prognostic
    enrichment, not anatomical origin, so it does not test either mechanism; it
    does mean the case for adding an origin-site layer has to rest on
    mechanistic rather than prognostic grounds.
  evidence:
  - reference: PMID:38267190
    reference_title: "A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Our biological definition establishes a staging system, the neuronal α-synuclein disease integrated staging system (NSD-ISS), rooted in the biological anchors (S and D) and the degree of functional impairment caused by clinical signs or symptoms."
    explanation: >-
      Names the anchors of the NSD-ISS - alpha-synuclein seeding, dopaminergic
      dysfunction, and functional impairment - none of which encodes where
      pathology began, which is the gap this discussion records.
  - reference: PMID:39973492
    reference_title: "SynNeurGe: The road ahead for a biological definition of Parkinson's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, SynNeurGe provides a broader, more flexible framework that integrates α-synuclein pathology (S), neurodegeneration (N), and genetics (G), linked to clinical features (C)."
    explanation: >-
      The competing biological classification is organized on the same kind of
      axes, so the absence of an origin-site layer is common to both frameworks
      rather than particular to one.
  - reference: PMID:42286020
    reference_title: "Comparative analysis of progression milestones across Parkinson's disease clinical, pathological, and data-driven subtypes: a 10-year follow-up."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Data-driven subtypes exhibited the highest progression rates, with DM patients attaining 63.0% of milestones, surpassing PIGD (55.6%) and body-first (54.0%) subtypes."
    explanation: >-
      Quantifies the prognostic half of the gap in the PPMI cohort: the
      body-first label is outperformed by a data-driven subtype for identifying
      rapid progressors. This bears on the utility of origin-site stratification
      for trial design, not on whether central or peripheral initiation occurs.
  notes: >-
    Recorded from the 2026 OpenScientist hypothesis-search reports for both
    origin-site models, which independently raise the missing origin-site layer
    as a curation-level knowledge gap. The two staging-framework citations and
    the progression-milestone comparison ground claims that the
    mechanistic_hypotheses notes previously asserted without references. An
    earlier preprint of the milestone comparison (PMID:40678221) reported lower
    milestone proportions (50%, 43%, 42%) than the final publication cited here;
    cite the published version.

computational_models:
- name: Alpha-Synuclein Aggregation BST Model
  description: >
    Biochemical Systems Theory (BST) model of alpha-synuclein aggregation kinetics
    in dopaminergic neurons. Integrates dopamine metabolism, ubiquitin-proteasome
    system, and lysosomal degradation pathways. Simulates effects of oxidative
    stress and proteasome inhibition on synuclein accumulation.
  modeled_mechanisms:
  - target: Alpha-Synuclein Aggregation
    description: Models alpha-synuclein aggregation kinetics and degradation-pathway effects in dopaminergic neurons.
  model_type: KINETIC
  repository_url: https://www.ebi.ac.uk/biomodels/BIOMD0000000575
  model_id: BIOMD0000000575
  publication: PMID:19136028
  notes: First comprehensive kinetic model of PD-related protein aggregation
- name: Whole Dopaminergic Neuron SBML Model
  description: >
    Large-scale Systems Biology Markup Language (SBML) model of dopaminergic
    neuron containing 139 reactions and 111 metabolites. Captures dopamine
    synthesis, vesicular storage, release, reuptake, and degradation alongside
    mitochondrial function and oxidative stress.
  modeled_mechanisms:
  - target: Striatal Dopamine Deficiency
    description: Models dopamine synthesis, storage, release, reuptake, and degradation in dopaminergic-neuron physiology.
  - target: Mitochondrial Dysfunction
    description: Models mitochondrial metabolism alongside dopamine handling in dopaminergic neurons.
  model_type: KINETIC
  repository_url: https://www.ebi.ac.uk/biomodels/MODEL1302200000
  model_id: MODEL1302200000
  publication: PMID:24196439
  model_format: SBML
  notes: Enables simulation of drug effects on dopaminergic neurotransmission
- name: Basal Ganglia Spiking Neural Network
  description: >
    Computational model of the basal ganglia circuit capturing dopamine-modulated
    dynamics between striatum, globus pallidus, subthalamic nucleus, and
    substantia nigra. Simulates pathological beta-band oscillations and motor
    dysfunction in PD.
  modeled_mechanisms:
  - target: Basal Ganglia Circuit Dysfunction
    description: Models dopamine-modulated basal ganglia circuit dynamics, beta-band oscillations, and DBS effects.
  model_type: PHYSIOLOGICAL
  publication: PMID:29666208
  notes: Models circuit-level effects of dopamine depletion and DBS therapy
- name: Alpha-Synuclein Prion-like Spreading Model
  description: >
    Network diffusion model simulating prion-like propagation of misfolded
    alpha-synuclein through brain connectome. Uses graph-theoretical approach
    to predict spatial patterns of neurodegeneration from initial seeding sites.
  modeled_mechanisms:
  - target: Alpha-Synuclein Aggregation
    description: Models connectome-based propagation of misfolded alpha-synuclein pathology.
  model_type: AGENT_BASED
  notes: Predicts Braak staging patterns from connectivity-based spreading
- name: PD Map Cohort-Specific Probabilistic Boolean Models
  description: >-
    Probabilistic Boolean Networks (PBNs) built from the Parkinson's disease map, the
    largest curated repository of PD pathway diagrams. Pathways enriched in the
    Parkinson's Progression Markers Initiative (PPMI) cohort were exported from the PD
    map in CellDesigner SBML format, translated to SBML-qual with CaSQ, and
    parameterised against cohort miRNA and transcriptomic data so that each model
    represents a specific PD subgroup (prodromal, SWEDD, parkinsonism). Simulating the
    resulting models with pyMaBoSS reveals subtype-specific differences in dopamine
    transcription, PI3K/AKT signalling, FOXO3 activity, mTOR-MAPK signalling and PRKN
    mitophagy. The probabilistic parameterisation, rather than plain Boolean logic, is
    what lets cohort-level data enter the model.
  model_type: BOOLEAN_NETWORK
  model_format: SBML-qual
  model_software: CaSQ, pyMaBoSS, CellDesigner
  repository_url: https://gitlab.lcsb.uni.lu/lcsb-biocore/publications/hemedan23-boolean-modelling-of-pd
  publication: PMID:39429779
  modeled_mechanisms:
  - target: Autophagy-Lysosome Pathway Dysfunction
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: MOLECULAR
    divergences:
    - divergence_type: PROXY_QUANTITY
      materiality: QUALIFYING
      description: >-
        The model represents transcriptional regulation of the autophagy-lysosome
        pathway. The node describes the degradative process itself -- flux through
        that pathway -- which transcript abundance constrains but does not measure.
    - divergence_type: CALIBRATION_PROVENANCE
      materiality: QUALIFYING
      description: >-
        Node transition probabilities were fitted to cohort-level miRNA and
        transcriptomic data, not to any direct assay of autophagic flux.
    - divergence_type: SCALE_EXTRAPOLATION
      materiality: QUALIFYING
      description: >-
        A molecular signalling network standing for a cell-scale degradative
        process.
    description: >-
      PRKN mitophagy is one of the enriched PD map pathways converted into a
      cohort-parameterised Boolean model, and autophagy/mitophagy activity is one of
      the axes on which the subtypes separate.
    limitations: >-
      The model is parameterised from cohort-level miRNA and transcriptomic data rather
      than from direct measurement of autophagic flux, so it represents transcriptional
      regulation of the pathway rather than the degradative process itself.
    readouts:
    - name: PRKN-mitophagy model activity across PD subgroups
      target: Autophagy-Lysosome Pathway Dysfunction
      direction: ALTERED
      interpretation: >-
        Mitophagy and autophagy activities differ between the SWEDD, prodromal and
        parkinsonism subgroups rather than moving in one direction across all of PD.
      evidence:
      - reference: PMID:39429779
        supports: SUPPORT
        evidence_source: COMPUTATIONAL
        snippet: >-
          differences in autophagy and mitophagy activities were observed, suggesting
          unique disease mechanisms within each PD subtype
        explanation: >-
          Reports the subtype-dependent autophagy/mitophagy readout this link records.
    evidence:
    - reference: PMID:39429779
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        The enriched pathways included dopamine transcription pathways, PI3k/AKT
        signaling, FOXO3 activity, mTOR-MAPK signaling, and PRKN mitophagy
      explanation: >-
        Names PRKN mitophagy among the pathways modelled, linking this model to the
        autophagy-lysosome node.
  - target: Striatal Dopamine Deficiency
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    model_scale: MOLECULAR
    divergences:
    - divergence_type: PROXY_QUANTITY
      materiality: INVALIDATING
      description: >-
        The model's quantity is transcriptional regulation of dopamine-synthesis
        genes. The node's quantity is dopamine concentration in the striatum.
        These are different measurements separated by transcription, translation,
        synthesis, transport and terminal survival, and the model cannot be read
        as reporting the second. This is the divergence behind the link's LOW
        fidelity, and it is invisible to the scale comparison alone.
    - divergence_type: BOUNDARY_OMISSION
      materiality: QUALIFYING
      description: >-
        Nigrostriatal terminal loss and the presynaptic deficit that clinically
        defines this node are not in the model.
    - divergence_type: SCALE_EXTRAPOLATION
      materiality: QUALIFYING
      description: >-
        Two scale steps: a molecular network inferring the dopaminergic tone of an
        anatomical structure.
    - divergence_type: CALIBRATION_PROVENANCE
      materiality: QUALIFYING
      description: >-
        Parameterised from cohort-level omics rather than from striatal dopamine
        measurement in the cohorts the model stratifies.
    description: >-
      Dopamine transcription pathways are among the enriched PD map diagrams converted
      to Boolean models and show distinct behaviour across subtypes.
    limitations: >-
      The model represents transcriptional regulation of dopamine synthesis in a
      cohort-parameterised signalling network; it does not represent striatal dopamine
      concentration, nigrostriatal terminal loss, or the presynaptic deficit that
      defines this node clinically.
    evidence:
    - reference: PMID:39429779
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: COMPUTATIONAL
      snippet: >-
        These models revealed distinct behaviors in key molecular pathways across PD
        subtypes, including dopamine transcription, PI3K/AKT signaling, FOXO3 activity,
        mTOR-MAPK signaling, and PRKN mitophagy
      explanation: >-
        Supports a transcription-level dopamine claim. Indirect: the quote asserts
        subtype-specific behaviour of dopamine-transcription pathways, and striatal
        dopamine deficiency follows only by an inference step across transcription,
        synthesis and terminal survival -- which is also why fidelity here is LOW.
  findings:
  - statement: >-
      Cohort-level and real-world patient data were integrated into the logical models
      to represent subtype-specific pathway deregulation.
    evidence:
    - reference: PMID:39429779
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        By integrating cohort-level and real-world patient data, we modeled PD's
        subtype-specific pathway deregulations, providing a refined representation of
        its molecular landscape
      explanation: States the data-integration step that makes these models cohort-specific.
  evidence:
  - reference: PMID:39429779
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      we employed systems medicine approaches using the PD map, a detailed repository
      of PD-related interactions and applied Probabilistic Boolean Networks (PBNs) to
      capture the stochastic nature of molecular dynamics
    explanation: >-
      Establishes the PD map as the knowledge source and PBNs as the modelling
      formalism for this entry.
  - reference: PMID:39429779
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      The pathways identified via the enrichment analysis were exported from the PD map
      in CellDesigner SBML format and translated into SBML-qual files by the CaSQ tool
    explanation: >-
      Documents the CaSQ map-to-model translation and the SBML-qual format recorded in
      model_format.
  notes: >-
    Curated as part of the Boolean/logical modelling track; see
    docs/superpowers/plans/2026-08-28-boolean-modeling-and-pathographs.md.
    Literature-referenced, not runnable in-repo: dismech-perturb has no SBML-qual
    execution path yet. Note this is a *probabilistic* Boolean network — cohort data enter as node
    transition probabilities, so it is not a plain deterministic Boolean model.
references:
- reference: DOI:10.2147/ndt.s540718
  title: Updates on Parkinson’s Disease
  findings: []
- reference: DOI:10.3389/fnagi.2025.1617106
  title: 'Understanding Parkinson’s disease: current trends and its multifaceted complications'
  findings: []
- reference: DOI:10.3390/cells14151161
  title: 'Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation'
  findings: []
- reference: DOI:10.3390/ijms25137183
  title: 'A Comprehensive Approach to Parkinson’s Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects'
  findings: []

📚

References & Deep Research

References

DOI:10.2147/ndt.s540718

Updates on Parkinson’s Disease

No top-level findings curated for this source.

DOI:10.3389/fnagi.2025.1617106

Understanding Parkinson’s disease: current trends and its multifaceted complications

No top-level findings curated for this source.

DOI:10.3390/cells14151161

Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation

No top-level findings curated for this source.

DOI:10.3390/ijms25137183

A Comprehensive Approach to Parkinson’s Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects

No top-level findings curated for this source.

Deep Research

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Disorder ▸

Disorder

Name: Parkinson's Disease
Category: Complex
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 67

Key Pathophysiology Nodes

Dopaminergic Neuron Loss
Alpha-Synuclein Aggregation
Mitochondrial Dysfunction
Neuroinflammation
Autophagy-Lysosome Pathway Dysfunction
Gut-Brain Axis Dysfunction
Oxidative Stress
Calcium Dysregulation
Endoplasmic Reticulum Stress
Synaptic Dysfunction
Iron Accumulation and Ferroptosis
Blood-Brain Barrier Dysfunction

Citation Inventory (for evidence mapping)

DOI:10.1016/s0140-6736(23
DOI:10.2147/ndt.s540718
DOI:10.3389/fnagi.2025.1617106
DOI:10.3390/cells14151161
DOI:10.3390/ijms25137183

Falcon ▸

Disease Pathophysiology Research Report

Edison Scientific Literature 15 citations 2025-12-17T18:36:16.429486

Disease Pathophysiology Research Report

Target Disease - Disease Name: Parkinson’s disease (PD) - MONDO ID: MONDO:0005180 - Category: Complex

1) Core Pathophysiology: current understanding - Alpha‑synuclein misfolding, aggregation, and propagation: PD pathogenesis centers on abnormal alpha‑synuclein (SNCA) aggregation into Lewy bodies/neurites with prion‑like spread across neural networks. Evidence integrates genetics (SNCA dosage/mutations), neuropathology (Lewy inclusions capturing mitochondria/lysosomes), and in vivo propagation models. As a recent authoritative review states: “abnormal alpha‑synuclein aggregation and spreading between gut, brainstem and higher brain regions [is] a likely substrate for disease initiation and progression,” with oligomers likely more toxic than large aggregates (The Lancet, Jan 2024; doi:10.1016/S0140-6736(23)01478-2) (morris2024thepathogenesisof pages 1-4). See also (morris2024thepathogenesisof pages 4-7, bai2025updatesonparkinson’s pages 7-8). - Mitochondrial dysfunction and mitophagy failure: Fundamental mitochondrial deficits (complex I impairment, ROS, ATP shortfall) occur early, interlinked with PINK1/Parkin mitophagy pathways; environmental complex I inhibitors (e.g., MPTP/pesticides) converge on this axis (Lancet 2024) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4). - Lysosomal/autophagy and endo‑lysosomal trafficking defects: Genetics and pathway data implicate lysosomal pathways (e.g., GBA1, LRRK2, VPS35), with impaired proteostasis driving alpha‑syn accumulation (Lancet 2024; 2024 IJMS review) (morris2024thepathogenesisof pages 1-4, alvarez2024acomprehensiveapproach pages 2-4). - Neuroinflammation and glial crosstalk: Chronic microglial/astrocytic activation, cytokine cascades, and gut–brain immune signaling likely contribute to progression; immune‑inflammatory mechanisms are highlighted as key but incompletely resolved (Lancet 2024) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4). - Calcium homeostasis, synaptic and axonal dysfunction: Early synaptic injury (vesicle trafficking, axonal transport) and calcium dysregulation precede neuronal loss, particularly in vulnerable nigrostriatal dopaminergic neurons (Lancet 2024) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4). - Body‑first vs brain‑first and gut–brain axis: Both Braak’s peripheral‑to‑central model and a “brain‑first” trajectory are supported; prodromal autonomic/GI features and RBD support a body‑first subtype in a substantial subgroup (Lancet 2024; 2025 narrative synthesis) (morris2024thepathogenesisof pages 1-4, tanaka2025parkinson’sdiseasebridging pages 6-7, chaudhary2025understandingparkinson’sdisease pages 2-3).

2) Key Molecular Players - Genes/Proteins (HGNC): - SNCA (alpha‑synuclein): causal; mutations/dosage increase aggregation and drive aggressive phenotypes (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - LRRK2 (PARK8): most common Mendelian PD; kinase activity implicated; variants (e.g., G2019S, R1441) and downstream lysosomal/endolysosomal effects (Lancet 2024; IJMS 2024) (morris2024thepathogenesisof pages 1-4, alvarez2024acomprehensiveapproach pages 2-4). - PRKN (Parkin; PARK2), PINK1 (PARK6): recessive; central to mitophagy, mitochondrial quality control (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - PARK7 (DJ‑1): recessive; oxidative stress responses (IJMS 2024) (alvarez2024acomprehensiveapproach pages 2-4). - GBA1 (glucocerebrosidase): strongest risk factor among lysosomal enzyme genes; glucosylceramide handling, autophagy‑lysosomal pathways (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - VPS35: endosomal trafficking; links to lysosome/autophagy (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - Polygenic risk: “90 independent variants across 74 genomic loci” implicating lysosome–autophagy and immune pathways (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - Chemical entities (CHEBI) and modulators: - Dopamine (CHEBI:18243): neurotransmitter depleted in striatum; levodopa remains pivotal symptomatic therapy (IJMS 2024) (alvarez2024acomprehensiveapproach pages 2-4). - Glucosylceramide (CHEBI:18238): substrate in GBA1 pathway; links lipid metabolism to alpha‑syn burden (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - Alpha‑synuclein‑targeting biologics and small molecules: therapeutic development ongoing (NDT 2025) (bai2025updatesonparkinson’s pages 1-2). - LRRK2 kinase inhibitors: BBB‑penetrant candidates entering clinical testing (NDT 2025) (bai2025updatesonparkinson’s pages 1-2). - Cell types (CL): - Midbrain dopaminergic neuron, substantia nigra pars compacta (CL:0002609): selectively vulnerable (Lancet 2024) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4). - Microglia (CL:0000129) and astrocytes (CL:0000127): drivers and modulators of neuroinflammation (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - Enteric neurons/glia (ENS): peripheral initiation sites in body‑first subtype (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - Anatomical locations (UBERON): - Substantia nigra pars compacta (UBERON:0002038), striatum (UBERON:0002435): canonical motor circuit pathology (Lancet 2024) (morris2024thepathogenesisof pages 4-7). - Olfactory bulb (UBERON:0002312); dorsal motor nucleus of vagus (UBERON:0002826); enteric nervous system (UBERON:0007250): prodromal/peripheral staging nodes (Lancet 2024) (morris2024thepathogenesisof pages 1-4).

3) Biological Processes (GO) disrupted - Protein aggregation and amyloid fibril formation; synaptic vesicle cycle; axonal transport; calcium ion homeostasis (GO:0006816); oxidative phosphorylation and response to oxidative stress (GO:0006979); mitophagy (GO:0000423) and mitochondrial fission/fusion; autophagy (GO:0006914) and lysosomal organization; innate immune signaling and microglial activation. Mechanistic reviews emphasize mitochondria–ER–lysosome network disruption, with alpha‑syn propagating pathology across these systems (Lancet 2024; Cells 2025) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4, tanaka2025parkinson’sdiseasebridging pages 6-7).

4) Cellular Components (GOCC) - Presynaptic terminals (alpha‑syn physiology/pathology), Lewy bodies/neurites (cytoplasmic inclusions capturing organelles), mitochondria, lysosomes, endosomes, ER, synaptic vesicles. Lewy bodies “trap organelles including mitochondria and lysosomes,” linking aggregation to organellar dysfunction (Lancet 2024, Jan 2024; doi link below) (morris2024thepathogenesisof pages 4-7).

5) Disease Progression and Staging - Sequence of events: prodrome → early synaptic/metabolic stress → alpha‑syn oligomer accumulation and fibril formation → organellar (mitochondria/lysosome) stress and impaired mitophagy → neuroinflammation/glial activation → progressive nigrostriatal degeneration and network spread → clinical motor syndrome and expanding non‑motor burden (Lancet 2024) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4). - Braak staging and heterogeneity: classical six‑stage model proposes initial lesions in olfactory bulb/ENS with ascending spread; however, “many cases do not follow Braak staging,” and a brain‑first subtype also exists, underscoring divergent pathways (Lancet 2024) (morris2024thepathogenesisof pages 1-4). Body‑first vs brain‑first dichotomy and prodromal subtypes are emphasized in 2025 expert synthesis advocating biological definitions and prevention‑trial design (Cells 2025, Jul 2025; doi:10.3390/cells14151161) (tanaka2025parkinson’sdiseasebridging pages 6-7). - Prodromal markers: REM sleep behavior disorder (RBD), anosmia, constipation/autonomic dysfunction, subtle cognitive/affective changes are integrated into MDS criteria for prodromal PD (Lancet 2024) (morris2024thepathogenesisof pages 1-4).

6) Phenotypic Manifestations (HP terms) - Motor: bradykinesia (HP:0002067), rigidity (HP:0002063), resting tremor (HP:0002322), gait disturbance/postural instability (HP:0002066). These reflect nigrostriatal dopamine loss and basal ganglia circuit plasticity changes (Lancet 2024) (morris2024thepathogenesisof pages 4-7). - Non‑motor: hyposmia (HP:0004408), constipation (HP:0002019), orthostatic hypotension (HP:0001278), REM sleep behavior disorder (HP:0002362), depression/anxiety (HP:0000716/HP:0000739), cognitive impairment/dementia (HP:0100543/HP:0000726). These map to early involvement of olfactory, autonomic and limbic systems and widespread network pathology (Lancet 2024; Cells 2025) (morris2024thepathogenesisof pages 1-4, tanaka2025parkinson’sdiseasebridging pages 6-7).

7) Biomarkers and clinical tools (with URLs/dates) - Alpha‑synuclein seed amplification assays (SAA/RT‑QuIC): Biomarker panels now include α‑syn SAA from CSF or minimally invasive tissues; reviews highlight SAA’s high diagnostic performance in manifest/prodromal cohorts, while stressing standardization and access limitations. Notably, “alpha‑synuclein seed amplification assays…are being used clinically for biochemical diagnosis” in synucleinopathies, although broader deployment requires harmonization (published 2025/2024 syntheses) (NDT 2025, Sep 2025, https://doi.org/10.2147/ndt.s540718; Lancet 2024, Jan 2024, https://doi.org/10.1016/S0140-6736(23)01478-2) (bai2025updatesonparkinson’s pages 1-2, morris2024thepathogenesisof pages 1-4). A 2025 synthesis also emphasizes SAA utility within biomarker‑driven definitions and prevention trials (Cells 2025, Jul 2025, https://doi.org/10.3390/cells14151161) (tanaka2025parkinson’sdiseasebridging pages 6-7). - Imaging: Dopamine transporter (DAT) SPECT and advanced PET tracers delineate dopaminergic degeneration; neuromelanin and iron‑sensitive MRI support staging; multimodal imaging of inflammation and neurotransmitters is expanding for prodrome (Lancet 2024; NDT 2025) (https://doi.org/10.1016/S0140-6736(23)01478-2; https://doi.org/10.2147/ndt.s540718) (morris2024thepathogenesisof pages 1-4, bai2025updatesonparkinson’s pages 1-2). - Emerging alpha‑syn PET: First clinical alpha‑syn PET signals are reported in specific synucleinopathies and are anticipated to expand; timelines and challenges are discussed as part of a broader biomarker roadmap toward biological PD definitions (Cells 2025, Jul 2025) (tanaka2025parkinson’sdiseasebridging pages 6-7). - Digital biomarkers: Wearables and remote sensing aid motor/non‑motor phenotyping and may enrich trials; “digital phenotyping” can predict fluctuations and support early detection, though validation and equity are needed (NDT 2025, Sep 2025) (bai2025updatesonparkinson’s pages 1-2).

8) Current applications and real‑world implementations - Clinical practice: Combined use of clinical criteria (MDS), dopaminergic imaging when indicated, and selective application of fluid/tissue α‑syn SAA is growing in expert centers; expert reviews call for standardization and access expansion (Lancet 2024; NDT 2025) (morris2024thepathogenesisof pages 1-4, bai2025updatesonparkinson’s pages 1-2). - Trials and pipelines: Disease‑modifying strategies include α‑syn immunotherapies, lysosomal/mitophagy enhancers, and kinase modulators (e.g., LRRK2 inhibitors). Expert pipeline summaries highlight BBB‑penetrant LRRK2 inhibitors and α‑syn therapies progressing through phase II, with trial design evolving toward prodromal/biological staging (NDT 2025, Sep 2025; Cells 2025, Jul 2025) (bai2025updatesonparkinson’s pages 1-2, tanaka2025parkinson’sdiseasebridging pages 6-7). - Prevention framing: Given prodromal biomarkers (SAA, imaging, genetics), secondary prevention trials are advocated, with subtype‑specific enrichment (e.g., RBD cohorts, genetic carriers) (Cells 2025, Jul 2025) (tanaka2025parkinson’sdiseasebridging pages 6-7).

9) Expert opinions and analysis (authoritative sources, 2023–2025) - The Lancet 2024 review synthesizes genetics, organellar pathology, immune mechanisms, and heterogeneity, concluding: “There are currently no disease‑modifying treatments, but mechanistic insights… provide a basis for targeted neuroprotective strategies” (Jan 2024, https://doi.org/10.1016/S0140-6736(23)01478-2) (morris2024thepathogenesisof pages 1-4). - Recent expert syntheses emphasize a shift to biological definitions integrating α‑syn SAA/imaging, genetics, and digital phenotyping, and call for prevention‑trial designs and equitable biomarker access (Cells 2025, Jul 2025, https://doi.org/10.3390/cells14151161; NDT 2025, Sep 2025, https://doi.org/10.2147/ndt.s540718) (tanaka2025parkinson’sdiseasebridging pages 6-7, bai2025updatesonparkinson’s pages 1-2).

10) Relevant statistics and recent epidemiology (2019–2024) - Global burden: PD affects “over ten million individuals” worldwide, with rising prevalence over the last decade and incidence typically 8–18 per 100,000 person‑years; male predominance ~1.5×; early‑onset PD 5–10% (NDT 2025, Sep 2025, https://doi.org/10.2147/ndt.s540718) (bai2025updatesonparkinson’s pages 1-2). Contemporary global analyses cited by these reviews corroborate increasing age‑standardized prevalence and regional heterogeneity (Lancet 2024, Jan 2024, https://doi.org/10.1016/S0140-6736(23)01478-2) (morris2024thepathogenesisof pages 1-4).

Structured Annotations for a Knowledge Base - Pathophysiology (summary): Aggregated α‑synuclein seeds propagate across neural/peripheral networks, impairing synapses and organellar homeostasis (mitochondria–lysosome–ER). Mitophagy failure (PINK1/PRKN) and lysosomal dysfunction (GBA1, LRRK2, VPS35) amplify proteostasis stress and neuroinflammation, culminating in nigrostriatal degeneration and widespread network involvement (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4). - Gene/Protein annotations (HGNC): SNCA; LRRK2; PRKN; PINK1; PARK7; GBA; VPS35 (morris2024thepathogenesisof pages 1-4, alvarez2024acomprehensiveapproach pages 2-4). - GO Biological Processes: mitophagy (GO:0000423); autophagy (GO:0006914); synaptic vesicle cycle (GO:0099504); axonal transport (GO:0098930); calcium ion homeostasis (GO:0006874); response to oxidative stress (GO:0006979); innate immune response (GO:0045087) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4). - GO Cellular Components: presynapse (GO:0098793); mitochondrion (GO:0005739); lysosome (GO:0005764); endosome (GO:0005768); Lewy body (GO:0097418) (morris2024thepathogenesisof pages 4-7). - Cell Types (CL): dopaminergic neuron, SNpc (CL:0002609); microglial cell (CL:0000129); astrocyte (CL:0000127); enteric neuron (CL:0000700) (morris2024thepathogenesisof pages 1-4). - Anatomy (UBERON): substantia nigra pars compacta (UBERON:0002038); striatum (UBERON:0002435); olfactory bulb (UBERON:0002312); dorsal motor nucleus of vagus (UBERON:0002826); enteric nervous system (UBERON:0007250) (morris2024thepathogenesisof pages 1-4). - Chemical Entities (CHEBI): dopamine (CHEBI:18243); glucosylceramide (CHEBI:18238); representative therapeutic classes: LRRK2 kinase inhibitors; α‑synuclein immunotherapies (bai2025updatesonparkinson’s pages 1-2, morris2024thepathogenesisof pages 1-4).

Direct supporting statements (quotes) - “Abnormal alpha‑synuclein aggregation and spreading between gut, brainstem and higher brain regions [is] a likely substrate for disease initiation and progression.” (The Lancet, Jan 2024, https://doi.org/10.1016/S0140-6736(23)01478-2) (morris2024thepathogenesisof pages 1-4) - “Cellular mechanisms implicated across monogenic and sporadic PD include mitochondrial, lysosomal and endosomal dysfunction, and maladaptive immune/inflammatory responses.” (The Lancet, Jan 2024, ibid.) (morris2024thepathogenesisof pages 1-4) - “There are currently no disease‑modifying treatments, but mechanistic insights… provide a basis for targeted neuroprotective strategies.” (The Lancet, Jan 2024, ibid.) (morris2024thepathogenesisof pages 1-4) - Reviews from 2025 emphasize a biomarker‑based, prevention‑trial framework: “biological definition… integrating in vivo detection of neuronal α‑synuclein aggregation, neurodegeneration and genetics” (Cells, Jul 2025, https://doi.org/10.3390/cells14151161) (tanaka2025parkinson’sdiseasebridging pages 6-7).

Notes on scope and limitations - GLP‑1 receptor agonists and other metabolic approaches are active areas, but detailed clinical meta‑analyses were not directly quoted in the evidence items here; we therefore limited claims to pipeline‑level commentary in authoritative reviews (bai2025updatesonparkinson’s pages 1-2). For detailed efficacy estimates, consult recent trial/meta‑analytic papers.

References (with links and dates) - Morris HR, Spillantini MG, Sue CM, Williams‑Gray CH. The pathogenesis of Parkinson’s disease. The Lancet. 2024 Jan;403:293–304. doi:10.1016/S0140-6736(23)01478-2. https://doi.org/10.1016/S0140-6736(23)01478-2 (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4) - Bai H, Ma W, Zhu L, et al. Updates on Parkinson’s Disease. Neuropsychiatric Disease and Treatment. 2025 Sep;21:1945–1953. doi:10.2147/ndt.s540718. https://doi.org/10.2147/ndt.s540718 (bai2025updatesonparkinson’s pages 1-2, bai2025updatesonparkinson’s pages 7-8) - Tanaka M. Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation. Cells. 2025 Jul;14:1161. doi:10.3390/cells14151161. https://doi.org/10.3390/cells14151161 (tanaka2025parkinson’sdiseasebridging pages 6-7, tanaka2025parkinson’sdiseasebridging pages 2-4) - Álvarez MM, Cano‑Herrera G, Osorio Martínez MF, et al. A Comprehensive Approach to Parkinson’s Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects. International Journal of Molecular Sciences. 2024 Jun;25:7183. doi:10.3390/ijms25137183. https://doi.org/10.3390/ijms25137183 (alvarez2024acomprehensiveapproach pages 2-4)

Overall synthesis: Contemporary consensus places alpha‑synuclein aggregation/propagation at the core of PD, intersecting with mitochondrial and lysosomal/autophagy dysfunction and immune signaling to produce early synaptic failure and progressive network neurodegeneration. Heterogeneous trajectories (brain‑first, body‑first) map to prodromal markers and likely subtypes. Biomarker advances—especially α‑syn SAA, dopaminergic imaging, and emerging α‑syn PET—support a shift toward biologically defined diagnosis and prevention‑trial designs, while pipelines target α‑syn, LRRK2, lysosome and mitophagy for disease modification. The global burden continues to rise with aging populations, underscoring the urgency of biomarker‑driven, mechanistically informed interventions (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4, bai2025updatesonparkinson’s pages 1-2).

References

(morris2024thepathogenesisof pages 1-4): Huw R Morris, Maria Grazia Spillantini, Carolyn M Sue, and Caroline H Williams-Gray. The pathogenesis of parkinson's disease. The Lancet, 403:293-304, Jan 2024. URL: https://doi.org/10.1016/s0140-6736(23)01478-2, doi:10.1016/s0140-6736(23)01478-2. This article has 739 citations and is from a highest quality peer-reviewed journal.
(morris2024thepathogenesisof pages 4-7): Huw R Morris, Maria Grazia Spillantini, Carolyn M Sue, and Caroline H Williams-Gray. The pathogenesis of parkinson's disease. The Lancet, 403:293-304, Jan 2024. URL: https://doi.org/10.1016/s0140-6736(23)01478-2, doi:10.1016/s0140-6736(23)01478-2. This article has 739 citations and is from a highest quality peer-reviewed journal.
(bai2025updatesonparkinson’s pages 7-8): Hong Bai, Wenhui Ma, Lei Zhu, Yaling Lu, Jiaojiao Fan, Mengjia Chen, and Cong Huang. Updates on parkinson’s disease. Neuropsychiatric Disease and Treatment, Volume 21:1945-1953, Sep 2025. URL: https://doi.org/10.2147/ndt.s540718, doi:10.2147/ndt.s540718. This article has 1 citations and is from a peer-reviewed journal.
(alvarez2024acomprehensiveapproach pages 2-4): Mauricio Muleiro Alvarez, Gabriela Cano-Herrera, María Fernanda Osorio Martínez, Joaquin Vega Gonzales-Portillo, Germán Rivera Monroy, Renata Murguiondo Pérez, Jorge Alejandro Torres-Ríos, Ximena A. van Tienhoven, Ernesto Marcelo Garibaldi Bernot, Felipe Esparza Salazar, and Antonio Ibarra. A comprehensive approach to parkinson’s disease: addressing its molecular, clinical, and therapeutic aspects. International Journal of Molecular Sciences, 25:7183, Jun 2024. URL: https://doi.org/10.3390/ijms25137183, doi:10.3390/ijms25137183. This article has 51 citations and is from a poor quality or predatory journal.
(tanaka2025parkinson’sdiseasebridging pages 6-7): Masaru Tanaka. Parkinson’s disease: bridging gaps, building biomarkers, and reimagining clinical translation. Cells, 14:1161, Jul 2025. URL: https://doi.org/10.3390/cells14151161, doi:10.3390/cells14151161. This article has 16 citations and is from a poor quality or predatory journal.
(chaudhary2025understandingparkinson’sdisease pages 2-3): Sameer A. Chaudhary, Sapana Chaudhary, and Sakshi Rawat. Understanding parkinson’s disease: current trends and its multifaceted complications. Frontiers in Aging Neuroscience, Sep 2025. URL: https://doi.org/10.3389/fnagi.2025.1617106, doi:10.3389/fnagi.2025.1617106. This article has 1 citations and is from a peer-reviewed journal.
(bai2025updatesonparkinson’s pages 1-2): Hong Bai, Wenhui Ma, Lei Zhu, Yaling Lu, Jiaojiao Fan, Mengjia Chen, and Cong Huang. Updates on parkinson’s disease. Neuropsychiatric Disease and Treatment, Volume 21:1945-1953, Sep 2025. URL: https://doi.org/10.2147/ndt.s540718, doi:10.2147/ndt.s540718. This article has 1 citations and is from a peer-reviewed journal.
(tanaka2025parkinson’sdiseasebridging pages 2-4): Masaru Tanaka. Parkinson’s disease: bridging gaps, building biomarkers, and reimagining clinical translation. Cells, 14:1161, Jul 2025. URL: https://doi.org/10.3390/cells14151161, doi:10.3390/cells14151161. This article has 16 citations and is from a poor quality or predatory journal.

Ask OpenScientist

OpenScientist Report

Mappings

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Stages

Prevalence

Related Datasets

Computational Models

Source YAML

References & Deep Research

References

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)